US Pat. No. 10,557,194

SYSTEMS AND METHODS FOR OPTIMAL SOURCE MATERIAL DEPOSITION ALONG HOLE EDGES

UNITED TECHNOLOGIES CORPO...

1. A method for depositing a coating of a MCrAIY-type source material onto a panel, the panel defining an edge and a front panel surface, the method comprising:providing a cathodic arc, the cathodic arc including a target surface, the target surface disposed along a target deposition axis and able to emit the MCrAIY-type source material as both a cloud of MCrAIY-type source material vapor and a generally conical stream of liquid particles of the MCrAIY-type source material;
positioning the panel relative to the target surface based on a deposition angle, the deposition angle being between the target surface and an outer limit of the generally conical stream of liquid particles of the source material;
emitting the MCrAIY-type source material from the target surface as the cloud of MCrAIY-type source material vapor and the generally conical stream of liquid particles of the MCrAIY-type source material; and
coating the edge with the cloud of MCrAIY-type source material vapor to provide an edge coating
wherein the panel is a combustor panel and the panel defines at least one hole,
wherein the edge is a hole edge of the at least one hole, and
wherein coating the edge with the cloud of MCrAIY-type source material vapor to provide an edge coating includes coating the hole edge of the at least one hole, and further wherein the target deposition axis defines a target deposition plane, and
wherein positioning the panel relative to the target surface based on the deposition angle includes positioning the entire panel above or below the target deposition plane and within the generally conical stream of liquid particles.

US Pat. No. 10,557,193

METHOD FOR MANUFACTURING THIN FILMS BY UTILIZING SHORT LASER PULSES AND COMPOSITE TARGET MATERIALS

Pulsedeon Oy, Tampere (F...

1. A method for manufacturing a thin film type of coating by means of laser pulses, said method comprising the steps of:providing a coated powder, formed of at least a first and a second material, wherein the first material is metallic, inorganic or organic material, and the second material is a powdery substance, and the ablation threshold (J/cm2) of the first material is lower than the ablation threshold of the second material, and the first material forms a coating on the second material particles;
manufacturing a target of a desired shape from the coated powder by means of pressure and/or temperature by compressing;
directing laser pulses to the target for detaching the target materials and for forming particles with a desired size and material distribution, wherein the duration of an individual laser pulse is less than 10 ns; and
directing the materials detached from the target towards a substrate to form a coating on the surface or part of the surface of the substrate.

US Pat. No. 10,557,192

METHOD FOR USING SPUTTERING TARGET AND METHOD FOR FORMING OXIDE FILM

Semiconductor Energy Labo...

1. A method for using a sputtering target including a polycrystalline oxide containing a plurality of crystal grains, wherein the polycrystalline oxide contains indium, zinc, and one selected from the group consisting of gallium, tin, aluminum, titanium, nickel, zirconium, lanthanum, cerium, neodymium, hafnium, tantalum, and tungsten, the method comprising:generating a flat-plate-like particle having a flat plane by making an ion collide with the sputtering target, so that an equivalent circle diameter of the flat plane is greater than or equal to 1/3000 and less than or equal to 1/20 of an average grain size of the plurality of crystal grains, and
forming an oxide semiconductor film suitable as a channel region of a transistor by depositing the flat-plate-like particle.

US Pat. No. 10,557,191

METHOD FOR PRODUCING DEPOSITION MASK, DEPOSITION MASK, AND METHOD FOR PRODUCING ORGANIC SEMICONDUCTOR DEVICE

Sakai Display Products Co...

1. A vapor deposition mask comprising:a frame;
a magnetic metal body supported on the frame and including at least one first opening;
a resin layer arranged on the magnetic metal body so as to cover the at least one first opening; and
an adhesive layer located between the resin layer and the magnetic metal body for attaching together the resin layer and the magnetic metal body, wherein:
the resin layer has a tensile stress in an layer in-plane direction; and
the magnetic metal body receives a compressive stress in an in-plane direction from the resin layer, wherein:
a width of the at least one first opening is 30 mm or more; and
a maximum bend amount ? of a region of the resin layer that is located in the at least one first opening of the magnetic metal body when the magnetic metal body is held in a horizontal direction is 5 ?m or less.

US Pat. No. 10,557,190

SUBSTRATE PROCESSING APPARATUS AND SUSCEPTOR

Tokyo Electron Limited, ...

1. A substrate processing apparatus comprising: a chamber; a susceptor to receive a substrate and provided in the chamber, the susceptor including a first ceramics base member including a flow passage to let a coolant pass through and formed therein and a first conductive layer formed on a top surface of the first ceramics base member, the top surface of the first ceramics base member is configured to receive and support the substrate, and a side surface of the first ceramics base member; a gas supply source to supply a predetermined gas into the chamber; and a high frequency power source electrically connected via a conducting member contacting the first conductive layer at an outer surface of the first ceramics base member to generate plasma.

US Pat. No. 10,557,189

NI BASED SUPERALLOY, MEMBER OF NI BASED SUPERALLOY, AND METHOD FOR PRODUCING SAME

Mitsubishi Hitachi Power ...

1. A manufacturing process of a Ni based superalloy softening material comprising:a step for preparing a raw material of a Ni-based superalloy, the raw material of a Ni-based superalloy being subjected to a softening step in a next step;
a step for softening the raw material of the Ni based superalloy and improving workability, the step being performed subsequently to the step for preparing a raw material of a Ni-based superalloy, wherein
the step for softening the Ni based superalloy and improving workability is a step for precipitating a gamma prime phase that is incoherent with a gamma phase that is a matrix of the Ni based superalloy by 20 vol % or more, and the step of softening the Ni based superalloy and improving workability comprises:
a first step for hot-forging the Ni based superalloy at a temperature below the solvus of the gamma prime phase; and
a second step, being performed subsequently to the first step, for precipitating the gamma prime phase that is incoherent with a gamma phase that is a matrix by 20 vol % or more by slow cooling at equal to or more than 10° C./h and equal to or less than 100° C./h from a temperature below the solvus of the gamma prime phase and increasing the amount of the gamma prime incoherent phase,
wherein the solvus of the gamma prime phase is 1,050° C. or above; and further comprising a step of cooling the Ni based superalloy by quenching after the second step.

US Pat. No. 10,557,188

ALUMINUM ALLOY COMPOSITION AND METHOD

Rio Tinto Alcan Internati...

1. An extruded aluminum alloy product formed of an aluminum alloy having a composition consisting essentially of, in weight percent:0.5-0.7 manganese;
0.05-0.15 iron;
0.3-0.5 silicon;
0.005-0.020 nickel;
0.05-0.15 titanium;
0.01 max copper; and
0.10 max zinc,
with the balance being aluminum and unavoidable impurities, wherein the alloy includes manganese and silicon in a Mn/Si ratio of 2.25 or less,
wherein the extruded product is formed of an intermediate aluminum alloy product that was homogenized in a single homogenization step at a homogenization temperature of 500° C. to 595° C.

US Pat. No. 10,557,186

WROUGHT ALUMINUM ALLOY

KOREA AUTOMOTIVE TECHNOLO...

8. A wrought aluminum alloy comprising:0.01 to 0.15 wt % of Ti;
5.5 to 6.0 wt % of Zn;
more than 2.0 wt % but not more than 2.25 wt % of Mg;
0.4 to 0.8 wt % of Cu;
0.1 to 0.2 wt % of Cr;
at most 0.2 wt % (and more than 0 wt %) of Fe;
at most 0.2 wt % (and more than 0 wt %) of Mn; and
at most 0.2 wt % (and more than 0 wt %) of Si, with the remainder being Al,
wherein a change in volume change ratio along the solidus is in the range of 0.11% to 0.27%, wherein extrusion is possible at an extrusion speed in the range of 1.0 mm/s to 1.4 mm/s, and wherein the yield strength is greater than 508 MPa but not greater than 515 MPa when T6 heat treatment is performed after the extrusion.

US Pat. No. 10,557,185

FREE-CUTTING COPPER ALLOY, AND METHOD FOR PRODUCING FREE-CUTTING COPPER ALLOY

Mitsubishi Shindoh Co., L...

3. A method of manufacturing a free-cutting copper alloy worked material, the method comprising:any one or both of a cold working step and a hot working step; and
a low-temperature annealing step that is performed after the cold working step or the hot working step, wherein in the low-temperature annealing step, conditions are as follows:
the material's temperature is in a range of 240° C. to 350° C.;
the heating time is in a range of 10 minutes to 300 minutes; and
when the material's temperature is represented by T° C. and the heating time is represented by t min, 150?(T-220)×(t)1/2?1200 is satisfied,
the manufactured free-cutting copper alloy worked material comprises:
75.0 mass % to 78.5 mass % of Cu;
2.95 mass % to 3.55 mass % of Si;
0.07 mass % to 0.28 mass % of Sn;
0.06 mass % to 0.14 mass % of P;
0.022 mass % to 0.25 mass % of Pb; and
a balance including Zn and inevitable impurities,
a total amount of Fe, Mn, Co, and Cr as the inevitable impurities is lower than 0.08 mass %,
when a Cu content is represented by [Cu] mass %, a Si content is represented by [Si] mass %, a Sn content is represented by [Sn] mass %, a P content is represented by [P] mass %, and a Pb content is represented by [Pb] mass %, the relations of
76.25?f1=[Cu]+0.8×[Si]?8.5×[Sn]+[P]+0.5×[Pb]?80.3 and
61.5?f2=[Cu]?4.3×[Si]?0.7×[Sn]?[P]+0.5×[Pb]?63.3
are satisfied,
in constituent phases of metallographic structure of the manufactured free-cutting copper alloy worked material, when an area ratio of a phase is represented by (?)%, an area ratio of ? phase is represented by (?)%, an area ratio of ? phase is represented by (?)%, an area ratio of K phase is represented by (?)%, and an area ratio of ? phase is represented by (?)%, the relations of
25?(?)?65,
0?(?)?1.5,
0?(?)?0.2,
0?(?)?2.0,
97.0?f3=(?)+(?),
99.4?f4=(?)+(?)+(?)+(?),
0?f5=(?)+(?)?2.5, and
27?f6=(?)+6×(?)1/2+0.5×(?)?70
are satisfied,
the length of the long side of ? phase is 30 ?m or less,
the length of the long side of ? phase is 25 ?m or less, and
? phase is present in a phase.

US Pat. No. 10,557,184

METHOD FOR MANUFACTURING COPPER ALLOY AND COPPER ALLOY

NGK Insulators, Ltd., Na...

1. A method for manufacturing a copper alloy, the method comprising the steps of:(a) weighing a copper powder and one of a Cu—Zr master alloy and a ZrH2 powder such that an alloy composition of Cu-xZr (x is the atomic % of Zr, and 0.5?x?8.6 is satisfied) is obtained and pulverizing and mixing the copper powder and the one of the Cu—Zr master alloy and the ZrH2 powder in an inert atmosphere until an average particle diameter D50 falls within the range of from 1 ?m to 500 ?m to thereby obtain a powder mixture; and
(b) subjecting the powder mixture to spark plasma sintering by holding the powder mixture at a prescribed temperature lower than eutectic temperature while the powder mixture is pressurized at a pressure within a prescribed range,
wherein the copper alloy has a structure in which a second phase is dispersed in a Cu matrix phase, the copper alloy having the following features (1) to (3):
(1) the average particle diameter D50 of the second phase in cross section is within the range of 1 ?m to 100 ?m;
(2) the Cu matrix phase and the second phase are present as two separate phases, and the second phase contains a Cu—Zr-based compound; and
(3) the second phase has an outer shell composed of a Cu—Zr-based compound phase and a core portion including a Zr-rich Zr phase.

US Pat. No. 10,557,183

WORK HARDENABLE YIELD RATIO-CONTROLLED STEEL AND METHOD OF MANUFACTURING THE SAME

KOREA INSTITUTE OF MACHIN...

1. A method of manufacturing a yield ratio-controlled steel, comprising the steps of :subjecting an alloy of steel, comprising 0.10 to 0.40 wt % carbon (C), 0.90 to 1.50 wt % manganese (Mn), 0.50 to 2.50 wt % silicon (Si), and 0.060 wt % or less but exceeding 0 wt % aluminum (Al), with a remainder of iron (Fe) and unavoidable impurities, to rolling or wire drawing, thus obtaining a material;
performing a first heat treatment on the material, in which the material is heated to and maintained for a first predetermined period of time at a first temperature ranging from Ac1 to Ac3, which are Ac1 and Ac3 transformation temperatures; and
immediately after the end of the first predetermine period of time, cooling the material to a second temperature ranging from (25° C+Ms)/2 to Ms, where Ms is a martensite start temperature;
performing a second heat treatment immediately after the material is cooled to the second temperature, in which the material is maintained at the second temperature for a second predetermined period of time; and
generating in the material bainite or martensite based on ferrite.

US Pat. No. 10,557,182

SYSTEMS AND METHODS FOR TAILORING COEFFICIENTS OF THERMAL EXPANSION BETWEEN EXTREME POSITIVE AND EXTREME NEGATIVE VALUES

1. A method of manufacturing a metallic material with a tailored thermal expansion coefficient in a selected range, comprising:plastically deforming said metallic material comprising a first phase and a first thermal expansion coefficient;
transforming, in response to said plastic deforming, at least some of said first phase into a second phase; and
orienting said metallic material in at least one selected orientation;
wherein:
said metallic material comprises an alloy with a mixture of phases;
said mixture of phases comprises at least one phase capable of a martensitic transformation that is embedded in another phase or phases that may or may not be capable of martensitic transformation;
said second phase comprises martensite;
said plastic deforming comprises mechanical deformation;
said metallic material, subsequent to said plastic deformation, comprises a second thermal expansion coefficient;
said second thermal expansion coefficient is within a selected range; and
said second thermal expansion coefficient quantifies thermal expansion of said metallic material in at least one selected direction.

US Pat. No. 10,557,181

VALVE BODY TREATED BY AUTOFRETTAGE

Luxembourg Patent Company...

1. A method for improving the mechanical behavior of treatment of a body with threaded ports of a gas valve, comprising:providing at least two bores in the body and at least one bore intersection defining an internal volume;
closing the internal volume of the valve body by screwing plugs on the threaded ports, respectively; and
subjecting the internal volume to an autofrettage by applying a pressure of a value between 100 MPa and 500 MPa by means of a liquid, for improving the mechanical behavior of said body;
wherein a diameter of the at least two bores at the at least one bore intersections is between 1 mm and 20 mm; and
wherein the threads of the threaded ports have each a diameter delimiting a cross-section of the corresponding plug that is subject to the pressure of autofrettage, said diameter being at least three times greater than a diameter of the at least two bores at the at least one bore intersection.

US Pat. No. 10,557,179

METHOD FOR MANUFACTURING REDUCED IRON

POSCO, Pohang-si (KR) Pr...

1. A method for manufacturing reduced iron, comprising:drying ores in an ore drier;
supplying the dried ores to at least one reduction reactor;
reducing the ores in the at least one reduction reactor and manufacturing reduced iron;
discharging exhaust gas by which the ores are reduced in the at least one reduction reactor;
branching the exhaust gas and providing the branched exhaust gas as ore feeding gas; and
exchanging heat between the exhaust gas and the ore feeding gas and transferring the sensible heat of the exhaust gas to the ore feeding gas,
wherein in the supplying of the dried ores to the at least one reduction reactor, the dried ores are supplied to the at least one reduction reactor by using the ore feeding gas, and
wherein the supplying of the dried ores to the at least one reduction reactor comprises supplying the dried ores along a first direction, supplying the dried ores along a second direction crossing the first direction and raising the dried ores along the second direction, and supplying the dried ores to the at least one reduction reactor through a plurality of third feeding gas pipe parts connected to the at least one reduction reactor in a radial direction.

US Pat. No. 10,557,176

METHOD FOR DETECTING TRACE FUNGI USING SINGLE-CELL SEQUENCING AND KIT THEREOF

BEIJING INSTITUTE OF RADI...

1. A method for detecting trace fungi using a single-cell sequencing, comprising the following steps:(1) acquisition of trace fungal cells: coating trace fungi samples onto a membrane glass slide for laser microdissection, finding target cells using a laser microdissection system, and performing the laser microdissection on one of the target cells by a laser with a laser power of 37-43 micro joules to obtain a single target cell; wherein the above operation is repeated to obtain the target cells with a total number of 1-100;
(2) wall-breaking of fungal cell walls: extraction of fungal protoplasm by a chemical method combined with a mixed enzymatic method;
1) adding 0.8 M D-sorbitol solution into a centrifuge tube containing the target cells to immerse the target cells at 4° C. for 2 h;
2) preparation of a composite pretreatment agent: mixing 50 mM Tris, 5 mM EDTA and 5% ?-mercaptoethanol evenly;
3) preparation of a mixed enzyme treatment agent: preparing the mixed enzyme treatment agent according to any one of the following formula:
A: 6 mg/mL of snail enzyme and 4 mg/mL of lywallzyme,
B: 6 mg/mL of snail enzyme and 4 mg/mL of lysozyme,
C: 4 mg/mL of snail enzyme, 4 mg/mL of lywallzyme and 4 mg/mL of lysozyme,
D: 4 mg/mL of snail enzyme, 3 mg/mL of lywallzyme and 3 mg/mL of cellulase,
E: 4 mg/mL of snail enzyme, 3 mg/mL of lysozyme and 3 mg/mL of cellulase,
F: 5 mg/mL of lywallzyme, 4 mg/mL of lysozyme and 3 mg/mL of cellulase, and
G: 4 mg/mL of snail enzyme, 2 mg/mL of lywallzyme, 3 mg/mL of lysozyme and 4mg/mL of cellulase;
4) adding the composite pretreatment agent into the centrifuge tube containing the target cells to treat the target cells at 35° C. for 1 h;
5) subjecting the centrifuge tube to a centrifugation to collect the target cells to a bottom of the centrifuge tube, then discarding the composite pretreatment agent;
6) adding sterile water into the centrifuge tube to wash the target cells twice, centrifuging, and discarding liquid;
7) adding the mixed enzyme treatment agent into the centrifuge tube to treat the target cells at 35-45° C. for 3-12 h;
8) subjecting the centrifuge tube to a centrifugation to collect the target cells to a bottom of the centrifuge tube, then discarding liquid; and
9) adding PBS (phosphate-buffered saline) into the centrifuge tube to wash the target cells once, centrifuging, discarding liquid, and retaining 4-10 ?l of cell suspension;
(3) extraction fungal gDNA from the fungal protoplasm and amplification of the fungal gDNA: using a single-cell whole genome amplification kit to perform a nucleic acid extraction and amplification reaction on the 4-10 ?l cell suspension obtained in the step 9) to obtain the fungal gDNA;
(4) library construction of trace gDNA: constructing a library of the fungal gDNA using a DNA library construction kit;
(5) genome sequencing: performing whole genome sequencing on the fungal gDNA after constructing the library; and
(6) bioinformatics analysis: assembling data obtained from sequencing by using a relevant software to obtain assembled results, and the assembled results are compared with a relevant public database to determine a species of the trace fungi.

US Pat. No. 10,557,174

SYSTEM AND METHOD FOR DETERMINING COPIES-PER-UNIT-VOLUME USING PCR AND FLOW CONTROL OF DROPLETS

Life Technologies Corpora...

1. A method for quantification of a target nucleic acid in a sample, the method comprising:forming a plurality of discrete sample portions, each of the plurality of discrete sample portions comprising a portion of the sample, a reference dye, and a reaction mixture, wherein the plurality of discrete sample portions comprises discrete sample portions of a plurality of sizes;
amplifying the plurality of discrete sample portions to form a plurality of discrete processed sample portions including at least one discrete processed sample portion containing nucleic acid amplification reaction products;
detecting one or more fluorescence signals from the at least one of the plurality of discrete processed sample portions to determine a presence of the at least one target nucleic acid;
detecting one or more reference fluorescence signals of the reference dye from the at least one of the plurality of discrete processed sample portions to determine respective volume(s) by analyzing the reference fluorescence signal(s); and
estimating the number of copies-per-unit-volume of the at least one target nucleic acid in the sample based on the number of discrete processed sample portions determined to contain the at least one target nucleic acid therein.

US Pat. No. 10,557,169

POOLED ADAPTER STRATEGY FOR REDUCING BIAS IN SMALL RNA CHARACTERIZATION

Mount Sinai School of Med...

1. A mixture of 5? adapters for small RNA characterization comprising:a plurality of modified adapter sequences that are covalently extended at the 3? ends by addition of at least two random nucleotides, wherein the modified adapter sequences comprise the structure fNN, wherein f is the adaptor sequence, and wherein NN are at least two random nucleotides that have been covalently attached to the 3? end of the adapter sequence;
wherein the mixture comprises at least sixteen modified adapter sequences for each unique adapter sequence, wherein the at least sixteen modified adapter sequences comprise fAA, fAC, fAG, fAT, fCA, fCC, fCG, fCT, fGA, fGC, fGG, fGT, fTA, fTC, fTG, and fTT.

US Pat. No. 10,557,167

BIOMOLECULE SEQUENCING DEVICES, SYSTEMS AND METHODS

QUANTUM BIOSYSTEMS INC., ...

1. A system for detecting a biomolecule using at least one pair of nanogap electrodes, comprising:a fluid flow unit comprising at least one pump for directing a plurality of monomers with reference substances bound thereto to the at least one pair of nanogap electrodes, wherein the reference substances comprise a first reference substance bound to a first monomer and a second reference substance bound to a second monomer, wherein the first reference substance is different than the second reference substance; and
a computer processor coupled to the at least one pair of nanogap electrodes and programmed to:
(a) measure tunneling nanocurrent signals resulting from the plurality of monomers with reference substances bound thereto using the at least one pair of nanogap electrodes, wherein the tunneling nanocurrent signals correspond to the reference substances, wherein the first reference substance and the second reference substance correspond to different tunneling nanocurrent signals; and
(b) identify a monomer of the plurality of monomers with reference substances bound thereto based on the tunneling nanocurrent signals measured in (a).

US Pat. No. 10,557,165

NUCLEIC ACID DETECTION METHOD AND ASSAY KIT

KABUSHIKI KAISHA TOSHIBA,...

1. A method for detecting target nucleic acid in a sample, the target nucleic acid including a first sequence, the method comprising:(A) forming a reaction field by placing a reaction mixture on an electrode,
the reaction mixture comprising:
the sample;
a primer set for amplifying the first sequence to obtain an amplification product, wherein the primer set contains at least a first primer complementary to a terminal of the first sequence and a second primer homologous to the other terminal of the first sequence;
a corresponding amplification enzyme;
4 mM to 30 mM in concentration of magnesium ion; and
a redox probe having an oxidation reduction potential of ?0.5 V to 0.5 V, which generates a detectable electric signal;
(B) maintaining the reaction field under an amplification reaction condition to generate the amplification product, wherein, with the increase in the amount of the amplification product, a magnesium pyrophosphate is generated from the magnesium ion and the magnesium pyrophosphate precipitates with the redox probe on the electrode;
(C) chronologically detecting the electric signal from the redox probe with the electrode while maintaining the reaction field under the amplification reaction condition, wherein the electric signal increases with the increase in the amount of the amplification product present in a reaction field; and
(D) determining existence or quantity of the target nucleic acid based on chronological variation in the amplitude of the electric signal, obtained in (C).

US Pat. No. 10,557,163

BACTERIAL DETECTION CARTRIDGE

Becton Dickinson and Comp...

1. An apparatus for determining the presence of a microorganism in a sample, the apparatus comprising:a container assembly having a top, a bottom, an inner side wall, an outer side wall, a plurality of walls extending radially from the inner side wall to the outer side wall defining a plurality of compartments, and a plunger device adapted to move from a first position to a second position,
wherein, when in the first position, the plunger device defines a flow pathway adapted to receive a sample, the flow pathway being in fluid communication with an exterior of the container assembly and also with the plurality of compartments;
wherein, when in the second position, the plunger device seals the flow pathway, such that the plurality of compartments are not in fluid communication with each other, and the sample in each of the plurality of compartments is isolated from the sample in other compartments.

US Pat. No. 10,557,150

AUTOMATED NUCLEIC ACID ASSEMBLY AND INTRODUCTION OF NUCLEIC ACIDS INTO CELLS

Inscripta, Inc., Boulder...

1. An automated instrument comprising:a housing configured to house all of some modules;
one or more receptacles configured to receive nucleic acids and cells;
a growth module configured to grow the cells;
a cell concentration module configured to concentrate and render the cells electrocompetent;
a flow-through electroporation (FTEP) module configured to introduce the nucleic acids into the cells;
a selection module configured to select for transformed cells; and
a processor configured to operate the automated instrument based on user input and/or selection of a pre-programmed script; and
an automated liquid handling system to move liquids from the one or more receptacles to the growth module, from the growth module to the cell concentration module, from the cell concentration module to the FTEP module, and from the FTEP module to the selection module, all without user intervention.

US Pat. No. 10,557,146

MODIFIED PLANTS

THE INSTITUTE OF GENETICS...

1. A mutant wheat plant or plant part comprising a loss of function mutation in a TaMLO-A1, TaMLO-B1 and a TaMLO-D1 nucleic acid sequence, wherein said mutation has been introduced into SEQ NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16 or SEQ ID NO. 17 by using targeted genome modification, and wherein said mutation confers resistance to powdery mildew.

US Pat. No. 10,557,137

MODULATING APOLIPOPROTEIN (A) EXPRESSION

Ionis Pharmaceuticals, In...

1. A method of treating a disease or condition in a human comprising administering to the human 75 mg to 85 mg of an oligomeric compound having the following structure:and thereby treating the disease or condition in the human.

US Pat. No. 10,557,134

PROTECTION OF BARCODES DURING DNA AMPLIFICATION USING MOLECULAR HAIRPINS

TRUSTEES OF BOSTON UNIVER...

1. A method of amplifying a target nucleic acid in a sample comprising:a. contacting a sample comprising a target nucleic acid with a target-specific hairpin barcode forward primer and a target-specific reverse primer,
wherein the hairpin barcode forward primer comprises, in a 5? to 3? direction: a 5? stem sequence, an adaptor sequence, a barcode sequence, a 3? stem sequence, and a 3? target-specific sequence, wherein the 5? stem sequence and the 3? stem sequence each comprise sequence complementary to each other and the complementary sequences hybridize to each other under a closed annealing temperature and do not hybridize to each other at an open annealing temperature;
b. amplifying the target nucleic acid by performing 2-5 cycles of PCR pre-amplification on the target nucleic acid, wherein the 2-5 cycles of PCR pre-amplification have an annealing temperature less than or equal to the closed annealing temperature of the hairpin barcode forward primer, to generate a plurality of pre-amplification target nucleic acids;
c. contacting the plurality of pre-amplification target nucleic acids with an adaptor-specific forward primer and an adaptor-specific reverse primer; and
d. amplifying the pre-amplification target nucleic acid by performing at least 10 cycles of PCR amplification on the pre-amplification target nucleic acids, wherein at least 3 of the at least 10 cycles of PCR-based amplification have an annealing temperature greater than or equal to the open annealing temperature of the hairpin barcode forward primer, to generate a plurality of target nucleic acid amplicons, wherein the target nucleic acid amplicons comprise the adaptor sequence and the barcode sequence.

US Pat. No. 10,557,132

MICROFLUIDIC CARTRIDGE FOR PROCESSING AND DETECTING NUCLEIC ACIDS

NeuMoDx Molecular, Inc., ...

1. A cartridge for processing a sample, the cartridge comprising:a first layer comprising a sample port and a fluid port at a surface of the first layer;
an intermediate substrate coupled to the first layer and defining a chamber opposing the first layer, wherein the chamber comprises an external surface defining a set of voids configured to receive a set of pins;
an actuation layer between the first layer and the intermediate substrate; and
a fluidic pathway defined by at least a portion of the first layer and at least partially separated from the chamber by the actuation layer, the fluidic pathway fluidly coupled to the sample port and the fluid port, and configured to transport fluid through the cartridge upon manipulation of the actuation layer by the set of pins; and
a set of chamber inlets configured to deliver fluid from the fluidic pathway into the chamber, wherein the chamber is fluidly accessible at more than one location along the fluidic pathway through the set of chamber inlets, and wherein the cartridge is configured to drive fluid from the fluidic pathway into the chamber, through at least a subset of the set of chamber inlets, upon manipulation of the actuation layer by the set of pins.

US Pat. No. 10,557,125

SELECTION MARKER FOR CELL TRANSFECTION AND PROTEIN PRODUCTION

SANOFI, Paris (FR)

1. An expression vector comprising the nucleotide sequence of SEQ ID NO:3 encoding a mammalian dihydroorotate dehydrogenase (DHODH) and at least one expression cassette for expressing a recombinant protein, wherein the DHODH comprises the amino acid sequence of SEQ ID NO:4, wherein the DHODH is inhibited by at least one DHODH inhibitor.

US Pat. No. 10,557,113

SURFACE DETECTION AND PICKTOOL MANIPULATOR

BD KIESTRA B.V., Drachte...

1. A device for collecting a specimen from a culture medium, comprising:a body comprising a cavity structure for receiving a replaceable picktool, the body and picktool being in approximately axial alignment; and
a detector configured to generate a signal in response to a force applied to the picktool when the picktool is brought into contact with a specimen disposed on a culture medium,
wherein the device is configured to operate in at least first and second modes, wherein the first mode permits the body and the picktool to move freely in an axial direction, which is proximately perpendicular to a surface of the culture medium, and the second mode applies more resistance to the axial movement of the body and the picktool than when the device is in the first mode;
wherein the device further comprises a device structure coupled to the body, wherein the body moves more freely in the axial direction relative to the device structure in the first mode, and the body is locked from such axial movement in the axial direction in the second mode and a key coupled to the body, wherein the key cooperates with an opening in the device structure above the key so that the key does not engage and may advance into and through the device structure in the first mode and in which the key cannot advance into and through the device structure in the second mode.

US Pat. No. 10,557,111

CELL CULTURE VESSEL

DAI NIPPON PRINTING CO., ...

1. A cell culture vessel comprising a bottom and a sidewall, whereinthe bottom has a cell containing section in which a plurality of microwells for containing cells are disposed, wherein the plurality of microwells comprises 4 or more microwells whose centroids are positioned on a same axis and includes every microwell present on the cell culture vessel,
one or more microscopic identifiers are disposed in the vicinities of each of the 4 or more microwells and outside the 4 or more microwells so as to form respective identifier-microwell pairs, said microscopic identifiers being visible under a microscope and disposed on the same axis, and
the relative position of each of the one or more microscopic identifiers to a partner microwell varies in every pair.

US Pat. No. 10,557,109

INFUSION FILTER ARRANGEMENT WITH FORCED INFUSION SYSTEM FOR BEER-BREWING SYSTEM

1. An infusion filter arrangement for use with a brewing kettle of a beer-brewing system, the infusion filter arrangement comprising:a filter body configured to be placed and maintained in a kettle cavity of the brewing kettle during a mash cycle and having perforated outer walls defining a filter cavity configured to hold grains defining a grain bed in the filter cavity during the mash cycle; and
a forced infusion system including an infusion liquid delivery system configured to release water or wort out of the infusion liquid delivery system inside the filter cavity at an intermediate segment of the filter cavity and at a location relative to the grain bed for establishing a flow of the water or wort from the intermediate segment of the filter cavity radially outwardly through the grain bed that agitates the grains in the grain bed contained within the filter cavity.

US Pat. No. 10,557,106

ENHANCED PEROXYGEN STABILITY USING ANIONIC SURFACTANT IN TAED-CONTAINING PEROXYGEN SOLID

Ecolab USA Inc., Saint P...

1. A stabilized solid activated bleach composition comprising:from about 10 wt-% to about 80 wt-% of at least one alkaline solidification matrix;
from about 20 wt-% to about 75 wt-% of an active oxygen source;
from about 0.01 wt-% to about 50 wt-% of an acid source;
between about 20 wt-% to about 50 wt-% of a bleach activating agent; and
up to about 25 wt-% of a binding system comprising from about 0.1 wt-% to about 15 wt-% of an anionic sulfate and/or sulfonate surfactant and from about 1 wt-% to about 10 wt-% of a cellulose component;
wherein the solid composition has less than 1 wt-% water;
wherein the solid composition is a pressed, cast, flowable, or extruded solid; and
wherein the active oxygen source and bleach activating agent remain unreacted in the solid composition until a point of use or dilution.

US Pat. No. 10,557,105

EXTRACTION SYSTEMS AND METHODS

Bao Tran, Saratoga, CA (...

1. A method for extracting oil from a biomass, comprising:applying a cryogen to a tank to render brittle the biomass;
reducing the cryogenically frozen biomass to small portions;
placing the reduced cryogenically frozen biomass in the tank filled with a liquid;
generating shock waves and pressure variations with cavitation;
applying the shock waves and pressure variations to a mixture formed from the liquid and the reduced cryogenically frozen biomass with oil dissolved or entrained within a fluid of the mixture; and
extracting oil from the fluid.

US Pat. No. 10,557,104

MODULAR, MOBILE, AND AUTOMATED SOLVENT EXTRACTION AND DISTILLATION SYSTEMS, AND METHODS OF USING THE SAME

Botanex Intelletual Prope...

1. An automated system for solvent extraction of a plant-based raw material or other biomass material to produce a botanical extract, fats, oils, or other desirable solute, said system comprising:(a) an extraction reactor configured with (i) a sealed feed inlet for feeding a plant-based solid raw material, biomass, or other feed stock material, (ii) a solvent inlet for introducing lean solvent to said extraction reactor, (iii) one or more gas ports for introducing an inert non-condensable gas and/or a solvent vapor to said extraction reactor and/or for removing gases from said extraction reactor; (iv) optionally, a refrigeration cycle with the interior of said extraction reactor acting as an evaporator of said solvent, to sub-cool said plant-based solid raw material, biomass or other feed stock material; (v) a solid outlet for conveying solid material out of said extraction reactor; and (vi) a product outlet for removing rich solvent containing a botanical extract, or other precipitate, out of said extraction reactor;
(b) a closed-loop continuous-flow distillation unit configured to generate purified botanical extract and recovered solvent from said rich solvent containing said botanical extract; and
(c) a second-stage purge chamber configured to (i) receive said solid material and (ii) receive a heated inert non-condensable gas and/or said solvent vapor, wherein said second-stage purge chamber is effective to recover residual solvent contained in said solid material.

US Pat. No. 10,557,101

PHOSPHONO PARAFFINS

THE BOEING COMPANY, Chic...

1. A method of making a secondary phosphono paraffin, comprising:mixing
(i) a secondary haloparaffin,
(ii) a phosphite, wherein a molar ratio of phosphite to secondary haloparaffin is from about 1:1 to about 10:1, and
(iii) one or more of sodium iodide, potassium iodide, or potassium bromide to form a reaction mixture, wherein a molar ratio of the sodium iodide, potassium iodide, or potassium bromide to secondary haloparaffin is from 1:1 to about 10:1; and
heating the reaction mixture to form a secondary phosphono paraffin at an overall yield of from about 20% to about 80%.

US Pat. No. 10,557,100

HIGH VISCOSITY BASE STOCK COMPOSITIONS

ExxonMobil Research and E...

1. A base stock composition comprising a Group III base stock having a number average molecular weight (Mn) of 2500 g/mol to 10000 g/mol, a weight average molecular weight (Mw) of 4000 g/mol to 30000 g/mol, a polydispersity (Mw/Mn) of at least 1.6, a sulfur content of 0.03 wt % or less, an aromatics content of 10 wt % or less, a kinematic viscosity at 100° C. of at least 350 cSt, a kinematic viscosity at 40° C. of at least 2500 cSt, and a viscosity index of 120 to 180.

US Pat. No. 10,557,098

SYNTHESIS OF HYDROCHAR FROM JACKFRUIT

King Saud University, Ri...

1. A method of synthesizing hydrochar from jackfruit, comprising the steps of:adding a jackfruit peel biomass to a liquid carrier;
subjecting the jackfruit peel biomass in the liquid carrier to hydrothermal carbonization to provide a hydrochar, the hydrothermal carbonization comprising heating the jackfruit peel biomass in the liquid carrier to a temperature ranging from 150° C. to 250° C. for 3 hours; and
separating the hydrochar from the liquid carrier.

US Pat. No. 10,557,097

SOLID FUEL MANUFACTURING APPARATUS AND METHOD FOR MANUFACTURING SOLID FUEL

AISAKU CO., LTD., Toyota...

1. A solid fuel manufacturing apparatus comprising:a mixture producing means configured to produce a mixture by kneading combustible waste containing moisture and a dehydrating agent acting to accelerate removal of the moisture from the combustible waste;
a rotary drum configured to be cylindrical and rotatable, the rotary drum being configured to contain the mixture produced by the mixture producing means in an internal space;
an intake means configured to introduce outside air into the rotary drum;
an exhaust means configured to discharge exhaust air out of the rotary drum;
a drive means configured to rotate the rotary drum;
a plurality of load sensors arranged at different positions around a perimeter of the rotary drum;
a plurality of drum lower side supports located in four locations, each of the plurality of drum lower side supports provided with one of the plurality of load sensors, each of the plurality of load sensors being configured to detect a load acting on a predetermined portion of each of the plurality of drum lower side supports;
a control board configured to: (i) calculate a percentage of moisture content in the mixture within the rotary drum based on detection signals from the plurality of load sensors, (ii) control operations of the drive means based on the calculated percentage of moisture content in the mixture within the rotary drum, and (iii) control rotational movement of the drive means by changing a rotational direction of the drive means to reverse a rotational direction of the rotary drum to return a center of gravity of the rotary drum to an initial position based on each detection signal received from the plurality of load sensors;
a rake disposed inside the internal space of the rotary drum at an opening of rotary drum, the rake being formed of a plurality of rods arranged at intervals, the rake being configured to divide the mixture contained in the rotary drum; and
a breaking means configured to break up the mixture contained in the rotary drum, wherein:
the dehydrating agent is a treatment agent made of an emulsion containing synthetic resin; and
the breaking means includes a plurality of blades placed along an inner peripheral wall of the rotary drum in an axial direction and a circumferential direction of the rotary drum, the plurality of blades being configured to scoop the mixture upward in the internal space and allow the mixture to freely fall from above in the internal space by rotation of the rotary drum, each of the plurality of blades has a plate shape including a first plane and a second plane, which are bent at a predetermined bending angle, the plurality of blades being arranged at first predetermined intervals in the circumferential direction of the rotary drum, such that each first plane of each blade is tilted with respect to a tangent to the inner peripheral wall of the rotary drum and each second plane of each blade is fixed to the inner peripheral wall of the rotary drum, and the plurality of blades are arranged at second predetermined intervals in the axial direction of the rotary drum, such that the second plane of one blade of the plurality of blades that is located closest to a first end of the rotary drum is inclined in a clockwise direction with respect to the axial direction of the rotary drum, and the second plane of one blade of the plurality of blades that is located closest to a second end of the rotary drum, which is opposite to the first end in the axial direction, is inclined in a counter-clockwise direction with respect to the axial direction of the rotary drum.

US Pat. No. 10,557,095

GASIFICATION PROCESS AND FEED SYSTEM

Air Products and Chemical...

1. A process for the gasification of a solid carbonaceous feed, the process comprising the steps of:introducing a batch of the solid carbonaceous feed into a sluice vessel, while an internal pressure in the sluice vessel is at a first pressure;
introducing a CO2-containing feedback gas comprising methanol into the sluice vessel via one or more gas inlets covered by the solid carbonaceous feed, to pressurize the sluice vessel from the first pressure to a second pressure exceeding the first pressure, during a predetermined time period;
closing the one or more gas inlets;
opening a feed outlet of the sluice vessel to supply the batch of the solid carbonaceous feed to a feed vessel for feeding the solid carbonaceous feed to a gasification reactor;
closing the feed outlet;
venting the sluice vessel to reduce the internal pressure to the first pressure; and repeating the process;
wherein the CO2-containing feedback gas is introduced into the sluice vessel only via the one or more gas inlets which are covered by the solid carbonaceous feed, and at a flow rate which is at most 0.3 m3 per minute for each 0.5 kg of solid carbonaceous feed in the batch.

US Pat. No. 10,557,094

CRUDE UNIT OVERHEAD CORROSION CONTROL USING MULTI AMINE BLENDS

BHARAT PETROLEUM CORPORAT...

1. A method for inhibiting corrosion on internal metal surfaces of an overhead condenser of a crude distillation unit, the method comprising: adding to the overhead condenser an amine composition in an amount and at a rate sufficient to maintain pH of water condensate in the condenser above a pH of about 5, the amine composition consisting of monoethanloamine, methoxypropyl amine, morpholine and cyclohexylamine.

US Pat. No. 10,557,093

PROCESS FOR PRODUCING NAPHTHENIC BASE OILS

ERGON, INC., Flowood, MS...

1. A process for producing a naphthenic base oil comprising the steps of:a) hydrotreating a naphthenic feedstock having a sulfur content of up to about 5% by weight (as measured by ASTM D4294) and a nitrogen content of up to about 3% by weight (as measured by ASTM D5762) and comprising more than 50 wt. % naphthenic vacuum distillate fractions in the presence of a hydrotreating catalyst and hydrotreating conditions to produce a hydrotreated naphthenic effluent;
b) dewaxing the hydrotreated naphthenic effluent having a sulfur content of about 0.0005% to about 0.5% by weight (as measured by ASTM D4294) and a nitrogen content of up to about 0.1% by weight (as measured by ASTM D5762) in the presence of a dewaxing cracking catalyst and under catalytic dewaxing conditions to produce a dewaxed effluent;
c) hydrofinishing the dewaxed effluent in the presence of a hydrofinishing catalyst and under catalytic hydrofinishing conditions to produce a dewaxed hydrofinished effluent having reduced levels of polycyclic aromatic hydrocarbon compounds and reduced levels of unstable olefinic compounds; and
d) fractionating the dewaxed hydrofinished effluent to remove one or more low viscosity high volatility fractions and provide a naphthenic base oil having a pour point (as measured by ASTM D5949) below about ?5° C., at a yield greater than 85% of total naphthenic base oil over total hydrotreated naphthenic feedstock.

US Pat. No. 10,557,092

RAFFINATE HYDROCONVERSION FOR PRODUCTION OF HIGH PERFORMANCE BASE STOCKS

ExxonMobil Research and E...

1. A method for making a base stock, comprising:performing solvent extraction on a feedstock to form a raffinate comprising a solvent dewaxed viscosity index (VI) of 80 to 105 at a pour point of ?18° C., the feedstock comprising at least 50 wt % of a mineral feedstock;
hydroconverting at least a portion of the raffinate under hydroconversion conditions to form a hydroconverted effluent, the hydroconversion conditions being effective for conversion of at least 15 wt % of the at least a portion of the raffinate relative to a conversion temperature of 370° C., the hydroconverted effluent comprising a VI at least 20 greater than the solvent dewaxed VI of the raffinate, a 343° C.+ portion of the hydroconverted effluent comprising a sulfur content of 50 wppm or less;
separating at least a portion of the hydroconverted effluent to form at least a lower boiling fraction and a lubricant boiling range fraction having a T10 distillation point of at least 343° C.;
dewaxing at least a portion of the lubricant boiling range fraction under catalytic dewaxing conditions to form a dewaxed effluent; and
fractionating at least a portion of the dewaxed effluent to form a base stock comprising a viscosity index of greater than 120, a sulfur content of less than 300 wppm, and a saturates content of at least 90 wt %.

US Pat. No. 10,557,091

PROCESS FOR INCREASING HYDROCARBON YIELD FROM CATALYTIC REFORMER

UOP LLC, Des Plaines, IL...

1. A process for increasing a C5+ hydrocarbon yield in a reforming reactor unit, the processing comprising:passing a catalyst through a conduit in a non-reactive zone of a reactor to a reaction zone of the reactor, the non-reactive zone comprising a first portion and a second portion, the first portion and the second portion separated by a baffle;
injecting a hydrocarbon feed stream into the first portion of the non-reactive zone of the reactor;
injecting a purge gas into the second portion of the non-reactive zone of the reactor to generate a positive differential pressure between the first portion and the second portion of the non-reactive zone; and
passing the feed stream from the first portion of the non-reactive zone to the reaction zone, wherein the catalyst in the conduit is isolated from the feed stream in the non-reactive zone.

US Pat. No. 10,557,090

PROCESS FOR PRODUCING TRANSPORT FUEL BLENDSTOCK

Patrick James Cadenhouse-...

1. A process for producing transport fuel blendstocks, the process comprising:providing a first feedstock comprising butane and propane, and a second feedstock comprising benzene;
dehydrogenating the first feedstock in a first reactor to produce a C4 product comprising butane and butene and a C3 product comprising propane and propylene;
splitting, via a C3/C4 splitter, the C4 product from the C3 product that are produced in the first reactor;
oligomerizing the C4 product in a second reactor to produce a first transport fuel blendstock; and
alkylating the C3 product with the second feedstock in a third reactor to produce a second transport fuel blendstock.

US Pat. No. 10,557,089

EMULSION AND SYSTEM FOR CATALYTIC PYROLYSIS

1. An emulsion having utility as a reactor feedstock, comprising:100 parts by weight heavy oil;
from about 5 to about 100 parts by weight water; and
from about 1 to about 20 parts by weight solid catalyst particulates comprising ferric ions and chloride ions supported on clay.

US Pat. No. 10,557,088

CONVERSION OF POLYMER CONTAINING MATERIALS TO PETROLEUM PRODUCTS

PK Clean Energy Pte Ltd, ...

1. A method comprising:heating streams of feedstock of polymer containing materials prior to delivery into a cylindrical reactor body, the cylindrical reactor body comprising an axis perpendicular to a radius of a circular cross section of the cylindrical reactor body;
applying heat from an external heat source to the reactor body to heat an interior of the reactor body;
subjecting the heated streams of feedstock to pyrolysis in the heated reactor body;
rotating the reactor body;
rotating two or more internal augers within the interior of the reactor body, wherein the augers are each disposed to promote directional movement of materials within the reactor body in the direction from an inlet to an outlet of the reactor body, wherein the augers are positioned to scrape reacted feedstock from a portion of the reactor body adjacent to the augers as the reactor body rotates past the augers and move the reacted feedstock toward the outlet, wherein the augers are offset from the axis of the reactor body, wherein the augers are in a same half of the reactor body;
utilizing a plug or baffle at an end of the reactor body to reduce heat loss at an exit where char is moved out of the end of the reactor body;
outputting a portion of the reacted feedstock from the outlet of the reactor body; and
putting a portion of the reacted feedstock through a condensing system to convert the reacted feedstock into petroleum products.

US Pat. No. 10,557,087

METHOD AND SYSTEM FOR UTILIZING MATERIALS OF DIFFERING THERMAL PROPERTIES TO INCREASE FURNACE RUN LENGTH

AMEC FOSTER WHEELER USA C...

1. A method of manufacturing a heater process coil, the method comprising:forming a plurality of straight tubes from a first material;
forming a plurality of return bends from a second material;
joining the plurality of straight tubes to the plurality of return bends;
orienting the plurality of straight tubes and the plurality of return bends within a furnace such that the plurality of straight tubes are at least partially disposed within a heated portion of the furnace and the plurality of return bends are disposed within an unheated portion of the furnace;
wherein the first material exhibits a design-maximum tube-metal temperature greater than the second material; and
wherein the second material is harder than the first material.

US Pat. No. 10,557,086

RESVERATROL-BASED FLAME RETARDANT MATERIALS

International Business Ma...

1. A process of forming a resveratrol-based flame retardant polymer, the process comprising:forming a resveratrol-based flame retardant small molecule via a chemical reaction of a resveratrol molecule with a phosphorus-containing molecule that includes a chloride group and a terminal functional group, the terminal functional group selected from the group consisting of: an allyl group; an epoxide group; a lactone group; an amine group; and a carboxyl group; and
utilizing the resveratrol-based flame retardant small molecule to form a resveratrol-based flame retardant polymer via a chemical reaction of the terminal functional group.

US Pat. No. 10,557,084

ALIGNMENT FILM COMPOSITION, LIQUID CRYSTAL DISPLAY DEVICE, AND METHOD OF MANUFACTURING LIQUID CRYSTAL DISPLAY DEVICE

Samsung Display Co., Ltd....

1. An alignment film composition, comprising:a copolymer of a dianhydride-based compound and a diamine-based compound, the copolymer having a structure represented by Chemical Formula Ia or Chemical Formula Ib in a repetitive unit; and
a cross-linker represented by Chemical Formula IIa or Chemical Formula IIb,
wherein:

wherein:
in Chemical Formula Ia and Chemical Formula Ib, R1 is
and R2 is a divalent alicyclic group;in Chemical Formula Ib, R3 and R4 are each independently hydrogen, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group;
in Chemical Formula IIa and Chemical Formula IIb:
X1 to X4 are each independently any one of a hydroxyl group (—OH), an amino group (—NH2), an epoxy group, an aziridine group, a carbodiimide group, an acrylate group, a methacrylate group, and a vinyl group;
Y1 and Y2 are each independently any one of a single bond, —CO—, —COO—, —OCO—, —S—, —O—, —OOC— —CH2CH2O—, —OCH2CH2—, an aromatic compound of 6 to 30 carbon atoms, and an alicyclic compound of 4 to 20 carbon atoms;
m1 to m4 are each independently an integer of 0 to 6; and
n is an integer of 2 to 18; and
in Chemical Formula IIa, Z1 and Z2 are each independently any one of
R being H or an alkyl group of 1 to 3 carbon atoms, an aromatic compound of 6 to 30 carbon atoms, and an alicylic compound of 4 to 20 carbon atoms.

US Pat. No. 10,557,083

LIQUID CRYSTAL MEDIUM

MERCK PATENT GMBH, Darms...

1. A liquid crystal (LC) medium comprisingone or more polymerisable compounds having two polymerisable groups at a concentration of 0.1 to 0.5% by weight, and
one or more polymerisable compounds having three polymerisable groups at a concentration of 0.01 to 0.1% by weight, which are selected from the following trireactive polymerisable compounds

in which
Sp1, Sp2, Sp3 each, independently of one another, denotes a spacer group or a single bond,
P1, P2, P3 each, independently of one another, denotes a polymerisable group,
and
one or more compounds of the following formulae

wherein
a denotes 1 or 2,
b denotes 0 or 1,

 denotes

R1 and R2 each, independently of one another, denotes alkyl having 1 to 12 C atoms, in which one or two non-adjacent CH2 groups are optionally replaced by —O—, —CH?CH—, —CO—, —OCO— or —COO— in such a way that O atoms are not linked directly to one another,
Zx and Zy each, independently of one another, denotes —CH2CH2—, —CH?CH—, —CF2O—, —OCF2—, —CH2O—, —OCH2—, —CO—O—, —O—CO—, —C2F4—, —CF?CF—, —CH?CH—CH2O— or a single bond,
L1-4 each, independently of one another, denotes F, Cl, OCF3, CF3, CH3, CH2F, or CHF2,
wherein the concentration of the compounds having two polymerisable groups is higher than the concentration of the compounds having three polymerisable groups, and
wherein the LC medium does not contain any unpolymerisable compounds having a terphenyl group.

US Pat. No. 10,557,082

LIQUID CRYSTAL COMPOSITION AND APPLICATION THEREOF

BEIJING BAYI SPACE LCD TE...

1. A liquid crystal composition, comprising, in percentages by weight, 5-40% of one or more compounds represented by general formula I, 2-30% of one or more compounds represented by general formula II, and 20-70% of one or more compounds represented by general formula III,
wherein R1 independently represents a C1-C12 linear alkyl group or a C2-C12 linear alkenyl group; and R2 independently represents a C1-C12 linear alkyl group, a C1-C12 linear alkoxy group or a C2-C12 linear alkenyl group; R4 and R5 each independently represent an unsubstituted C1-C12 linear alkyl group or a C1-C12 linear alkyl group having one or more non-adjacent CH2 substituted with O, S or CH?CH;
X1 independently represents F, CI, CN, a C1-C12 linear alkyl group, a C1-C12 linear alkoxy group or a C2-C12 linear alkenyl group;
Z1 and Z2 each independently represent a single bond or an acetylenic bond, with at least one of Z1and Z2 being an acetylenic bond;
L1 independently represents H or F;
A1, A2 and A3 each independently represent:

A4 independently represents:

A5 and A6 each independently represent a trans-1,4-cyclohexylene group or a 1,4-phenylene group; and m and n each independently represent 0 or 1.

US Pat. No. 10,557,081

LIGHT-CONVERTING MATERIAL

Merck Patent GmbH, Darms...

1. A light-converting material comprising semiconductor nanoparticles and an unactivated crystalline material, where the semiconductor nanoparticles are located on the surface of the unactivated crystalline material,where the unactivated crystalline material is a matrix material of an inorganic phosphor selected from the list consisting of: unactivated crystalline phosphates and halophosphates, unactivated crystalline borates and borosilicates, unactivated crystalline aluminates, gallates and alumosilicates, unactivated crystalline molybdates and tungstates, unactivated crystalline sulfides, selenides and tellurides, unactivated crystalline nitrides and oxynitrides, unactivated crystalline SiAlONs and other unactivated crystalline materials selected from unactivated crystalline complex metal-oxygen compounds, unactivated crystalline oxysulfides or oxychlorides and unactivated crystalline silicates or halosilicates selected from the list consisting of M2+SiO3, M2+2SiO4, M2+2(Si,Ge)O4, M2+3SiO5, M3+2SiO5, M3+M+SiO4, M2+Si2O5, M2+2Si2O6, M2+3Si2O7, M2+2M+2Si2O7, M3+2Si2O7, M2+4Si2O8, M2+2Si3O8, M2+3M3+2Si3O12, M+M3+M2+4Si4O10, M+M2+4M3+Si4O14, M2+3M3+2Si6O18, M3+SiO3X, M2+3SiO4X2, M2+5SiO4X6, M+2M2+2Si4O10X2, M2+5Si4O10X6, M+2SiX6, M2+3SiO3X4 and M2+9(SiO4)4X2; where M+ is one or more alkali metals; M2+ is Zn, Fe, Co, Ni, Cd, Cu and/or one or more alkaline-earth metals; M3+ is Al, Sc, Y, La and/or one or more rare-earth metals selected from Sc, Y, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu; and X is one or more halogens.

US Pat. No. 10,557,080

QUANTUM DOTS, A COMPOSITION OR COMPOSITE INCLUDING THE SAME, AND AN ELECTRONIC DEVICE INCLUDING THE SAME

SAMSUNG DISPLAY CO., LTD....

1. A quantum dot comprising:a semiconductor nanocrystal particle;
a first ligand bound to a surface of the semiconductor nanocrystal particle; and
a second ligand bound to the surface of the semiconductor nanocrystal particle,
wherein the second ligand comprises a compound represented by Chemical Formula 2-1, Chemical Formula 2-2, or Chemical Formula 2-3:
Ra-L-(CRR)nSM  Chemical Formula 2-1RRNCSSM  Chemical Formula 2-3
wherein
Ra includes a substituted or unsubstituted C1 to C24 alkyl group, a substituted or unsubstituted C2 to C24 alkenyl group, and a substituted or unsubstituted C6 to C20 aryl group, R is the same or different, and is each independently hydrogen or a substituted or unsubstituted C1 to C24 alkyl group, n is an integer of 0 to 15, L is a direct bond, a sulfonyl (—S(?O)2—), carbonyl (—C(?O)—), ether group (—O—), sulfide group (—S—), sulfoxide group (—S(?O)—), ester group (—C(?O)O—), amide group (—C(?O)NR—) (wherein R is hydrogen or a C1 to C10 alkyl group), a substituted or a unsubstituted C1 to C10 alkylene, a C2 to C10 alkenylene, or a combination thereof, and M is hydrogen, lithium, sodium, potassium, or a combination thereof
wherein the first ligand comprises a compound represented by Chemical Formula 1:
MAn  Chemical Formula 1
wherein M is Mg, Ca, Zn, Ga, or In, n is determined depending on a valency of the M and is an integer of greater than or equal to 2, each A is the same or different, and is independently a C1 to C10 organic group, a halogen, or a combination thereof, and
wherein the first ligand comprises an organic metal salt, a halogenated metal, a hydrocarbyl metal, a hydrocarbyl metal halide, or a combination thereof,
wherein when a plurality of the quantum dots are included in a composition comprising a binder polymer having a carboxylic acid group and the composition is left at 4° C. for 144 hours, an increase of a viscosity of the composition is less than about 10% with respect to an initial viscosity of the composition.

US Pat. No. 10,557,079

METHOD OF MAKING ROD-SHAPED PARTICLES FOR USE AS PROPPANT AND ANTI-FLOWBACK ADDITIVE

Schlumberger Technology C...

1. A method for forming rod-shaped particles, comprising:(i) inducing flow of a slurry comprised of particles and a reactant through one or more orifices, forming a continuous uninterrupted stream;
(ii) allowing the continuous uninterrupted stream to become submerged in a coagulation solution, wherein the continuous uninterrupted stream forms a continuous rod;
(iii) at least partially coagulating the reactant of the continuous rod in the coagulation solution, wherein the continuous rod is pre-sintered; and
(iv) applying mechanical vibration or using a rotating cutting mechanism to break the pre-sintered continuous rod into rods of reduced length.

US Pat. No. 10,557,076

LOSS CIRCULATION COMPOSITIONS (LCM) HAVING PORTLAND CEMENT CLINKER

Saudi Arabian Oil Company...

1. A lost circulation material (LCM) composition, comprising:Portland cement clinker, wherein the Portland cement clinker consists of non-hydraulic, non-cementiceous unground Portland cement clinker particles;
a carrier fluid, wherein the carrier fluid comprises an aqueous carrier fluid that includes at least one of diutan gum, xanthan gum, and welan gum; and
particulate glass having an aspect ratio greater than 1 or less than 1.

US Pat. No. 10,557,075

OVERCOMING THE RETARDATION OF CEMENT HYDRATION FROM DISPERSING AGENTS USED IN SUSPENSION OF ADDITIVES

Halliburton Energy Servic...

1. A method of making a well cement composition comprising:forming a cement composition comprising:
a cementitious material;
an aqueous base fluid;
combining the cement composition with a nano-reinforcement particle suspension comprising:
a surfactant;
nano-reinforcement particles wherein the nano-reinforcement particles are at least one selected from single wall carbon nano tubes (SWCNT), multi-wall carbon nanotubes (MWCNT), and combinations thereof; and
a pozzolanic material, wherein the pozzolanic material is selected from the group consisting of micro-pozzolanic material, nano-pozzolanic material, and combinations thereof; and wherein the rate of hydration of the surfaces of the cementitious material is less retarded by the surfactant than an equivalent cement composition without pozzolanic material.

US Pat. No. 10,557,073

DRILLING FLUID FOR DOWNHOLE ELECTROCRUSHING DRILLING

Halliburton Energy Servic...

21. An electrocrushing drilling system comprising:a drill string;
an electrocrushing drill bit attached to a distal end of the drill string for fracturing rock in a formation, the electrocrushing drill bit comprising electrodes through which a voltage may be discharged that are at least 0.4 inches apart at their closest spacing; and
an electrocrushing drilling fluid that circulates downhole through the drill string and then moves the fractured rock uphole,
wherein the electrocrushing drilling fluid comprises:
a polar oil, a non-polar oil, or a combination thereof; and
water;
wherein a ratio of oil:water is between 50:50 and 90:10 (v:v), and
wherein the electrocrushing drilling fluid has a dielectric strength of at least 100 kV/cm at 10 microseconds rise time.

US Pat. No. 10,557,072

DRILLING FLUID FOR DOWNHOLE ELECTROCRUSHING DRILLING

Halliburton Energy Servic...

1. An electrocrushing drilling fluid comprising a electrocrushing drilling base fluid comprising:a polar oil, a non-polar oil or a combination thereof; and
glycerine carbonate;
wherein the electrocrushing drilling base fluid has a dielectric constant of at least 6 at 100 kHz frequency; and
wherein the electrocrushing drilling base fluid has an electric conductivity of less than 10?5 mho/cm.

US Pat. No. 10,557,071

NANOSILICA DISPERSION WELL TREATMENT FLUID

Saudi Arabian Oil Company...

1. A method to reduce water production in a treatment zone in carbonate formation, consisting of:introducing a treatment fluid into the wellbore such that the treatment fluid contacts the treatment zone and reduces the water production in the treatment zone, wherein the treatment fluid consists of an acidic nanosilica dispersion, the acidic nanosilica dispersion consisting of amorphous silicon dioxide, water, and acetic acid,
wherein the acidic nanosilica dispersion comprises an initial pH in the range of 2 to 4 before introducing the treatment fluid into the wellbore and an increased pH after the treatment fluid contacts the treatment zone in the carbonate formation,
wherein the treatment fluid forms a gelled solid after contact with the treatment zone in the carbonate formation for a contact period in the range of 0.5 hours to 24 hours.

US Pat. No. 10,557,069

FLUORINATED OLEFINS AS WORKING FLUIDS AND METHODS OF USING SAME

3M Innovative Properties ...

1. A fire extinguishing composition comprising:(a) a compound represented by the following general formula (I):

wherein (i) Rf1 and Rf2 are independently linear or branched perfluoroalkyl groups having with 1-4 carbon atoms and optionally comprise at least one catenated heteroatom, or (ii) Rf1 and Rf2 are bonded together to form a ring structure having 4-6 carbon atoms and optionally comprise one or more catenated heteroatoms;
with the proviso that if Rf1 and Rf2 are bonded together to form a ring structure comprising a nitrogen heteroatom, said nitrogen heteroatom is tertiary and is bonded to a perfluoroalkyl group having 1-3 carbon atoms; and
(b) at least one co-extinguishing agent comprising one or more hydrofluorocarbons, hydrochlorofluorocarbons, perfluorocarbons, perfluoropolyethers, hydrofluoroethers, hydrofluoropolyethers, chlorofluorocarbons, bromofluorocarbons, bromochlorofluorocarbons, iodofluorocarbons, hydrobromofluorocarbons, fluorinated ketones, hydrobromocarbons, fluorinated olefins, hydrofluoroolefins, fluorinated sulfones, fluorinated vinylethers, and mixtures thereof,
wherein (a) and (b) are present in an amount sufficient to suppress or extinguish a fire.

US Pat. No. 10,557,067

ABRASIVE ARTICLE INCLUDING SHAPED ABRASIVE PARTICLES

1. A shaped abrasive particle comprising a body comprising a first major surface, a second major surface, and a side surface extending between the first major surface and the second major surface, wherein the body comprises a two-dimensional shape as viewed in a plane parallel to the first major surface includes a first portion of the side surface having a first curved section between a first linear section and a second linear section, wherein the first linear section terminates at a first external corner of the body and the second linear section terminates at a second external corner of the body, and wherein the first curved section has a first curved section length (Lc1) that is a fraction of a total length of the first portion (Lfp1) of the side surface, further comprising a length factor (Lc1/Lfp1) of not greater than 0.95.

US Pat. No. 10,557,066

ADHESIVE COMPOSITION FOR PHOTOCURABLE INTERFACE AND SURFACE MODIFICATION METHOD OF SUBSTRATE USING THE SAME

Chem Optics Inc., Daejeo...

1. An adhesive composition for photocurable interface comprising:an organic functional silane compound represented by Chemical Formula 1 below,
a silane compound represented by Chemical Formula 2 below, and methoxypropanol:

in Chemical Formula 1,
R1 is C3-C20 alkyl substituted with an organic functional group selected from the group consisting of mercapto, epoxy, methacryloxy, acryloxy, chloro, cyano, ketone, aldehyde, carboxylate, amine, C1-C10 alkylamine, amide, isocyanurate, glycidyloxy and C1-C10 alkylamino, and
R2, R3 and R4 are the same as each other or different from each other, and each independently selected from the group consisting of C1-C10 alkyl, C1-C10 alkyl substituted with C1-C10 alkoxy, and C6-C20 aryl, and

in Chemical Formula 2,
R5, R6, R7, R8, R9 and R10 are each independently selected from the group consisting of C1-C10 alkyl, C1-C10 alkyl substituted with C1-C10 alkoxy, and C6-C20 aryl, and
A is selected from the group consisting of C1-C10 alkylene, and C6-C20 arylene; and
wherein the organic functional silane compound represented by Chemical Formula 1 has 0.01 to 2 wt % of the total composition, and the silane compound represented by Chemical Formula 2 has 0.001 to 0.5 wt % of the total composition.

US Pat. No. 10,557,065

ADHESIVE LAYER-EQUIPPED TRANSPARENT SURFACE MATERIAL, DISPLAY DEVICE AND PROCESSES FOR THEIR PRODUCTION

AGC Inc., Chiyoda-ku (JP...

1. An adhesive layer comprising:a cured product of a composition which comprises a curable component and a non-curable oligomer,
wherein:
the curable component comprises a curable oligomer which comprises a curable group and a urethane bond,
the non-curable oligomer comprises a hydroxy group and does not undergo a curing reaction with the curable component,
the non-curable oligomer has a number average molecular weight per one hydroxy group of from 400 to 8,000,
the number of hydroxy groups per one molecule of the non-curable oligomer is from 1.8 to 3,
the curable oligomer and the non-curable oligomer comprise:
a same repeating unit comprising a polyoxyalkylene structure; or
repeating units derived from a same monomer comprising a polyoxyalkylene structure,
a content of the non-curable oligomer is from 10 to 70 mass % in a total of the composition, and
the adhesive layer has a shear modulus at 35° C. of from 0.5 to 100 kPa.

US Pat. No. 10,557,062

COMPOSITION FOR FORMING ADHESIVE LAYER, ADHESIVE LAYER, MANUFACTURING METHOD FOR ADHESIVE LAYER, COMPOSITE MATERIAL, SHEET, HEAT DISSIPATION MEMBER, ELECTRONIC DEVICE, BATTERY, CAPACITOR, AUTOMOBILE COMPONENT AND MACHINE MECHANISM COMPONENT

JNC CORPORATION, Tokyo (...

1. A composition for forming an adhesive layer, comprising a polyvinyl acetal resin and a compound having an oxazoline group, wherein the compound having the oxazoline group is contained in an amount of 0.1 to 1 part by mass based on 1 part by mass of the polyvinyl acetal resin, andwherein the polyvinyl acetal resin comprises constitutional units A, B and C:
wherein, in constitutional unit A, R is independently hydrogen;

US Pat. No. 10,557,061

ADHESIVE TAPE

DIC CORPORATION, Tokyo (...

1. An adhesive tape for portable electronic devices comprising:a foam base; and
an adhesive layer disposed on at least one surface of the foam base, wherein
an average bubble diameter in a machine direction and an average bubble diameter in a cross-machine direction of the foam base are each 150 ?m or less,
a ratio represented by the average bubble diameter in the machine direction/an average bubble diameter in a vertical direction and a ratio represented by the average bubble diameter in the cross-machine direction/the average bubble diameter in the vertical direction are each 6 or less,
the foam base has an interlaminar strength of 20 N/cm to 150 N/cm,
the foam base has a 25% compressive strength of 80 kPa or more and a thickness of 150 ?m to 1,000 ?m,
the adhesive layer includes an acrylic copolymer and 18.8 parts to 60 parts by mass of a tackifier resin based on 100 parts by mass of the acrylic copolymer, and
the acrylic polymer is prepared from 80-98.5 mass % of a (meth) acrylate having 1 to 12 carbon atoms.

US Pat. No. 10,557,058

POLISHING AGENT, POLISHING AGENT SET, AND SUBSTRATE POLISHING METHOD

HITACHI CHEMICAL COMPANY,...

6. A polishing method for a base substrate, comprising a step of polishing a surface to be polished of a base substrate using a polishing agent obtained by mixing the first liquid and the second liquid of the polishing agent set according to claim 5.

US Pat. No. 10,557,056

ABS/POLYCARBONATE/POLY(STYRENE-CO-MALEIMIDE) PART MATERIAL FOR ELECTROPHOTOGRAPHY-BASED ADDITIVE MANUFACTURING

Evolve Additive Solutions...

1. A part material for printing three-dimensional parts with an electrophotography-based additive manufacturing system, the part material comprising:a composition comprising:
a grafted polymer comprising acrylonitrile units, butadiene units, aromatic units, polycarbonate and poly(styrene-co-maleimide);
a charge control agent; and
a heat absorber;
wherein the part material is provided in a powder form having a D50 particle size ranging from about 5 micrometers to about 30 micrometers; and
wherein the part material is configured for use in the electrophotography-based additive manufacturing system having a layer transfusion assembly for printing the three-dimensional parts in a layer-by-layer manner.

US Pat. No. 10,557,054

AZLACTONE BASED THERMALLY CROSSLINKABLE POLYMER COATING FOR CONTROLLING CELL BEHAVIOR

Wisconsin Alumni Research...

1. A random copolymer of glycidyl methacrylate, 4,4-dimethyl-2-vinylazlactone and polyethylene glycol methyl ether methacrylate comprising the structure:wherein x, y and z represent the mole fractions of the polymerized glycidyl methacrylate, 4,4-dimethyl-2-vinylazlactone and polyethylene glycol methyl ether methacrylate monomers; n represents the number of repeat units in the polyethylene glycol chain; the glycidyl groups, the azlactone groups and the polyethylene glycol groups are distributed randomly along the copolymer backbone chain; and the random copolymer comprises from about 1 to about 15 mole percent of the polymerized glycidyl methacrylate monomer, from about 15 to about 60 mole percent of the polymerized 4,4-dimethyl-2-vinylazlactone monomer, from about 30 to about 85 mole percent of the polymerized polyethylene glycol methyl ether methacrylate monomer, and no greater than about 30 mole percent of additional monomer.

US Pat. No. 10,557,052

INK SET AND RECORDING METHOD

Seiko Epson Corporation, ...

1. An ink set comprising:two ink jet ink compositions comprising a first ink composition containing a resin and a second ink composition containing a wax; and
a coagulant solution containing a coagulant for a component of at least one of the first ink composition and the second ink composition,
wherein the resin has a greater aggregability than the wax,
the resin in the first ink composition is present in an amount, on a solid basis, that is 0.5% by mass or more and 15% by mass or less of a total amount of the first ink composition, and the wax in the second ink composition is present in an amount, on a solid basis, that is 0.5% by mass or more and 15% by mass or less of a total amount of the second ink composition.

US Pat. No. 10,557,050

METALLIC IMAGE FORMING METHOD

Canon Kabushiki Kaisha, ...

1. A metallic image forming method for forming an image having a metallic hue derived from an organic coloring agent, the method comprising:preparing a metallic ink containing the organic coloring agent,
preparing a recording medium provided with an undercoat layer thereon having (i) a black color for absorbing diffusion light of the metal particles or (ii) an opposite color to the color of diffused light from the organic coloring agent for cancelling the diffusion light of the organic coloring agent, and
printing with the metallic ink onto the recording medium so as to cover at least part of the undercoat layer,
wherein the undercoat layer has the opposite color to the color of diffused light from the organic coloring agent, and
wherein the ink having the opposite color to the color of the diffusion light from the organic coloring agent contains a coloring material capable of exhibiting the opposite color to the color of diffused light from the organic coloring agent.

US Pat. No. 10,557,049

AQUEOUS DISPERSION, METHOD FOR MANUFACTURING THE SAME, AND IMAGE FORMING METHOD

FUJIFILM CORPORATION, To...

1. An aqueous dispersion comprising:a microcapsule that contains a core and a shell;
a dispersant that is at least one of a carboxylic acid (A) represented by Formula (A) or a salt of the carboxylic acid (A); and
water,

wherein, in Formula (A), L represents a divalent linking group, X represents O, NH, or, NR2, R1 represents a hydrocarbon group having 9 or more carbon atoms, R2 represents a hydrocarbon group having 1 to 20 carbon atoms, and n represents 0 or 1, and
wherein the shell has a three-dimensional cross-linked structure containing at least one bond selected from a urethane bond or a urea bond.

US Pat. No. 10,557,047

GA-NAPHTHALOCYANINE CHROMOPHORES WITH SHORT CHAIN ALKOXY AXIAL SUBSTITUENTS

BASF SE, Ludwigshafen (D...

1. A printing ink formulation, comprising:at least one compound of the formula (I)

wherein R is C1-C6alkyl.

US Pat. No. 10,557,046

FILM-FORMING INK, FILM FORMATION METHOD, DEVICE WITH FILM, AND ELECTRONIC APPARATUS

SEIKO EPSON CORPORATION, ...

1. A film-forming ink comprising:a film-forming material; and
a liquid medium in which the film-forming material is dissolved or dispersed,
wherein the liquid medium contains a first component which has a boiling point at an atmospheric pressure of 250° C. or higher and 298° C. or lower, and a second component which has a boiling point at an atmospheric pressure lower than the first component, and
a content of the second component with respect to a total amount of the film-forming ink is 5.0 wt % or more and 30 wt % or less.

US Pat. No. 10,557,044

SLIPPERY ANTI-FOULING SURFACES FABRICATED FROM REACTIVE POLYMER MULTILAYERS

Wisconsin Alumni Research...

19. A slippery liquid-infused porous surface (SLIPS) multilayer film comprising:a) a multilayer film comprising one or more bilayers, wherein each bilayer comprises a first polymer layer in contact with a second polymer layer, where the multilayer film has nanoscale or microscale porosity and at least a portion of the multilayer film is functionalized to be hydrophobic; and
b) a hydrophobic oil selected from the group consisting of a silicone oil, a vegetable oil, a mineral oil, a thermotropic liquid crystal, and combinations thereof, wherein said oil coats at least the functionalized portion of the multilayer film and said oil at least partially fills the pores of at least the functionalized portion of the multilayer film.

US Pat. No. 10,557,029

AUTOMOTIVE INTERIOR AND EXTERIOR MEMBER

MAZDA MOTOR CORPORATION, ...

1. An automotive interior and exterior member comprising a polycarbonate resin composition,wherein the polycarbonate resin composition contains polycarbonate resin which is a composite including a plurality of carbonate copolymers each (i) including a structural unit (an ISB unit) derived from a dihydroxy compound represented by a general formula (1) below and a structural unit (a CHDM unit) derived from cyclohexanedimethanol and (ii) having a different copolymerization ratio,
the ISB unit and the CHDM unit in the polycarbonate resin are contained in a molar ratio ranging from 67/33 to 69/31 (molar ratio),
in the polycarbonate resin composition, (i) 4.9 parts by weight to 5.1 parts by weight of butyl acrylate-methyl methacrylate-styrene based rubber and (ii) components (A) to (H) in contents below are contained with respect to a total 100 parts by weight of the polycarbonate resin and the butyl acrylate-methyl methacrylate-styrene based rubber:
a component (A) containing 0.09 parts by weight to 0.11 parts by weight of a hindered phenol based antioxidant having a molecular weight ranging from 1100 to 1200;
a component (B) containing 0.001 parts by weight to 0.015 parts by weight of dibutylhydroxytoluene;
a component (C) containing 0.049 parts by weight to 0.051 parts by weight of 1,1,3-tris-(2-methyl-4-hydroxy-5-t-butylphenyl) butane;
a component (D) containing 0.049 parts by weight to 0.051 parts by weight of tris (2,4-di-t-butylphenyl) phosphite;
a component (E) containing 0.19 parts by weight to 0.21 parts by weight of bis (2,4-di-t-butylphenyl) pentaerythritol-diphosphite;
a component (F) containing 0.29 parts by weight to 0.31 parts by weight of a benzotriazole based weathering stabilizer having a melting point ranging from 102° C. to 106° C.;
a component (G) containing 0.09 parts by weight to 0.11 parts by weight of a hindered amine based weathering stabilizer having a melting point ranging from 125° C. to 130° C.; and
a component (H) containing 0.05 parts by weight to 0.07 parts by weight of perinone based colorant having a melting point ranging from 252° C. to 258° C.

US Pat. No. 10,557,028

FILLED POLYOLEFIN COMPOSITION

Basell Poliolefine Italia...

1. A polyolefin composition comprising:(A) from 97.0 to 45.0 wt % of a propylene-1-hexene random copolymer,
(B) from 2.0 to 50.0 wt % of fibers, and
(Q) from 0.3 wt % to 5.0 wt % of a compatibilizer,
the sum (A)+(B)+(Q) being 100,
wherein
(i) the copolymer has a content of 1-hexene derived units ranging from 0.6 wt % to 3.0 wt % with respect to the copolymer,
(ii) the copolymer has the melt flow rate (MFR) measured according to the method ISO 1133 (230° C., 2.16 kg) ranging from 0.2 up to 40 g/10min,
(iii) the fibers are selected from the group consisting of glass fibers, carbon fibers, metal fibers, mineral fibers and ceramic fibers.

US Pat. No. 10,557,024

SUSTAINABLE INJECTION MOLDED ARTICLES

Kimberly-Clark Worldwide,...

1. A thermoplastic material comprising:30 to 70 parts by weight of 100% virgin polymer selected from the group consisting of polypropylene, polyethylene, polystyrene, acrylonitrile-butadiene-styrene copolymers, polylactic acid, blends of polylactic acid and polyolefins and combinations thereof; and
the remaining parts by weight of a post-industrial-recycled material (PIR), wherein the PIR comprises a spun-bonded laminate comprising a thermoplastic polyolefin elastomer and a spunbonded fiber layer or an adhesive spun-bond film laminate comprising a polyolefin film layer and a spunbonded fiber layer.

US Pat. No. 10,557,022

HIGH-PERFORMANCE TIRE

PIRELLI TYRE S.P.A., Mil...

1. A tire for vehicle wheels comprising:a carcass structure; and
a tread band applied in radially outer position with respect to said carcass structure;wherein said tread band comprises a crosslinked elastomeric material obtained by crosslinking a crosslinkable elastomeric composition, wherein said elastomeric composition comprises at least a (iso-styrene/trans-butadiene):diene-terminated copolymer.

US Pat. No. 10,557,020

RENEWABLE AND COST-EFFECTIVE FILLERS FOR POLYMERIC MATERIALS

KING ABDULAZIZ CITY FOR S...

1. A process of preparing a reinforced polymer composite having a fibril melt fracture surface, comprising:blending a mixture of date pit particulate having an average size of between about 0.25 mm and 1.0 mm with a thermoplastic polymer that is high density polyethylene;
melting the mixture;
blending a coupling agent of di-phenylmethane with the melted mixture; and
forcing the melted mixture through a melt extruder to produce the reinforced polymer composite having the fibril melt fracture surface,
wherein the reinforced polymer composite has a tensile strength varying no more than about 10% from that of the thermoplastic polymer.

US Pat. No. 10,557,019

CARBON FIBER-REINFORCED POLYMER COMPOSITE AND METHOD OF PREPARING THE SAME

Hyundai Motor Company, S...

14. The method of claim 8, wherein the carbon fibers are modified by steps comprising:dissolving the block copolymer in a second solvent having a polarity of about 2.4 to 9.0 to form a polymer solution;
spraying the polymer solution on surfaces of the carbon fibers; and
mixing the carbon fibers with the solution at a temperature of about 70° C. to 90° C. for about 2 to 4 hours.

US Pat. No. 10,557,017

METHOD OF DECREASING ALDEHYDE CONTENT IN A POLYMERIC MATERIAL

Colormatrix Holdings, Inc...

1. A method of decreasing aldehyde content in a polymeric material, the method comprises the step of contacting the polymeric material with a compound (A) which includes:(I) a first fragment which comprises a moiety

and a moiety
NH  (B)
wherein the carbon atom of moiety (A) and the nitrogen atom of moiety (B) are separated by at least one and not more than two atoms;
(II) a second fragment which comprises a moiety

and a moiety
NH  (B)
wherein the carbon atom of moiety (A) and the nitrogen atom of moiety (B) are separated by at least one and not more than two atoms; and
(III) a third fragment which comprises a moiety

and a moiety
NH  (B).

US Pat. No. 10,557,016

FLAME RETARDANT RESIN COMPOSITION AND METHOD FOR PRODUCING THE SAME

Toyota Shatai Kabushiki K...

1. A flame retardant resin composition comprising:a thermoplastic resin;
flame retardant reinforced fibers dispersed in the thermoplastic resin; and
a flame retardant,
wherein the flame retardant reinforced fibers include cellulosic fibers, a phosphorus compound that is grafted to a surface of the cellulosic fibers, and a polyamine compound that is bound to the phosphorous compound,
the flame retardant reinforced fibers have an average fiber length of 1 to 25 mm, and
the flame retardant is a phosphorus-based flame retardant, and
the flame retardant resin composition has flame resistance of V-0 or higher in accordance with the UL-94 standard without the presence of a drip inhibitor.

US Pat. No. 10,557,014

COMPOSITE MATERIALS INCLUDING INORGANIC FULLERENE-LIKE PARTICLES AND INORGANIC TUBULAR-LIKE PARTICLES IN A POLYMER MATRIX

NANOTECH INDUSTRIAL SOLUT...

1. A composite comprising:a dispersed phase of an inorganic material of a metal chalcogenide composition with a fullerene like or tubular-like geometry having a diameter ranging from 1 nm to 300 nm that is present in a polymeric matrix, wherein the inorganic material of the metal chalcogenide has a molecular formula MX2, where M is a metallic element selected from the group consisting of titanium (Ti), vanadium (V), chromium (Cr), manganese (Mn), iron (Fe), cobalt (Co), nickel (Ni), copper (Cu), zinc (Zn), zirconium (Zr), niobium (Nb), molybdenum (Mo), technetium (Tc), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), cadmium (Cd), hafnium (Hf), tantalum (Ta), tungsten (W), rhenium (Re), osmium (Os), iridium (Ir), platinum (Pt), gold (Au), mercury (Hg) and combinations thereof, and X is a chalcogen element selected from the group consisting of sulfur (S), selenium (Se), tellurium (Te), oxygen (O) and combinations thereof, the fullerene like or tubular-like geometry being a multilayered structure having an outer layer comprising at least one sectioned portion, the at least one sectioned portion extending along a direction away from the curvature of the multilayered structure, the at least one sectioned portion engaged to a remaining section of the outer layer, the composite being a structural molded or extruded product having a rigid body, wherein the matrix providing a majority by volume of the rigid body for the structural molded or extruded product, the composite including at least one friction surface, wherein the friction surface making sliding contact in a friction event provides for exfoliating inorganic material of the metal chalcogenide composition with the fullerene like or the tubular-like geometry providing lubricating material, wherein as the friction surface wears additional amounts of the dispersed phase of the fullerene like or tubular-like geometry are exposed and additional amounts of said lubricating material is provided to contribute to a tribofilm lubricating layer on the friction surface from the at least one sectioned portion of the dispersed phase multilayered structure that are present at the friction surface of the composite.

US Pat. No. 10,557,011

METHODS FOR THE DECOMPOSITION OF CONTAMINATED PLASTIC WASTE

BioCellection Inc., Menl...

1. A method for decomposing polyethylene, comprising:a. adding polyethylene to a reaction vessel;
b. adding aqueous nitric acid (HNO3) to the reaction vessel to give a mixture, wherein the wt. ratio of polyethylene to aqueous nitric acid is greater than 1:10; and
c. subjecting the mixture obtained in b. to conditions effective to decompose the polyethylene to produce decomposition products, wherein the decomposition products comprise:
i. succinic acid, glutaric acid, adipic acid, pimelic acid, and azelaic acid, or the salts and esters thereof;
ii. at least one of oxalic acid, suberic acid, sebacic acid, undecanedioic acid, dodecanedioic acid, tridecanedioic acid, tetradecanedioic acid, pentadecanedioic acid, 2-octenedioic acid, 2-nonenedioic acid, 2-decenedioic acid, and 2-undecenedioic acid, or the salts or esters thereof; and
iii. at least one of C8-C20 dicarboxylic acid substituted with a single nitro group at the 2-position, or the salts or esters thereof.

US Pat. No. 10,557,010

ACETALDEHYDE SCAVENGER TREATMENT

Ford Motor Company, Dear...

1. A method of reducing aldehyde concentration in a vehicle cabin air, the method comprising:applying a solution comprising aldehyde scavenger(s) onto an outer surface of a foam article located or to be located within a vehicle cabin to form a top layer of the article such that aldehyde species are trapped within the article and prevented from being released into the cabin air, the scavenger(s) having cyclical structures configured to form inclusion complexes with the aldehyde species present in the foam article such that aldehyde enters internal cavities of the scavenger(s) to be encapsulated into the structure of the scavenger(s).

US Pat. No. 10,557,009

THERMALLY EXPANDABLE MICROCAPSULE COMPLEX, METHOD FOR MANUFACTURING SAME, RUBBER COMPOSITION IN WHICH COMPLEX IS BLENDED, AND PNEUMATIC TIRE USING COMPOSITION

The Yokohama Rubber Co., ...

1. A rubber composition, comprising:from 1 to 30 parts by mass of a thermally expandable microcapsule complex per 100 parts by mass of a rubber component, the thermally expandable microcapsule complex having a structure comprising a plurality of thermally expandable microcapsules adhered on cellulose fibers, wherein the thermally expandable microcapsule complex has a structure comprising a plurality of the thermally expandable microcapsules connected in a thread-like, band-like, or clustered manner on the cellulose fibers, the cellulose fibers being cellulose microfibrils.

US Pat. No. 10,557,008

POROUS MATERIALS AND METHOD OF MAKING POROUS MATERIALS

International Business Ma...

1. A method, comprising:forming a mixture comprising: i) trifunctional ethynyl monomer, ii) a polythioaminal, and iii) a solvent;
heating the mixture to a first temperature at which the trifunctional ethynyl monomer polymerizes to a first resin and the polythioaminal is substantially stable; and
heating the mixture to a second temperature at which the first resin further polymerizes to a second resin that is a crosslinked resin and the polythioaminal decomposes, the second temperature being higher than the first temperature.

US Pat. No. 10,557,007

FLAME RETARDANT, COMPOSITE FLAME RETARDANT, FLAME RETARDANT ANTISTATIC COMPOSITION AND FLAME RESISTANT METHOD

1. A composite flame retardant, comprising a flame retardant comprising a complex of phosphine oxide and transition metal salt, and an inorganic flame retardant component, wherein the weight ratio of said complex to said inorganic flame retardant component is (2-5):1.

US Pat. No. 10,557,006

COMPOSITION, AND METHOD FOR PRODUCING FOAM MOLDED MATERIAL AND ELECTRIC WIRE

DAIKIN INDUSTRIES, LTD., ...

1. A composition comprising:a fluororesin (A);
boron nitride having an average particle size of 13.0 ?m or greater; and
a compound (B) which is a barium salt, potassium salt, sodium salt, or rubidium salt of a sulfonic acid, the sulfonic acid being represented by the following formula (1):
F(CF2)nSO3H  (1)
wherein n is 4, or the following formula (2):
F(CF2)nCH2CH2SO3H  (2)
wherein n is 4,
wherein the amount of the barium salt is 1000 ppm or less based on the amount of the fluororesin (A),
wherein the amount of the potassium salt is 2000 ppm or less based on the amount of the fluororesin (A),
wherein the amount of the sodium salt is 250 ppm or less based on the amount of the fluororesin (A), and
wherein the amount of the rubidium salt is 250 ppm or less based on the amount of the fluororesin (A).

US Pat. No. 10,557,004

LONG FILM

ZEON CORPORATION, Chiyod...

1. A long-length film comprising a plurality of knurl portions shaped by continuous linear concavo-convex portions on at least one surface thereof, whereinthe plurality of knurl portions are aligned in a lengthwise direction of the long-length film,
a planar shape of the knurl portion seen from a thickness direction of the long-length film includes:
10 or more corners having a curvature radius of 0.3 mm or less and an angle of 100° or less or a curvature radius of 0.2 mm or less and an angle of 120° or less, per one planar shape of the knurl portion; and
18 or more straight portions having a straight shape, per one planar shape of the knurl portion.

US Pat. No. 10,557,003

POLYIMIDE RESIN COMPOSITION

MITSUBISHI GAS CHEMICAL C...

1. A polyimide resin composition comprising:a polyimide resin produced by reactants consisting of (A) a tetracarboxylic dianhydride and (B) a diamine; and
silica microparticles,
in a ratio by mass of from 25/75 to 60/40;
wherein the tetracarboxylic dianhydride (A) consists of at least one cycloalkanetetracarboxylic dianhydride; and
wherein the diamine (B) consists of from 10 to 90 mol % of a phenolic hydroxyl group-containing diamine represented by the following formula (1) and from 10 to 90 mol % of a diamine other than the phenolic hydroxyl group-containing diamine;
wherein, in the formula, X1 represents a direct bond, —CH2—, —O—, —S—, —SO2—, —CONH—, —CO—, or —C(CH3)2—; andwherein the diamine other than the phenolic hydroxyl group-containing diamine consists of 2,2?-bis(trifluoromethyl)benzidine, 4,4?-bis(4-aminophenoxy)biphenyl, or a combination of 2,2?-bis(trifluoromethyl)benzidine and 4,4?-diaminodiphenyl ether.

US Pat. No. 10,557,002

RESIN COMPOSITION FOR FIBER-REINFORCED PLASTIC, CURED PRODUCT THEREOF, FIBER-REINFORCED PLASTIC CONTAINING SAID CURED PRODUCT, AND METHOD FOR PRODUCING FIBER-REINFORCED PLASTIC

ADEKA CORPORATION, Tokyo...

10. A high-strength fiber-reinforced plastic obtained by curing the composition which uniformly contains the resin composition for fiber reinforced plastic according to claim 1 and a reinforcement fiber.

US Pat. No. 10,557,001

COMPOSITE MATERIAL AND RESIN COMPOSITION CONTAINING METASTABLE PARTICLES

CYTEC INDUSTRIES INC., P...

1. A fiber-reinforced polymeric composite material comprising:two or more layers of reinforcement fibers impregnated or infused with a curable thermoset matrix resin;
metastable thermoplastic particles positioned between adjacent layers of reinforcement fibers,
wherein the metastable thermoplastic particles are particles of semi-crystalline thermoplastic material with an amorphous polymer fraction that will undergo crystallization when the particles are heated to a crystallization temperature Tc.

US Pat. No. 10,557,000

METHOD FOR PREPARING OBLATE POLYMER PARTICLE

1. A method for preparing oblate polymer particles, comprising the steps of:(A) preparing spherical polymer particles;
(B) preparing a polymer film including the spherical polymer particles;
(C) adhering polymer sheets to both sides of the polymer film to form a multi-layer structure;
(D) heating the multi-layer structure to a temperature equal to or higher than the highest temperature of the respective glass transition temperatures of the polymer particle, the polymer film, and the polymer sheets, and lower than the lowest temperature of the respective melting temperatures thereof;
(E) squeezing in a direction perpendicular to each polymer sheet and toward the polymer film of the multi-layer structure to deform the polymer particles into an oblate shape; and
(F) dissolving the polymer film in a solvent to obtain the polymer particles of oblate shape.

US Pat. No. 10,556,998

ANTIOXIDANT STABILIZED CROSSLINKED ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE FOR MEDICAL DEVICE APPLICATIONS

Zimmer, Inc., Warsaw, IN...

1. A method of preparing an antioxidant-stabilized crosslinked UHMWPE blend for use in medical implants, the method comprising:preheating a consolidated blend to a preheat temperature greater than room temperature and below the melting point of the consolidated blend, the consolidated blend comprising UHMWPE and antioxidant; and
irradiating the preheated consolidated blend while maintaining the consolidated blend at a temperature below the melting point of the consolidated blend to form the antioxidant-stabilized crosslinked UHMWPE blend, wherein the irradiating is electron beam irradiating performed in a single pass;
wherein the crosslinked UHMWPE blend has a pin-on-disc wear rate of about 0.02 n g/Mc to about 0.69 mg/Mc.

US Pat. No. 10,556,996

METHOD FOR PREPARING A SOLUTION OF A SULFONATED POLYMER AND AN AMINO-PHOSPHONIC ACID IN AN APROTIC SOLVENT

1. A method for preparing a solution of sulfonated polymer and a phosphonic acid, comprising:dissolving the sulfonated polymer in an aprotic solvent; and
adding the phosphonic acid into the solution, wherein the phosphonic acid comprises a basic phosphonic acid that accepts a proton.

US Pat. No. 10,556,994

STRICTLY SEGMENTED THERMOPLASTIC ELASTOMERS AS BIODEGRADABLE BIOMATERIALS

SYMO-CHEM B.V., Eindhove...

1. A thermoplastic elastomer according to the formula [AB]n, wherein:n represents the number of repeats of the AB segment and is an integer of 2 to 100;
A represents a soft block according to formula (I):

B represents a hard block according to formula (II-A) or formula (II-B):

wherein:
every soft block A in the formula [AB]n is the same soft block A and every hard block B in the formula [AB]n is the same hard block B;
the morphology of the [AB]n material is characterized by displaying a Tg for the soft block A;
K is independently selected from C1-C36 alkylene groups, C6-C24 arylene groups, C7-C24 alkarylene groups, and C7-C24 arylalkylene groups, wherein at least one K is a C1-C36 alkylene group;
L is independently selected from a C1-C36 alkylene group, a C6-C24 arylene group, a C7-C24 alkarylene group or a C7-C24 arylalkylene group or L is absent;
M is independently selected from a C1-C36 alkylene group, a C6-C24 arylene group, a C7-C24 alkarylene group or a C7-C24 arylalkylene group or M is absent;
o, p, q, r, s and t are independently 0-50;
provided that:
(a) when o, q, r and t are 0, then p and s are independently 1-50;
(b) when p and s are 0, then o, q, r and t are independently 1-50;
(c) when o and t are 0, then p, q, r and s are independently 1-50;
(d) when q and r are 0, then o, p, s and t are independently 1-50;
HBG is a simple hydrogen bonding unit independently selected from the group consisting of amide, urea and urethane groups;
S is independently selected from a C1-C36 alkylene group, a C6-C24 arylene group, a C7-C24 alkarylene group or a C7-C24 arylalkylene group or, and only if B represents a hard block according to the formula (II-A), S can also be absent so that it represents a bond between two HBGs;
R is hydrogen, a C1-C24 alkyl group, a C6-C24 aryl group, a C7-C24 alkaryl group or a C7-C24 arylalkyl group;
x is 1, 2 or 3; and
y is 0 or 1.

US Pat. No. 10,556,992

METHOD OF MANUFACTURING POLYARYLENE SULFIDE, AND POLYARYLENE

KUREHA CORPORATION, Toky...

1. A method of manufacturing polyarylene sulfide, comprising:(a) a washing step of mixing a solvent containing water with a raw material mixture that contains polyarylene sulfide and an organic amide solvent to obtain a dispersion, dissolving the organic amide solvent in the solvent containing water, and then washing the polyarylene sulfide;
(b) a separating step of solid-liquid separating the dispersion in the washing step to obtain a separated liquid;
(c) a distilling step of separating the separated liquid into distilled vapor containing a solvent containing water having a smaller amount of the organic amide solvent, and recovered liquid containing a solvent containing water having a larger amount of the organic amide solvent by heating the separated liquid obtained in the separating step;
(d) an organic amide solvent concentrating step of distilling the recovered liquid to obtain a concentrated liquid containing a solvent with an even higher amount of the organic amide solvent,
wherein
heating in the distilling step is performed utilizing an increase in temperature based on compressing the distilled vapor and/or an increase in temperature based on compressing a heat medium heat-exchanged with the distilled vapor,
a distilled liquid containing a condensate of the distilled vapor is used as the solvent containing water in the washing step,
the raw material mixture is obtained through a preliminary washing step of mixing polyarylene sulfide or mixture containing polyarylene sulfide with a washing liquid containing an organic amide solvent to obtain a dispersion, and then washing the polyarylene sulfide, and
a ratio of the organic amide solvent in the concentrated liquid obtained in the organic amide solvent concentrating step is from 90 to 100 mass %.

US Pat. No. 10,556,991

BENZOXAZINE AND PHTHALONITRILE RESIN BLENDS

3M Innovative Properties ...

1. A resin blend comprising a blend of a benzoxazine resin and a phthalonitrile resin, wherein the benzoxazine resin is of Formula I or Formula II:
wherein
each R1 is H or an alkyl group, and is the residue of an aliphatic aldehyde,
R2 is a covalent bond, or a polyvalent (hetero)hydrocarbyl group;
R3 and R4 are independently selected from the (hetero)hydrocarbyl residues of a primary amino compound; and
z is at least 1;
with the proviso that neither R3 nor R4 is of Formula III:
where R is selected from a covalent bond, a C4-C20 alkyl chain, —NH, a phenol, biphenol, bisphenol, a polyvalent phenol, an imide, an ether, a thioether, amide, ester, or a polyvalent (hetero)hydrocarbyl residue;
wherein
each R1 is H or an alkyl group, and is the residue of an aliphatic aldehyde,
R2 is H, a covalent bond, a phenol or a polyvalent (hetero)hydrocarbyl group;
R4 is a (hetero)hydrocarbyl residue of a primary amino compound, R4(NH2)m, with the proviso that R4 is not of Formula III above;
where when R4 is an aryl group, m is 1-4; and x is at least 1; andwherein the phthalonitrile resin is of Formula IV:
where R? is selected from H, a covalent bond, —C(CH3)3, a C4-C20 alkyl chain, —NO2, —NH2, a phenol, biphenol, bisphenol, a polyvalent phenol, an imide, an ether, a thioether, amide, ester, a polyvalent (hetero)hydrocarbyl residue; and y is at least 1;
with the proviso that R? is not of Formula V or Formula VI:

wherein
each R1 is H or an alkyl group, and is the residue of an aliphatic aldehyde,
R2 is a covalent bond, or a polyvalent (hetero)hydrocarbyl group;
R3 and R4 are independently selected from the (hetero)hydrocarbyl residues of a primary amino compound; and

wherein
each R1 is H or an alkyl group, and is the residue of an aliphatic aldehyde,
R2 is H, a covalent bond, a phenol or a polyvalent (hetero)hydrocarbyl group;
R4 is a (hetero)hydrocarbyl residue of a primary amino compound, R4(NH2)m, where when R4 is an aryl group, m is 1-4; and x is at least 1.

US Pat. No. 10,556,990

POROUS/NANOPOROUS PHT

International Business Ma...

1. An article comprising a porous polymer having a plurality of hexahydrotriazine units, a plurality of hemiaminal units, or a combination thereof, the porous polymer having an average pore size less than about 100 nm and density less than about 1.5 g/cm3, wherein:each hexahydrotriazine unit has the general structure

each hemiaminal unit has the general structure
wherein at least one starred bond of each hexahydrotriazine unit or hemiaminal unit is bonded to a divalent bridging group or a trivalent bridging group, andthe divalent bridging group or a trivalent bridging group is bonded to at least two hexahydrotriazine units or hemiaminal units.

US Pat. No. 10,556,988

CATALYSTS

ECONIC TECHNOLOGIES LTD, ...

1. A catalyst comprising one of the following:

US Pat. No. 10,556,987

POLYCARBONATE RESIN

MITSUBISHI GAS CHEMICAL C...

1. A method for adjusting a total volume of oligomers represented by Formulae (1)-(4) below contained in a polycarbonate resin to be 2.5 wt % or less, wherein the polycarbonate resin contains a repeating unit represented by Formula (A) below in an amount of 1-99.5 wt %:
(in Formula (A), R1 and R2 each independently represent a hydrogen atom, a phenyl group, a C1-6 alkyl group or a C1-6 alkyloxy group)

(in Formula (1), R1 and R2 each independently represent a hydrogen atom, a phenyl group, a C1-6 alkyl group or a C1-6 alkyloxy group, and n represents an integer of 1-4)

(in Formula (2), R1 and R2 each independently represent a hydrogen atom, a phenyl group, a C1-6 alkyl group or a C1-6 alkyloxy group, and m represents an integer or 1-6)

(in Formula (3), R1 and R2 each independently represent a hydrogen atom, a phenyl group, a C1-6 alkyl group or a C1-6 alkyloxy group, and l represents an integer of 1-5)

(in Formula (4), R1 and R2 each independently represent a hydrogen atom, a phenyl group, a C1-6 alkyl group or a C1-6 alkyloxy group, and k represents an integer of 2-4).

US Pat. No. 10,556,986

POLYMER, ORGANIC LAYER COMPOSITION, AND METHOD OF FORMING PATTERNS

SAMSUNG SDI CO., LTD., Y...

1. A polymer comprising a structural unit represented by Chemical Formula 1:
wherein, in Chemical Formula 1,
A1 and A2 are independently a substituted or unsubstituted aromatic ring group, or a substituted or unsubstituted heteroaromatic ring group,
B is a divalent organic group,
X is O, S, Te, Se, or NRa, wherein Ra is hydrogen, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, a substituted or unsubstituted C7 to C30 arylalkyl group, a substituted or unsubstituted C1 to C30 heteroalkyl group, a substituted or unsubstituted C2 to C30 heterocycloalkyl group, a substituted or unsubstituted C2 to C30 heterocyclic group, a substituted or unsubstituted C2 to C30 alkenyl group, a substituted or unsubstituted C2 to C30 alkynyl group, a hydroxy group, a halogen atom, a halogen-containing group, or a combination thereof,
Y is a substituted or unsubstituted C6 to C30 aryl group, or a substituted or unsubstituted C3 to C30 heteroaryl group, and
* is a linking point.

US Pat. No. 10,556,985

NITROGEN-CONTAINING HETEROCYCLIC EPOXY CURING AGENTS, COMPOSITIONS AND METHODS

Evonik Operations GmbH, ...

1. An amine-epoxy curing agent comprising the contact product of:(a) an amine epoxy curing agent having at least one saturated heterocyclic compound having two nitrogen heteroatoms according to formula (I):

wherein X is independently selected from a hydrogen atom, a linear or branched C1 to C4 alkyl group and a substituted or un-substituted phenyl group, Y1 is a direct bond or a divalent polyethylene polyamine group having 1 to 8 nitrogen atoms, and R is independently a hydrogen atom or a group selected from C1-C8 linear, cyclic, and branched alkyl, alkenyl, and alkaryl groups; and
(b) at least one multifunctional amine having three or more active amine hydrogens per molecule.

US Pat. No. 10,556,983

PROCESS FOR THE PREPARATION OF SILYLATED POLYMERS HAVING LOW COLOR AND COLOR STABILITY

Momentive Performance Mat...

1. A quenched silylated polymer having the general Formula (11):
each occurrence of A1 is a functional group selected from the group consisting of —O—, —S— and —NH—;
each occurrence of A2 is a functional group selected from the group consisting of —S—, —NR6, where R6 is selected from the group consisting of hydrogen, an alkyl group containing from 1 to about 10 carbon atoms, cycloalkyl group containing from about 5 to about 10 carbon atoms, an aralkyl group containing from about 7 to about 10 carbon atoms, phenyl and —CH[(C?O)OR7]CHR8C(?O)OR7, where R7 is an alkyl group of from 1 to about 10 carbon atoms, a cycloalkyl group of from about 5 to about 10 carbon atoms, an aryl group of from about 6 to about 10 carbon atoms, and aralkyl group of from about 7 to about 10 carbon atoms and R8 is an alkyl group of from 1 to about 10 carbon atoms, a cycloalkyl group of from about 5 to about 10 carbon atoms, an aryl group of from about 6 to about 10 carbon atoms, and aralkyl group of from about 7 to about 10 carbon atoms;
R1 is an organic group containing from about 50 to about 4,000 carbon atoms and at least one functional group selected from group consisting of —O—, —S—, —OC(?O)NH—, —R2NC(?O)NH—, —C(?O)O—, —OC(?O)O—, —OCHR2O—, —C(?O)NR2— and —NR2—, wherein each occurrence of R2 is independently hydrogen, an alkyl group containing from 1 to about 6 carbon atoms or phenyl, preferably hydrogen;
R4 is a divalent alkylene group containing from 1 to about 10 carbon atoms, a cycloalkylene group containing from about 5 to about 10 carbon atoms and an arylene group containing from about 6 to about 10 carbon atoms;
each occurrence of R5 is an alkyl group of from 1 to about 18 carbon atoms or a —R9(OR10)cOR11, where R9 is an alkyl group of from 1 to about 18 carbon atoms, R10 is a divalent alkylene group of from about 2 to about 4 carbon atoms, and R11 is an alkyl group of from 1 to about 10 carbon atoms or —C(?O)R12, where R12 is hydrogen, or an alkyl group of from 1 to about 6 carbon atoms, and
the subscripts a, b, c and h are integers where a is 2 to about 5, b is 0 to about 2, c is 0 to about 5, and h is 1 to 6, with the proviso that when A1 is —O— or —S—, then A2 is —NH—.

US Pat. No. 10,556,981

PHOTOSTABLE COMPOSITIONS COMPRISING PARA-ALKOXYL PHENYL SUBSTITUTED PROPENOIC ACID (APP) COPOLYMER DERIVATIVES

Hallstar Beauty and Perso...

1. A photostable photoactive composition comprising:(a) at least one photoactive compound that develops within itself an excited state energy when subjected to UV radiation, and
(b) a block copolymer comprising a plurality of blocks, and
having a structure according to Formula I:
H3C-V-W-X-Y-Z—CH3
wherein the plurality of blocks comprises:
at least one block having a structure according to Formula II:

wherein:
R is C1-C30 alkyl;
R1 is selected from the group consisting of H, OH, and C1-C15 alkoxyl;
R2 is selected from the group consisting of H and C1-C15 alkyl;
K is C1-C15 alkyl;
B is selected from the group consisting of O and S;
A is selected from the group consisting of CN and (C?O)NR3(R4); and
each stereoisomer is selected from the group consisting of E, Z, R, S, and a combination thereof;
wherein R3 and R4 are independently C1-C15 alkyl;
wherein n is a number from 1 to 5,000;
wherein m is a number from 0 to 20;
wherein R, R1, R2, R3, and R4 may be either straight chain or branched chain;
at least one block having a structure according to Formula III:

wherein:
R5 is C1-C30 alkyl;
R6 is selected from the group consisting of H and C1-C15 alkyl;
L is C1-C15 alkyl;
D is selected from the group consisting of O and S;
C is selected from the group consisting of CN and (C?O)NR7(R8); and
each stereoisomer is selected from the group consisting of E, Z, R, S, and a combination thereof;
wherein R7 and R8 are independently C1-C15 alkyl;
wherein o is a number from 1 to 5,000;
wherein p is a number from 0 to 20;
wherein R5, R6, R7 and R8 may be either straight chain or branched chain;
at least one block having a structure according to Formula IV:

wherein:
R9 and R10 are independently C1-C15 alkyl, and
E is selected from the group consisting of O and S;
wherein q is a number from 1 to 5,000;
wherein r is a number from 0 to 20; and
at least one block having a structure according to Formula V:

wherein:
F is selected from the group consisting of O and S;
wherein s is a number from 1 to 5,000;
wherein t is a number from 0 to 20;
wherein the block copolymer is operable to quench the excited state energy.

US Pat. No. 10,556,979

MODIFIED POLYIMIDE AND CURABLE RESIN COMPOSITION

LG CHEM, LTD., Seoul (KR...

1. A modified polyimide represented by Formula 4:
wherein D is a heat curable or photocurable functional group, R is a divalent or higher polyvalent organic group, and n is an integer of 1 or greater, X1, X2, X3, and X4 are each independently a tetravalent organic group derived from a tetracarboxylic dianhydride, Y1, Y2, and Y3 are each independently a divalent organic group derived from a diamine, p, q, r, and v are each independently an integer of 0 or greater, with the proviso that p, q, r, and v are not simultaneously 0, and r+v is 1 or greater.

US Pat. No. 10,556,976

CATALYST COMPOSITION FOR PREPARING CONJUGATED DIENE-BASED POLYMER AND CONJUGATED DIENE-BASED POLYMER PREPARING USING THE SAME

LG Chem, Ltd., (KR)

1. A catalyst composition for preparing a conjugated diene-based polymer, the composition comprising:a functionalizing agent;
a rare earth metal compound;
an alkylating agent; and
a halogen compound,
wherein the functionalizing agent comprises one selected from the group consisting of the following Formulae 2a to 2l, or a mixture of at least two thereof:

wherein in Formulae 2a to 2l, TMS means trimethylsilyl, TES means triethylsilyl, and Me means methyl.

US Pat. No. 10,556,975

AQUEOUS POLYMERIZATION OF THERMORESPONSIVE FLOCCULANTS

Phillips 66 Company, Hou...

1. A method comprising:forming a monomer solution by mixing formula

and a water soluble monomer in the presence of an aqueous solution;
adding an initiator to the monomer solution to form a thermoresponsive polymer, wherein:
R1 is independently selected from the group consisting of H and alkyl groups;
R2 and R3 are independently selected from the group consisting of H, alkyl, olefinic, aromatics, heterocyclic, halogen, ammonium, nitroxides, nitrates, nitrite amides, amines, esters, ethers, carboxylic acids, acyl chlorides, alcohols, nitriles, phosphates, phosphonates, sulfates, sulfonates, sulfide, sulfite, thiol, and combinations thereof;
Y is selected from the group consisting of O, N and S;
X are methylene groups containing from about 0 to about 20 carbons, and
wherein the aqueous solution is an aqueous salt solution.

US Pat. No. 10,556,973

METHOD FOR THE PREPARATION OF NITRATED STYRENIC FLUOROPOLYMERS

Akron Polymer Systems, In...

1. A method for the preparation of a nitrated styrenic fluoropolymer having an average degree of substitution (DS) ranging from about 0.2 to about 1 of the nitro group on the styrenic ring comprising the steps of:i. providing a styrenic fluoropolymer having a styrenic unit of:

 wherein R1, R2, and R3 are each independently hydrogen atoms, alkyl groups, substituted alkyl groups, or halogens, wherein at least one of R1, R2, and R3 is a fluorine atom, and wherein R is hydrogen or a substituent on the styrenic ring;
ii. optionally mixing the styrenic fluoropolymer with an organic solvent;
iii. mixing the styrenic fluoropolymer of (i) or (ii) with a combination of nitric acid in an amount from about 0.2 to about 5 moles per styrenic unit and sulfuric acid in an amount from about 1 to about 20 moles per styrenic unit; and
iv. reacting the mixture of (iii) for a period of time to obtain the nitrated styrenic fluoropolymer having an average DS of from about 0.2 to about 1 of the nitro group.

US Pat. No. 10,556,971

PROCESS FOR DRYING POLYMERS

ExxonMobil Chemical Paten...

1. A process for drying a polymer product comprising providing a transfer line dryer (TLD) having at least an upstream steam jacket and a downstream steam jacket, supplying steam to the upstream steam jacket of the TLD at a first steam delivery rate or pressure at a point D1 at or adjacent to a polymer product inlet to the TLD and supplying steam to the downstream steam jacket of the TLD at a second, lower rate or pressure at a point D2 downstream of the polymer product inlet, in which the first steam delivery rate or pressure is a full steam delivery rate or pressure that is applied to a portion of the TLD between D1 and D2 and a second steam delivery rate or pressure is 0.6 of full steam delivery rate or pressure, or less, throughout a portion of the TLD distal from D2; and flowing the polymer product through the TLD to obtain a dried polymer.

US Pat. No. 10,556,965

METHODS AND MATERIALS FOR TREATING CANCER

Mayo Foundation for Medic...

1. A composition comprising particles, wherein said particles have a longest dimension of 1000 nm or less and comprise (a) an anti-cancer antigen antibody and (b) calreticulin, wherein incubation of cancer cells and antigen presenting cells in the presence of said composition results in increased phagocytosis of said cancer cells by said antigen presenting cells as compared to the level of phagocytosis of comparable cancer cells by comparable antigen presenting cells in the absence of said composition,wherein said anti-cancer antigen antibody is conjugated to a surface of said particles,
wherein said anti-cancer antigen antibody is an anti-CD340 antibody, an anti-EGFR antibody, or an anti-PSMA antibody.

US Pat. No. 10,556,933

POLYPEPTIDE LIBRARIES WITH A PREDETERMINED SCAFFOLD

AFFIBODY AB, Solna (SE)


wherein each X corresponds to a randomizable amino acid residue in a second polypeptide based on an original scaffold amino acid sequence and wherein said second polypeptide has affinity for said predetermined target.

US Pat. No. 10,556,923

AMINOSTEROIDS FOR THE TREATMENT OF A PTP1B ASSOCIATED DISEASE

Ohr Pharmaceutical Inc., ...

1. A compound of formula
or a pharmaceutically acceptable salt thereof,
wherein:

R2=H;
R3=OH;
R4=H; and

US Pat. No. 10,556,922

CRYSTALLINE AND AMORPHOUS FORMS OF 17-ALPHA-HYDROXYPROGESTERONE CAPROATE

AMAG PHARMACEUTICALS, INC...

1. A crystalline form of 17-?-hydroxyprogesterone caproate characterized by a powder X-ray diffraction pattern having a characteristic peak in degrees 2? at about 9.6, 12.2, and 18.3 and a differential scanning calorimetry endothermic peak at about 100-105° C.

US Pat. No. 10,556,921

DEHYDROGENATION OF NEAT FORMIC ACID

University of Southern Ca...

1. An organometallic complex having formula B:
wherein:
M is a metal selected from the group consisting of beryllium, magnesium, aluminum, scandium, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, gallium, germanium, yttrium, zirconium, niobium, molybdenum, technetium, ruthenium, rhodium, palladium, silver, cadmium, indium, tin, antimony, lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolimium, terbium, dysprosium, holmium, erbium, thalium, ytterbium, lutetium, hafnium, tantalum, tungsten, rhenium, osmium, iridium, gold, platinum, thallium, lead, bismuth, polonium, thorium, protactinium, uranium, neptunium, and plutonium;
E is P, N, or C;
R1, R2 are each independently C1-6 alkyl groups;
R3 are each independently hydrogen, C1-6 alkyl groups, OR14, NO2, or halogen;
o is 1, 2, 3, or 4;
R14 is hydrogen or a C1-6 alkyl group;
R15 is hydrogen or a C1-6 alkyl group; and
X? is a negatively charge counter ion.

US Pat. No. 10,556,920

PHOSPHORUS-CONTAINING HETEROCYCLES AND A METHOD FOR MAKING AND USING

University of Oregon, Eu...

1. A compound of formula Ior a pharmaceutically acceptable salt thereof, wherein:ring A is aryl;
X is NR3;
Y is CR4;
Z is CR4;
R1 is —OH, aryl, heteroaryl, —O-aliphatic, —O-aryl, —O-heteroaryl, —O-heterocyclic, or —O-heteroaliphatic;
R2 is oxo (?O), or ?S;
R3 is H, aliphatic, heteroaliphatic, heterocyclic, heteroaryl, acyl, carboxyl ester, or a lone pair of electrons;
each R4 independently is H, aliphatic, heteroaliphatic, aryl, heterocyclic, heteroaryl, halo, CN, NO2, sulfonyl, amino, carboxyl, carboxyl ester, aminosulfonyl, or aminocarbonyl; and
“---” represents a bond that may or may not be present.

US Pat. No. 10,556,919

LIMONENE-BASED, NON-HALOGENATED FLAME RETARDANTS FOR POLYMERIC APPLICATIONS

International Business Ma...

11. A limonene-based flame-retardant compound having the structure
wherein:
each FR includes a phosphate group or a phosphonate group; and
each R is independently

wherein:
y is an integer between 1 and 12, and
the dotted line bond indicates a connection to the phosphate group or phosphonate group.

US Pat. No. 10,556,918

METHOD FOR PREPARING AMINOSILANE-BASED COMPOUND

LG Chem, Ltd., (KR)

1. A method for preparing an aminosilane-based compound of the following Formula 1, the method comprising:dissolving each of a compound of the following Formula 2 and a compound containing at least one nitrogen atom in an organic solvent to prepare a solution of the compound of the following Formula 2 and a solution of the compound containing at least one nitrogen atom,
mixing the solution of the compound of the following Formula 2 and the solution of the compound containing at least one nitrogen atom, and
reacting the compound of the following Formula 2 with the compound containing at least one nitrogen atom,
wherein the compound containing at least one nitrogen atom is an aliphatic amine having 1 to 20 carbon atoms or a five-member or six-member ring compound containing 1 to 3 nitrogen atoms, and optionally at least one hydrogen atom in the compound is independently substituted with an alkyl group of 1 to 8 carbon atoms, an alkoxy group of 1 to 8 carbon atoms, an aryl group of 6 to 12 carbon atoms, a halogen group, a carboxyl group, an aldehyde group, an acyl group or a cyano group,

in Formula 1 and Formula 2,
A is an aliphatic amino group having 1 to 20 carbon atoms or a four-member or six-member ring containing 1 to 3 nitrogen atoms, and optionally at least one hydrogen atom in the aliphatic amino group or the five-member or six-member ring is independently substituted with an alkyl group of 1 to 8 carbon atoms, an alkoxy group of 1 to 8 carbon atoms, an aryl group of 6 to 12 carbon atoms, a halogen group, a carboxyl group, an aldehyde group, an acyl group or a cyano group,
X1 is a halogen group,
Y is a divalent hydrocarbon group of 1 to 20 carbon atoms, and
Z1 and Z2 are each independently a group of the following Formula 3:

in Formula 3,
“a” is an integer of 0 to 2,
R1 and R2 are each independently a monovalent hydrocarbon group of 1 to 10 carbon atoms, and
W is a divalent hydrocarbon group of 1 to 10 carbon atoms, which is unsubstituted or substituted with an alkyl group of 1 to 4 carbon atoms.

US Pat. No. 10,556,916

ZIRCONIUM-89 OXINE COMPLEX AS A CELL LABELING AGENT FOR POSITRON EMISSION TOMOGRAPHY

The United States of Amer...

1. A method of labeling a cell or microorganism with 89Zr-oxine complex comprising contacting the cell or microorganism with a 89Zr-oxine complex of the formula
in a buffer solution at 26° C. or below, wherein the 89Zr-oxine complex permeabilizes the cell membrane of the cell or microorganism.

US Pat. No. 10,556,914

SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE

ABBVIE INC., North Chica...

1. A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
X is O or S;
R1 is selected from the group consisting of C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, and phenyl; wherein,
C1-C6alkyl, C2-C6alkenyl, and C2-C6alkynyl are unsubstituted, partly or completely fluorinated and/or substituted with one or more substituents independently selected from the group consisting of C1-C6alkoxy, fluoroC1-C6alkoxy, hydroxy, and oxo;
C3-C6cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of C1-C6alkyl, C1-C6alkoxy, fluorine, fluoroC1-C6alkyl, fluoroC1-C6alkoxy, hydroxy, and oxo;
phenyl is optionally substituted with one or more substituents selected from the group consisting of C1-C6alkyl, C1-C6alkoxy, fluoroC1-C6alkyl, fluoroC1-C6alkoxy, and halo;
R2 is selected from the group consisting of 4-chlorophenylmethyl, 3-(trifluoromethyl)phenylmethyl, 4-(trifluoromethyl)phenylmethyl, 4-methoxy-3-(trifluoromethyl)phenylmethyl, 2-fluoro-5-(trifluoromethyl)phenylmethyl, 5-chloro-2-fluorophenylmethyl, 4-chloro-2-fluorophenylmethyl, 4-chlorophenylphenylmethyl, 2,4-difluorophenylmethyl, 4-fluoro-3-(trifluoromethyl)phenylmethyl, 4-chloro-3-(trifluoromethyl)phenylmethyl, 2-fluorophenylmethyl, 4-fluorophenylmethyl, 1-(4-chlorophenyl)ethyl, 2-(4-chlorophenyl)ethyl, 1-(4-(trifluoromethyl)phenyl)ethyl, and 4-pyridylmethyl;
R3 is selected from the group consisting of C1-C6alkyl, C3-C6cycloalkyl, phenyl, phenylC1-C6alkyl, bicyclic aryl, bicyclic arylC1-C6alkyl, monocyclic heteroarylC1-C6alkyl, monocyclic heteroaryl, and bicyclic heteroaryl; wherein
C1-C6alkyl is unsubstituted, partly or completely fluorinated and/or substituted with one or more substituents independently selected from the group consisting of C1-C6alkoxy, fluoroC1-C6alkoxy, hydroxy, and oxo;
C3-C6cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of C1-C6alkyl, C1-C6alkoxy, fluoroC1-C6alkoxy, fluorine, hydroxy, and oxo; and
phenyl, phenyl of phenylC1-C6alkyl, bicyclic aryl, bicyclic aryl of bicyclic arylC1-C6alkyl, monocyclic heteroaryl of monocyclic heteroarylC1-C6alkyl, monocyclic heteroaryl and bicyclic heteroaryl are optionally substituted with 1, 2, 3 or 4 substituents RAr, which are independently selected from the group consisting of C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, halogen,
cyano, —OR1a, —OC(O)R1a, —OC(O)N(Rd)(R3a), —SR1a, —S(O)2R2a, —S(O)2N(Rd)(R3a), —C(O)R1a, —C(O)OR1a, —C(O)N(Rd)(R3a), —N(Rd)(R3a), —N(Rc)C(O)R1a, —N(Rc)S(O)2R2a, —N(Rc)C(O)O(R1a), —N(Rc)C(O)N(Rd)(R3a), —(CR4aR5a)m—OR1a, —(CR4aR5a)m—OC(O)R1a, —(CR4aR5a)m—OC(O)N(Rd)(R3a), —(CR4aR5a)m—SR1a, —(CR4aR5a)m—S(O)2R2a, —(CR4aR5a)m—S(O)2N(Rd)(R3a), —(CR4aR5a)m—C(O)R1a, —(CR4aR5a)m—C(O)OR1a, —(CR4aR5a)m—C(O)N(Rd)(R3a), —(CR4aR5a)m—N(Rd)(R3a), —(CR4aR5a)m—N(Rc)C(O)R1a, —(CR4aR5a)m—N(Rc)S(O)2R2a, —(CR4aR5a)m—N(R)C(O)O(R1a), —(CR4aRsa)m—N(R)C(O)N(Rd)(R3a), cyanoC1-C6-alkyl, and fluoroC1-C6-alkyl;
m is 1, 2, 3, or 4;
Rc and Rd, at each occurrence, are each independently hydrogen, C1-C6alkyl, or fluoroC1-C6-alkyl;
R1a and R3a, at each occurrence, are each independently hydrogen, C1-C6alkyl, or fluoroC1-C6-alkyl; or
Rd and R3a, if present as a group N(Rd)(R3a), may together with the nitrogen atom of N(Rd)(R3a) also form an N-bound saturated 3 to 8 membered heterocycle, which in addition to the nitrogen atom may have 1 or 2 further heteroatoms as ring members, which are selected from the group consisting of O, S and N;
Rc and R1a, if present as a group —N(Rc)C(O)R1a, may together with the atoms of said moiety form an N-bound saturated 3 to 8 membered heterocycle, which has an oxo group in 2-position and which in addition to the nitrogen atom may have 1 or 2 further heteroatoms as ring members, which are selected from the group consisting of O, S and N;
R2a, at each occurrence, is independently C1-C6alkyl, or fluoroC1-C6-alkyl; and
R4a and R5a, at each occurrence, are each independently hydrogen, fluorine, C1-C6alkyl, or fluoroC1-C6-alkyl.

US Pat. No. 10,556,913

ASYMMETRIC PROCESS FOR THE PREPARATION OF THIENO-INDOLES DERIVATIVES

NERVIANO MEDICAL SCIENCES...

1. An intermediate compound of formula (XIa) or (XIb)
wherein:
R1 is hydrogen or linear or branched C1-C6 alkyl; and
P2 is a nitrogen protecting group.

US Pat. No. 10,556,912

DIARYLETHENE COMPOUNDS AND USES THEREOF

SWITCH MATERIALS, INC., ...

1. A compound according to Formula IA/IB, reversibly convertible under photochromic and electrochromic conditions between a ring-open isomer A and a ring-closed isomer B:
wherein:
Z is N, O or S;
each R1 is independently selected from H or halo;
each R2 is independently selected from the group consisting of H, halo, a polymer backbone, alkyl, and aryl; or both R2 together form CH?CH—;
each R3 is independently

 or alkyl;
each R4 is independently

X=N, O or S;
R5 is methyl;
each R6a, R6b, R6c is independently selected from the group comprising: H, Cl, Br, F, —CF3, —CN, —NO2, methyl, ethyl, propyl, iso-propyl, butyl, sec-butyl, iso-butyl, tert-butyl, saturated or unsaturated alkyl that is linear or branched with 5-12 carbons, —Si(R11)3, thiophene, substituted thiophene, benzyl, substituted benzyl, —CH?CH2, —OCH3, —COH, —OH, —CO2H, —COCH3, —C(CH3)2OH, —Si(CH3)3, —CH2CH2OCH3, —CH2CH2OH, —N(CH3)2, —CO2CH3, —OCH2OCH3, —SO2CH3, —OCH2C(CH3)3, —OCH2CH(CH3)2, —OC(CH3)3, —OCH?CH2, —O(CH2)4OH, —O(CH2)3OH, —C(CH3)2OH, —O(CH2)2OCH3, —O(CH2)4CN, —O(CH2)4COOH,

or R6a and R6b are each CH?CH— and join to form an unsaturated ring, or —CH2—CH2— and join to form a ring;
each R7a, R7b, R7c, each R8a, R8b, R8c, R8d, R8e, and each R9a, R9b, R9c, R9d, R9e, is independently selected from the group comprising: H, Cl, Br, F, —CF3, —CN, —NO2, methyl, ethyl, propyl, iso-propyl, butyl, sec-butyl, iso-butyl, tert-butyl, saturated or unsaturated alkyl that is linear or branched with 5-12 carbons, —Si(R11)3, thiophene, substituted thiophene, benzyl, substituted benzyl, —CH?CH2, —OCH3, —COH, —OH, —CO2H, —COCH3, —C(CH3)2OH, —Si(CH3)3, —CH2CH2OCH3, —CH2CH2OH, —N(CH3)2, —CO2CH3, —OCH2OCH3, —SO2CH3, —OCH2C(CH3)3, —OCH2CH(CH3)2, —OC(CH3)3, —OCH?CH2, —O(CH2)4OH, —O(CH2)3OH, —C(CH3)2OH, —O(CH2)2OCH3, —O(CH2)4CN, —O(CH2)4COOH,

n and m are independently any integer from 0 to 20;
R11 is independently selected from the group comprising R or —O—R, wherein:
R is a linear or branched, non-aromatic monocyclic or polycyclic, substituted or unsubstituted alkyl group comprising a carbon backbone comprising any one of 1 to 20 carbons; or
R is a heteroalkyl group comprising one or more of O, S, N, or Si; or
R is a linear or branched, saturated or unsaturated, alkyl group comprising a carbon backbone comprising any one of 1 to 12 carbons; or
R is a substituted or unsubstituted methyl, ethyl, propyl, iso-propyl, butyl, sec-butyl, iso-butyl, tert-butyl, pentyl or hexyl group;
at least one of R6a, R6b, R6c is not H;
at least one of R7a, R7b, R7c is not H;
at least one of R8a, R8b, R8c, R8d, R8e is not H; and
at least one of R9a, R9b, R9c, R9d, R9e is not H.

US Pat. No. 10,556,911

THIENOPYRIMIDINE COMPOUNDS

1. A method of treating a disorder which is responsive to antagonism of the adenosine A2B receptor in a subject in need thereof, the method comprising orally administering to the subject a compound of formula (I), or a pharmaceutically acceptable salt thereof, in an amount of from 0.1 mg to 3000 mg, once, twice, or three times per day, wherein the compound of formula (I) iswhereinR1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring;
R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl;
or R2 and R3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring;
R4 is C1-C3 alkyl, C2-C3 alkenyl, —N(—R5)—R6, or optionally substituted heteroarylmethylamino; and
R5 and R6 are independently selected from hydrogen or C1-C3 alkyl;
or R5 and R6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated ring.

US Pat. No. 10,556,910

SYNTHESIS OF HALICHONDRIN ANALOGS AND USES THEREOF

President and Fellows of ...

12. A compound selected from the group consisting of:and pharmaceutically acceptable salts thereof.

US Pat. No. 10,556,908

SUBSTITUTED IMIDAZO[1,2-A]PYRAZINES AS LSD1 INHIBITORS

Incyte Corporation, Wilm...

1. A method for treating cancer in a patient, wherein the cancer is selected from myelodysplasia syndrome, acute myelogenous leukemia, undifferentiated small cell lung cancer, Ewing's sarcoma, and primary myelofibrosis, comprising administering to the patient a therapeutically effective amount of a compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein:Ring A is C6-10 aryl or 5-10 membered heteroaryl comprising carbon and 1, 2, 3, or 4 heteroatoms selected from N, O, and S, wherein said C6-10 aryl and 5-10 membered heteroaryl are each optionally substituted by 1, 2, 3, or 4 substituents independently selected from RA;
Ring B is C6-10 aryl; 5-10 membered heteroaryl comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O, and S; C3-10 cycloalkyl; or 4-10 membered heterocycloalkyl comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O, and S; wherein said C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 substituents independently selected from RB;
R1 is halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, Cy1, CN, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(?NRe1)Rb1, C(?NRe1)NRc1Rd1, NRc1C(?NRe1)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, or S(O)2NRc1Rd1; wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, halo, CN, OH, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(?NRe1)Rb1, C(?NRe1)NRc1Rd1, NRc1C(?NRe1)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1;
R2 and R3 are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, Cy2, CN, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(?NRe2)Rb2, C(?NRe2)NRc2Rd2, NRc2C(?NRe2)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy2, halo, CN, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(?NRe2)Rb2, C(?NRe2)NRc2Rd2, NRc2C(?NRe2)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;
each RA is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)ORa4, NRc4C(O)NRc4Rd4, C(?NRe4)Rb4, C(?NRe4)NRc4Rd4, NRc4C(?NRe4)NRc4Rd4, NRc4S(O)Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, and S(O)2NRc4Rd4, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, or 3, substituents independently selected from halo, C1-6 haloalkyl, CN, NO2, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)ORa4, NRc4C(O)NRc4Rd4, C(?NRe4)Rb4, C(?NRe4)NRc4Rd4, NRc4C(?NRe4)NRc4Rd4, NRc4S(O)Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, and S(O)2NRc4Rd4;
each RB is independently selected from Cy3, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, ORa5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)ORa5, OC(O)Rb5, OC(O)NRc5Rd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)ORa5, NRc5C(O)NRc5Rd5, C(?NRe5)Rb5, C(?NRe5)NRc5Rd5, NRc5C(?NRe5)NRc5Rd5, NRc5S(O)Rb5, NRc5S(O)2Rb5, NRc5S(O)2NRc5Rd5, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, and S(O)2NRc5Rd5, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, or 3 substituents independently selected from Cy3, halo, C1-6 haloalkyl, CN, NO2, ORa5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)ORa5, OC(O)Rb5, OC(O)NRc5Rd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)ORa5, NRc5C(O)NRc5Rd5, C(?NRe5)Rb5, C(?NRe5)NRc5Rd5, NRc5C(?NRe5)NRc5Rd5, NRc5S(O)Rb5, NRc5S(O)2Rb5, NRc5S(O)2NRc5Rd5, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, and S(O)2NRc5Rd5;
each Cy1, Cy2, Cy3, and Cy4 is independently selected from C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from RCy;
each RCy is independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-4 alkyl-, C3-7 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-7 membered heterocycloalkyl)-C1-4 alkyl-, CN, NO2, ORa6, SRa6, C(O)Rb6, C(O)NRc6Rd6, C(O)ORa6, OC(O)Rb6, OC(O)NRc6Rd6, C(?NRe6)NRc6Rd6, NRc6C(?NRe6)NRc6Rd6, NRc6Rd6, NRc6C(O)Rb6, NRc6C(O)ORa6, NRc6C(O)NRc6Rd6, NRc6S(O)Rb6, NRc6S(O)2Rb6, NRc6S(O)2NRc6Rd6, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, and S(O)2NRc6Rd6, wherein said C1-4 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-4 alkyl-, C3-7 cycloalkyl-C1-4 alkyl-, (5-6 membered heteroaryl)-C1-4 alkyl-, and (4-7 membered heterocycloalkyl)-C1-4 alkyl- are each optionally substituted by 1, 2, or 3 substituents independently selected from C1-6 alkyl, C1-4 haloalkyl, C1-6 cyanoalkyl, halo, CN, NO2, ORa6, SRa6, C(O)Rb6, C(O)NRc6Rd6, C(O)ORa6, OC(O)Rb6, OC(O)NRc6Rd6, C(?NRe6)NRc6Rd6, NRc6C(?NRe6)NRc6Rd6, NRc6Rd6, NRc6C(O)Rb6, NRc6C(O)ORa6, NRc6C(O)NRc6Rd6, NRc6S(O)Rb6, NRc6S(O)2Rb6, NRc6S(O)2NRc6Rd6, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, and S(O)2NRc6Rd6;
each Ra1 is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Cy4; wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy4, halo, CN, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, C(?NRe3)Rb3, C(?NRe3)NRc3Rd3, NRc3C(?NRe3)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3;
each Rb1, Rc1, and Rd1 is independently selected from H, C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7;
or any Rc1 and Rd1 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C1-6 haloalkyl, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7, wherein said C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7;
each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7;
or any Rc2 and Rd2 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, C1-6 haloalkyl, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7, wherein said C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7;
each Ra3, Rb3, Rc3, and Rd3 is independently selected from H, C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7;
or any Rc3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, C1-6 haloalkyl, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7, wherein said C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7;
each Ra4, Rb4, Rc4, and Rd4 is independently selected from H, C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7;
or any Rc4 and Rd4 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7;
each Ra5, Rb5, Rc5, and Rd5 is independently selected from H, C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl-, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl-, C3-10 cycloalkyl-C1-4 alkyl-, (5-10 membered heteroaryl)-C1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C1-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7;
or any Rc5 and Rd5 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, C1-6 haloalkyl, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7, wherein said C1-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7;
each Ra6, Rb6, Rc6, and Rd6 is independently selected from H, C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4 cyanoalkyl, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7;
or any Rc6 and Rd6 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa7, SRa7, C(O)Rb7, C(O)NRc7Rd7, C(O)ORa7, OC(O)Rb7, OC(O)NRc7Rd7, NRc7Rd7, NRc7C(O)Rb7, NRc7C(O)NRc7Rd7, NRc7C(O)ORa7, C(?NRe7)NRc7Rd7, NRc7C(?NRe7)NRc7Rd7, S(O)Rb7, S(O)NRc7Rd7, S(O)2Rb7, NRc7S(O)2Rb7, NRc7S(O)2NRc7Rd7, and S(O)2NRc7Rd7;
each Ra7, Rb7, Rc7, and Rd7 is independently selected from H, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein said C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(C1-4 alkylamino, C1-4 haloalkyl, and C1-4 haloalkoxy; and
each Re1, Re2, Re3, Re4, Re5, Re6, and Re7 is independently selected from H, C1-4 alkyl, and CN.

US Pat. No. 10,556,907

FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS

ABBVIE INC., North Chica...

1. A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein
X, Y and Z are independently selected from the group consisting of N and CR5, with the proviso that one or two of X, Y and Z are N and at least one of X, Y and Z is CR5, and wherein each R5 is independently selected from the group consisting of hydrogen, a halogen atom, (C1-4)alkyl and (C1-4)alkyl substituted with one or more fluoro atoms;
m is 1 and n is 1;
R1 is selected from the group consisting of
—(C1-6)alkylene-R6 wherein one or more carbon atoms in the alkylene group, each independently, are optionally substituted with one or more halogen atoms or with (CH2)2 to form a cyclopropyl moiety or with (CH2)3 to form a cyclobutyl moiety,
—(C3-6)cycloalkylene-R6 in which one carbon atom in the (C3-6)cycloalkylene can optionally be replaced by oxygen,
—(C1-3)alkylene-(C3-6)cycloalkylene-R6,
—(C3-6)cycloalkylene-(C1-3)alkylene-R6 and
—C(O)—(C1-4)alkylene-R6,
wherein R6 is selected from the group consisting of —OH, —OPO3H2, —COOH, —COO(C1-4)alkyl and tetrazol-5-yl;
R2 is absent, one or more substituents independently selected from the group consisting of a halogen atom, oxo, (C1-4)alkyl optionally substituted with one or more halogen atoms and (C1-4)alkoxy optionally substituted with one or more halogen atoms;
L1 is absent or wherein

* indicates the bond to ring A and ** indicates the bond to R3; and
Ring B is selected from the group consisting of (C3-7)cycloalkyl, (C4-7)cycloalkenyl, phenyl, pyridyl, thienyl and thiazolyl, each optionally substituted with one or more substituents independently selected from the group consisting of
hydroxy,
cyano,
a halogen atom,
(C1-4)alkyl optionally substituted with one or more halogen atoms,
(C3-6)cyloalkyl optionally substituted with one or more halogen atoms,
(C1-4)alkoxy optionally substituted with one or more halogen atoms, and
phenyl optionally substituted with one or more substituents independently selected from the group consisting of a halogen atom, (C1-4)alkyl optionally substituted with one or more halogen atoms, and (C1-4)alkoxy optionally substituted with one or more halogen atoms; and
R3 is L2-R4, wherein:
L2 is absent or a group —W—(CH2)p-T- wherein:
W is attached to L1 and selected from the group consisting of a bond, —O—, —CO—, —S—, —SO—, —SO2—, —CH?CH—, —C(CF3)?CH—, CH?C(CF3)—, —CF2—CH2—, —CH2—CF2—, —CHF—CH2—, —CH2—CHF—, —C?C—, —CH2—O—, —O—CH2—, —O—CO—, —CO—O—, and cyclopropylene;
p is an integer from 0 to 10;
one or more C atoms of (CH2)p are optionally substituted with one or two fluoro atoms, and
T is absent or attached to R4 and selected from the group consisting of a bond, —O—, —S—, —SO—, —SO2—, —CO—, —CH?CH—, —C?C—, and cyclopropylene,
R4 is selected from the group consisting of:
(C3-6)cycloalkyl, (C4-6)cycloalkenyl or an 8-10 membered bicyclic group, each optionally substituted with a substituent selected from the group consisting of a halogen atom, (C1-4)alkyl optionally substituted with one or more fluoro atoms and (C1-4)alkoxy optionally substituted with one or more fluoro atoms,
phenyl, biphenyl or naphthyl, pyridyl, thienyl, thiazolyl optionally substituted with one or more substituents independently selected from the group consisting of:
a halogen atom,
hydroxy,
cyano,
(C1-4)alkyl optionally substituted with one or more fluoro atoms,
(C1-4)alkoxy optionally substituted with one or more fluoro atoms,
—S—(C1-4)-alkyl,
—SF5, and
(C3-6)cycloalkyl optionally substituted with phenyl whereby said phenyl is optionally substituted with a substituent selected from the group consisting of (C1-4)alkyl and a halogen atom, and
phenyl substituted with a substituent selected from the group consisting of phenoxy, benzyl, benzyloxy, phenylethyl and a monocyclic heterocycle, wherein each substituent is optionally substituted with one or more halogen atoms, (C1-4)alkyl, (C1-4)alkyl substituted with one or more fluoro atoms, (C1-4)alkoxy, or (C1-4)alkoxy substituted with one or more fluoro atoms.

US Pat. No. 10,556,905

PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND

MEIJI SEIKA PHARMA CO., L...

1. A compound of a formula selected from the group consisting ofwherein in the above formulae, TFA represents a trifluoroacetyl group, OMe represents a methoxy group, Boc represents a tert-butoxycarbonyl group, Teoc represents a 2-trimethylsilylethoxycarbonyl group, OBn represents a benzyloxy group, and Cbz represents a benzyloxycarbonyl group.

US Pat. No. 10,556,904

DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

NOVIRA THERAPEUTICS, INC....

1. A compound of Formula I
or a pharmaceutically acceptable salt thereof,whereinW1 and W are each independently selected from N, NRa, and CRa, wherein one of W1 and W is NRa;
X is N or CRb;
Y is selected from a bond, —C(O)—, and —SO2—;
Z is selected from —(CR5R6)m—, —(CR5R6)mO—, —(CR5R6)mCR5?CR5—, —(CR5R6)m—C3-C6-cycloalkylene-, and —(CR5R6)m—NR7—;
R1 is selected from C(O)ORc, C(O)Rc, C(O)NRdRe, NRdC(O)Rc, —OC(O)Rc, —C(O)NRdORe; and —C(O)NRdN(Rd)2;
R2 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
R3 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
R4 is selected from C1-C6-alkyl, (CR8R9)p—C3-C8-cycloalkyl, (CR8R9)p—C2-C8-heterocyclyl, (CR8R9)p—C6-C12-aryl, and (CR8R9)p—C1-C9-heteroaryl, wherein alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl are optionally substituted with 1, 2, 3, or 4 groups, each independently selected from —OH, halo, CN, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, C(O)N(Rf)2, C(O)ORf, —OCH2C(O)ORf, —SO2Rf, and C1-C6-alkyl-OH;
R5 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
alternatively, R4 and R5 are optionally joined to form a heterocyclic ring;
R6 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
R7 is selected from H, C1-C6-alkyl, and C1-C6-alkyl-OH;
R8 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
R9 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
Ra is selected from H, C1-C6-alkyl, and C1-C6-alkyl-OH;
Rb is selected from H and C1-C6-alkyl;
Rc is selected from H, C1-C6-alkyl, C1-C6-alkyl-OH, C0-C6-alkyl-C3-C8-cycloalkyl, C2-C8-heterocyclyl, C6-C12-aryl, and C1-C9-heteroaryl, wherein cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1, 2, or 3 groups, each independently selected from —OH, halo, CN, C1-C6-alkyl, C1-C6-haloalkyl, and —O—C1-C6-alkyl;
Rd is selected from H, C1-C6-alkyl, and C1-C6-alkyl-OH;
Re is selected from H, C1-C6-alkyl, C1-C6-alkyl-OH, C1-C6-alkyl-OC1-C6-alkyl, C0-C6-alkyl-C3-C8-cycloalkyl, C2-C8-heterocyclyl, C6-C12-aryl, and C1-C9-heteroaryl, wherein cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1, 2, or 3 groups, each independently selected from —OH, halo, CN, C1-C6-alkyl, C1-C6-haloalkyl, and —O—C1-C6-alkyl;
alternatively, Rd and Re are optionally joined to form a heterocyclic ring, which is optionally substituted with 1, 2, or 3 groups, each independently selected from —OH, halo, CN, C1-C6-alkyl, C1-C6-haloalkyl, and —O—C1-C6-alkyl;
Rf is, at each occurrence, independently selected from H and C1-C6-alkyl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, or 3; and
p is 0, 1, 2, 3, or 4.

US Pat. No. 10,556,903

NLRP3 MODULATORS

Innate Tumor Immunity, In...

1. A compound selected from:or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,556,902

GLYCOSIDASE INHIBITORS

Asceneuron SA, Lausanne ...

1. A compound of formula (I)
wherein
R is straight chain or branched alkyl having 1 to 6 carbon atoms, wherein 1 to 5 hydrogen atoms may be replaced by Hal or OH;
W is CH or N;
A denotes one of the following groups:

X is N or CR??;
X1, X2 is N or CR??;
X3 is N or CR???;
X4 is N or CR9;
R9 denotes Hal, NR3R4, CHR3R4, OR3, CN, straight chain or branched alkyl having 1 to 12 carbon atoms, wherein 1 to 3 CH2-groups may be replaced by a group selected from O, NR3, S, SO, SO2, S(O)(NH), CO, COO, OCO, CONR3, NR3CO and wherein 1 to 5 hydrogen atoms may be replaced by Hal, NR3R4 or NO2;
Y is O, S, SO or SO2;
R?, R? denote each independently H, Hal or straight chain or branched alkyl having 1 to 12 carbon atoms;
R??, R?? independently denote H, Hal, NR3R4, CHR3R4, OR3, CN, straight chain or branched alkyl having 1 to 12 carbon atoms, wherein 1 to 3 CH2-groups may be replaced by a group selected from O, NR3, S, SO, SO2, S(O)(NH), CO, COO, OCO, CONR3, NR3CO and wherein 1 to 5 hydrogen atoms may be replaced by Hal, NR3R4 or NO2;
R??? denotes H, Hal, NR3R4, CHR3R4, CN, straight chain or branched alkyl having 1 to 12 carbon atoms, wherein 1 to 3 CH2-groups may be replaced by a group selected from O, NR3, S, SO, SO2, S(O)(NH), CO, COO, OCO, CONR3, NR3CO and wherein 1 to 5 hydrogen atoms may be replaced by Hal, NR3R4 or NO2;
R3, R4 denote each independently H or a straight chain or branched alkyl group having 1 to 12 carbon atoms;
Q denotes one of the following groups:

Z1 is S, O, NR3;
Z2, Z3 independently denote CR5, CR6 or N;
Z2? is CR5? or N;
Z4 is N, CH, CON, COCH;
Z5 is S, O, NR8, SO2, CHR5;
Z5? is S, O, NR8, SO2;
Z6 is CH2, CO;
s denotes 0 or 1;
T is N, CH or CR7;
R3? denotes H or a straight chain or branched alkyl group having 1 to 12 carbon atoms, wherein 1 to 3 CH2-groups may be replaced by a group selected from SO2, CO, O and wherein 1 to 5 hydrogen atoms may be replaced by Hal;
R3? denotes a straight chain or branched alkyl group having 1 to 12 carbon atoms, wherein 1 to 3 CH2-groups are replaced by a group selected from SO2, CO, O and wherein 1 to 5 hydrogen atoms may be replaced by Hal;
R5, R5?, R6, R7 independently denote H, Hal, NR3R4, NO2, straight chain or branched alkyl having 1 to 12 carbon atoms, wherein 1 to 3 CH2-groups may be replaced by a group selected from O, NR3, S, SO, SO2, S(O)(NH), CO, COO, OCO, CONR3, NR3CO and wherein 1 to 5 hydrogen atoms may be replaced by Hal, NR3R4, NO2, OR3, Het, Ar, Cyc, or denote Ar, Het or Cyc;
R8 denotes H, methyl or straight chain or branched alkyl having 2 to 12 carbon atoms, wherein 1 to 3 CH2-groups may be replaced by a group selected from O, NR3, S, SO, SO2, S(O)(NH), CO, COO, OCO, CONR3, NR3CO and wherein 1 to 5 hydrogen atoms may be replaced by Hal, NR3R4 or NO2;
Hal denotes F, Cl, Br or I;
Het denotes a saturated, unsaturated or aromatic ring, being monocyclic or bicyclic or fused-bicyclic and having 3- to 8-members and containing 1 to 4 heteroatoms selected from N, O and S, which may be substituted by 1 to 3 substituents selected from R5, Hal and OR3;
Ar denotes a 6-membered carbocyclic aromatic ring or a fused or non-fused bicyclic aromatic ring system, which is optionally substituted by 1 to 3 substituents independently selected from R5, OR3 and Hal;
Cyc denotes a saturated or an unsaturated carbocyclic ring having from 3 to 8 carbon atoms which is optionally substituted by 1 to 3 substituents independently selected from R5 or Hal or OH;
m and n simultaneously denote 1;and solvates, salts, tautomers, enantiomers, racemates and stereoisomers thereof, including mixtures thereof in all ratios and compounds of formula I, wherein one or more H atoms are replaced by D (deuterium).

US Pat. No. 10,556,901

4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE AND 1,4,5,6,7,8-HEXAHYDROIMIDAZO[4,5-D]AZEPINE DERIVATIVES AS JANUS KINASE INHIBITORS

Topivert Pharma Limited, ...

1. A compound of formula I,wherein:X represents halo;
Ak represents C1-6 alkyl optionally substituted by one or more fluorine atoms;
s represents 1 or 2;
A represents C or S(?O);
R1 and R2 each independently represents H, C1-6 alkyl, C3-7 cycloalkyl, aryl, heteroaryl, or heterocyclyl, which latter five groups are optionally substituted by one or more substitutents selected from halo, cyano, CO2H, oxo, NR3SO2R4, —N?S(O)(R4)2, S(O)mR5, P(O)(R4)2, C(O)NR5R6, S(O)2NR5R6, —(OCH2CH2)0-4OR5, —(CH2)0-4—NR5R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, aryl, heteroaryl or heterocyclyl, which latter seven groups are optionally substituted by one or more substituents selected from halo, cyano, CO2H, C1-4 alkyl, C1-4 alkoxy, oxo and hydroxy;
or R1 and R2, together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated or partially unsaturated and which heterocyclic group contains one N atom (the atom to which R1 and R2 are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally fused to a benzene or heteroaromatic ring, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, CO2H, NR3SO2R4, S(O)mR5, C(O)NR5R6, —(CH2)0-4—NR5R6, —(OCH2CH2)0-4OR5, C1-4 alkyl, C1-4 alkoxy, aryl, heteroaryl, and heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, CO2H, C1-4 alkyl, C1-4 alkoxy, oxo and hydroxy;
R3 represents H or C1-4 alkyl optionally substituted by one or more substituents selected from halo, hydroxy and C1-2 alkoxy;
R4 represents C1-4 alkyl, C3-7 cycloalkyl, aryl, heteroaryl or heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, CO2H, C1-4 alkyl, oxo, hydroxy and C1-4 alkoxy;
R5 and R6 each independently represent H, C1-6 alkyl, C3-7 cycloalkyl, aryl, heteroaryl, or heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, CO2H, oxo, hydroxy, C1-4 alkyl, C1-4 alkoxy, S(O)pR7, C(O)NRaRb and —(CH2)0-4NRaRb, or —[C(R6b)(R6c)CH2Z]1-12—CH2CH2—R6a or —C(R6b)(R6c)—[C1-5 alkylene]-R6a;
or R5 and R6, together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated or partially unsaturated and which heterocyclic group contains one N atom (the atom to which R5 and R6 are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, CO2H, S(O)pR7, C(O)NRaRb, —(CH2)0-4—NRaRb, —(OCH2CH2)0-4ORc, C1-4 alkyl, C1-4 alkoxy, aryl, heteroaryl and heterocyclyl, which latter five groups are optionally substituted by one or more substituents selected from halo, cyano, CO2H, C1-4 alkyl, C1-4 alkoxy, oxo and hydroxy;
Z represents, independently upon each occurrence, O, C(O)N(R8) or N(R8)C(O);
R6a represents OR7a, —S(O)pR7, N(R7b)R7c or CO2H;
R6b, R6c and R8 independently represent H or methyl;
Ra, Rb and Rc independently represent H or C1-4 alkyl optionally substituted by one or more substituents selected from halo, hydroxy and —CO2H,
or Ra and Rb, together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated, partially unsaturated or fully aromatic and which heterocyclic group contains one N atom (the atom to which Ra and Rb are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, CO2H, C1-4 alkyl, C1-4 alkoxy and C1-4 hydroxyalkyl;
R7 represents C1-4 alkyl optionally substituted by one or more substituents selected from halo, hydroxy and C1-4 alkoxy;
R7a to R7c independently represent H or C1-4 alkyl optionally substituted by one or more halo atoms or by —CO2H,
or R7b and/or R7c represents —[Ca alkylene]-[Cb alkylene]-OR7d,
or R7b and R7c together with the N-atom to which they are attached, form a 4- to 7-membered heterocyclic group that is fully saturated, partially unsaturated or fully aromatic and which heterocyclic group contains one N atom (the atom to which R7b and R7c are attached) and, optionally, one or more further heteroatoms selected from O, S and N, and which heterocyclic group is optionally substituted by one or more substituents selected from halo, hydroxy, oxo, CO2H, C1-4 alkyl, C1-4 alkoxy and C1-4 hydroxyalkyl;
a and b independently represent an integer selected from 1, 2 and 3, wherein the sum of a and b is 2, 3 or 4;
R7d represents H or C1-4 alkyl optionally substituted by one or more halo atoms;
m and p represent, independently upon each occurrence, 0, 1 or 2;
or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.

US Pat. No. 10,556,900

TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

1. A compound of formula I:or a pharmaceutically acceptable salt thereof, wherein:A is phenyl, said phenyl optionally substituted with 1 to 3 groups of Ra;
B is represented by structural formula:

represents a double bond between X1-X2, X2-X3, X3-X4, and/or X4-X5, wherein no more than two double bonds are present at X1-X2, X3-X4, and/X4-X5 at the same time;
X1, X2, X3, X4 and X5 are represented as follows:
X1?C, X2?N, X3?CRc, X4?C, and X5?N;
X6 is CH;
X7 is CR7, wherein R7 is H;
R6 is independently selected from the group consisting of hydrogen, OH, C1-6alkyl, C6-10aryl, and halogen, said alkyl and aryl optionally substituted with 1 to 3 groups of Ra;
R8 is selected from the group consisting of C(CH3)2OH, CH(CH3)OH, methyl, ethyl and propyl;
R is selected from the group consisting of hydrogen, OH, or —C1-6alkyl;
Ra is selected from the group consisting of —CN, NO2, —O—C1-6alkyl, OH, —C1-4haloalkyl, —OC1-4haloalkyl, —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, —(CHR)nC6-10 aryl, —(CHR)nC4-10 heterocycle, C3-6cycloalkyl, —O—, —(CH2)nN(R)2, —C(O)CF3, COR, C(O)OR, —(CH2)nhalo, —(CH2)nNHC(O)R—(CHR)nC(O)N(R)2, said alkyl, cycloalkyl, aryl and heterocycle optionally substituted with 1 to 3 groups of Rb,
Rb is selected from the group consisting of —C1-6alkyl, —C1-6alkylOR, —C1-4haloalkyl, —(CH2)nN(R)2, —(CH2)nOR, —O—, halogen, —CN, —(CH2)nC6-10 aryl, —(CH2)nC4-10 heterocycle, —(CH2)nC(O)N(R)2, —(CH2)nNHC(O)R,
Rc is selected from the group consisting of —C1-6alkyl, —C1-6alkylOR, —C1-4haloalkyl, C(O)R, C(O)OR, —(CH2)nC(O)N(R)2, and —(CH2)nN(R)2, said alkyl optionally substituted with 1 to 3 groups of OH, CH3, and halogen, and
n represents 0-4, with the proviso that the n in —(CH2)nN(R)2 of Rc is 0.

US Pat. No. 10,556,899

METHOD FOR PREPARING MARAVIROC

SCI Pharmtech, Inc., Tao...

1. A method for preparation of maraviroc, comprising reacting an intermediate compound represented by formula (IV) below,with a chlorination agent to obtain an intermediate compound represented by formula (V) below,andcyclizing the intermediate compound represented by formula (V) to obtain an intermediate compound represented by formula (VI) below,
wherein the chlorination agent is SOCl2.

US Pat. No. 10,556,898

INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE

Lycera Corporation, Ann ...

1. A compound represented by Formula I:
or a pharmaceutically acceptable salt thereof, or a solvate of the foregoing; wherein:
R1 is hydrogen, halogen, C1-C3 alkyl, C1-C3haloalkyl, cyclopropyl, C2-C4 alkenyl, cyano, or —N(R6)(R7);
R2, R3, and R4 each represent independently for each occurrence hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C2-C4 alkenyl, or cyano;
R5 is hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, or —CO2R12;
R6 and R7 each represent independently for each occurrence hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, or C3-C6 cycloalkyl; or R6 and R7 when attached to the same nitrogen atom may be taken together with the nitrogen atom to form a 3-7 membered ring optionally substituted with 1 or 2 occurrences of R12;
R8 and R9 each represent independently for each occurrence hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, 3-7 membered heterocycloalkyl, —(C1-C6 alkylene)-O—(C1-C6 alkyl), or —(C1-C6 alkylene)-N(R6)(R7); or R8 and R9 when attached to the same nitrogen atom may be taken together with the nitrogen atom to form a 3-7 membered ring optionally substituted by 1, 2, or 3 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C6 cycloalkyl, C1-C6 alkoxyl, cyano, hydroxyl, —CO2R6, —C(O)N(R6)(R7), —N(R6)C(O)R6, —N(R6)2, and —(C1-C6 alkylene)-CO2R6;
R10 represents independently for each occurrence C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, —(C1-C6 alkylene)-(C3-C6 cycloalkyl), C1-C6 hydroxyalkyl, —(C1-C6 alkylene)-O—(C1-C6 alkyl), —(C1-C6 alkylene)-N(R8)(R9), —(C1-C6 alkylene)-CO2R6, —(C1-C6 alkylene)-(3-7 membered heterocycloalkyl), 3-7 membered heterocyclyl, phenyl, or aralkyl; wherein said cycloalkyl, heterocyclyl, phenyl, and aralkyl are optionally substituted by 1, 2, or 3 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C6 cycloalkyl, C1-C6 alkoxyl, cyano, and hydroxyl;
R11 represents independently for each occurrence a 5-6 membered heteroaryl, 3-7 membered heterocycloalkyl, or phenyl, each of which is optionally substituted with 1 or 2 occurrences of Y1;
R12 represents independently for each occurrence C1-C6 alkyl or C3-C6 cycloalkyl;
R13 represents independently for each occurrence C1-C6 alkyl, C3-C6 cycloalkyl, —(C1-C6 alkylene)-(C3-C6 cycloalkyl), or aralkyl;
A1 is a cyclic group selected from:
(a) phenyl, C3-C7 cycloalkyl, C3-C7 oxocycloalkyl, 5-10 membered heterocyclyl, 5-10 membered oxo-heterocyclyl, aralkyl, or heteroaralkyl, each being substituted by X1 and 0, 1, 2, or 3 occurrences of Y1; and
(b) 8-10 membered bicyclic heterocyclyl optionally substituted by C6 aryl and 0, 1, 2, or 3 occurrences of Y1;
X1 represents independently for each occurrence:
—N(R6)C(O)-(3-7 membered heterocyclyl), —N(R6)C(O)-(3-7 membered oxo-heterocyclyl), —N(R6)C(O)-phenyl, —N(R6)C(O)-aralkyl, or —N(R6)C(O)-heteroaralkyl; each of which is optionally substituted by 1, 2, or 3 occurrences of Y1;
—CO2R8, —C(O)N(R8)(R9), —C(O)R11, —C(O)R12, —C(O)-(3-7 membered heterocyclyl), —C(O)N(R8)(R10), —N(R6)C(O) R10, —N(R10)C(O)R10, —N(R6)CO2R10, —N(R8)SO2R10, —N(R6)—(C1-C6 alkylene)-C(O)N(R8)(R9), —N(R6)—C(O)—(C1-C6 hydroxyalkylene)-N(R8)(R9), —N(R6)—C(O)-(2-6 membered heteroalkyl), —N(R6)C(O)N(R6)(R7), —N(R6)C(O)N(R6)(R10), —N(R6)(R7), or —NO2;
—O—(C1-C6 alkylene)-CO2R8, —OC(O)R12, —O—(C1-C6 alkylene)-C(O)N(R8)(R9), —O—(C1-C6 alkylene)-N(R8)(R9), —O—(C1-C6 alkyl), —O-(3-7 membered heterocyclyl), —O—(C1-C6 alkylene)-aryl, or —O—(C1-C6 alkylene)-heteroaryl;
—SO2R10, —SO2N(R8)-heteroaryl, cyano, —P(O)(OR8)2, or —P(O)(R12)(R13);
5-6 membered heteroaryl, 3-7 membered heterocycloalkyl, 3-7 membered oxo-heterocycloalkyl, or 8-10 membered bicyclic heterocyclyl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of Y1, C6 aryl, and —C(O)—(C6 aryl); or
—(C1-C6 alkylene)-aryl, —(C1-C6 alkylene)-heterocyclyl, —(C1-C6 alkylene)-COR12, —(C1-C6 alkylene)-N(R6)C(O)R10, or —(C1-C6 alkylene)-C(O)N(R8)(R10); and
Y1 represents independently for each occurrence halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C6 cycloalkyl, C1-C6 alkoxyl, C2-C6 alkenyl, cyano, hydroxyl, —CO2R8, —C(O)N(R8)(R9), —N(R6)C(O)R10, —N(R6)C(O)N(R6)(R7), —N(R6)(R7), —(C1-C6 alkylene)-CO2R8, —(C1-C6 alkylene)-O—(C1-C6 alkyl), —(C1-C6alkylene)-N(R6)(R7), —(C1-C6alkylene)-N(R6)S(O)2R12, —(C1-C6alkylene)-S—C(O)R12, —S—R12, 3-7 membered heterocycloalkyl, or —(C1-C6 alkylene)-(3-7 membered heterocycloalkyl).

US Pat. No. 10,556,897

PROTEIN KINASE INHIBITORS

Princeton Drug Discovery,...

1. A method of treating a subject suffering from a cancer selected from Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma, marginal zone lymphomas, mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), T-cell lymphomas, and/or multiple myeloma, comprising administering to the subject a therapeutically effective amount of a compound having the structureand/or a salt, enantiomer, and enantiomeric mixture thereof.

US Pat. No. 10,556,896

CRYSTALLINE FORMS OF (3-AMINO-OXETAN-3-YLMETHYL)-[2-(5,5-DIOXO-5,6,7,9-TETRAHYDRO-5LAMBDA*6*-THIA-8-AZA-BENZOCYCLOHEPTEN-8-YL)-6-METHYL-QUINAZOLIN-4-YL]-AMINE

Hoffmann-La Roche Inc., ...

1. A method for the treatment or prophylaxis of respiratory syncytial virus infection or a disease caused by respiratory syncytial virus infection, which method comprises administering a therapeutically effective amount of the crystalline form of the compound of formula (I):
or a salt, solvent or combination of salts and solvates thereof; wherein the crystalline form is Form A, Form B, Form C, Form D, Form E or Form F, or a combination thereof.

US Pat. No. 10,556,895

QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF

Genentech, Inc., South S...

1. A linker-drug intermediate compound selected from:

US Pat. No. 10,556,894

ANTI-HCMV COMPOSITIONS AND METHODS

Evrys Bio, LLC, Doylesto...

5. A composition comprising a compound of Formula VII or a pharmaceutically acceptable salt thereof:
wherein X1 and X2 are independently selected from CH and N,
p is 0 or 1,
when p is 0, Z1 is CH2,
when p is 1, Z1 is CH2, O, S, or NR7,
R1 is H, halo, —CN, —NO2, —C(O)NR6R7, or C(O)OR6,
R2 is H or a lower straight or branched alkyl or alkenyl optionally substituted with one heteroatom selected of N and O,
R4 is H or a saturated 5- or 6-membered aryl or cycloalkyl with up to two heteroatoms selected from N, O and S,
R6 and R7 are independently selected in each instance from H and lower straight chain or branched alkyl,
when Ring A is aromatic, X5 is CH, CR1, or N, and
when Ring A is not aromatic, X5 is CH2, CHR1, O, S, or NR7.

US Pat. No. 10,556,892

PIPERAZINYL METHANONE NAAA INHIBITORS

The Regents of the Univer...

1. A compound having the formula:
wherein
R1 is independently halogen, —CF3, —CCl3, —CI3, —CBr3, —CHF2, —CHCl2, —CHI2, —CHBr2, —OCH2F, —OCH2Cl, —OCH2I, —OCH2Br, —OCHF2, —OCHCl2, —OCHI2, —OCHBr2, —OCF3, —OCCl3, —OCI3, —OCBr3, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC?(O)NHNH2, —NHC?(O)NH2, —NHSO2H, —NHC?(O)H, —NHC(O)—OH, —NHOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2 is independently halogen, —CF3, —CCl3, —CI3, —CBr3, —CHF2, —CHCl2, —CHI2, —CHBr2, —OCH2F, —OCH2Cl, —OCH2I, —OCH2Br, —OCHF2, —OCHCl2, —OCHI2, —OCHBr2, —OCF3, —OCCl3, —OCI3, —OCBr3, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC?(O)NHNH2, —NHC?(O)NH2, —NHSO2H, —NHC?(O)H, —NHC(O)—OH, —NHOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3 is independently halogen, —CF3, —CCl3, —CI3, —CBr3, —CHF2, —CHCl2, —CHI2, —CHBr2, —OCH2F, —OCH2Cl, —OCH2I, —OCH2Br, —OCHF2, —OCHCl2, —OCHI2, —OCHBr2, —OCF3, —OCCl3, —OCI3, —OCBr3, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC?(O)NHNH2, —NHC?(O)NH2, —NHSO2H, —NHC?(O)H, —NHC(O)—OH, —NHOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
Y is S or O;
z1 is independently an integer from 0 to 4;
z2 is independently an integer from 0 to 8; and
wherein the compound does not have the formula:

US Pat. No. 10,556,891

COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY

Rigel Pharmaceuticals, In...

1. A compound of formula I, or salt thereof,wherein:X and Y are each independently O, S, S(O), SO2 or NR1;
each R1 is independently for each occurrence H, optionally substituted C1-6alkyl, C(O)—C1-6alkyl, CO2—C1-6alkyl or R50;
each R50 is —C(R9)2-A-R10, where A is O or S; each R9 is independently for each occurrence H, optionally substituted C1-6alkyl, optionally substituted C6-10aryl or optionally substituted C7-16arylalkyl; or alternatively, two R9, together with the carbon to which they are attached, form an optionally substituted C3-8cycloalkyl group or an optionally substituted 3-8 membered heteroalicyclyl; R10 is Ra or —P(O)(OR11)2; each R11 is independently for each occurrence Ra or a monovalent cationic group; or two R11, together with the atoms to which they are attached, form a 4-8 membered cyclic phosphate group, or two R11 together represent a divalent cationic group;
ring A is bicyclic aryl ring system, or ring A is
where the Rb substituent foris OH, C1-6alkyl, —CO2C1-6alkyl, —C(O)C1-6alkyl or —S(O)2C1-6alkyl;each R2 is independently for each occurrence H, Re, Rb, Re substituted with one or more of the same or different Ra and/or Rb, —ORe substituted with one or more of the same or different Ra and/or Rb, —SRe substituted with one or more of the same or different Ra and/or Rb, —C(O)Re substituted with one or more of the same or different Ra and/or Rb, —N(Ra)Re where Re is substituted with one or more of the same or different Ra and/or Rb, —S(O)2Re substituted with one or more of the same or different Ra and/or Rb, —N(Ra)—S(O)2Re where Re is substituted with one or more of the same or different Ra and/or Rb, —B(ORa)2, —B(N(Rc)2)2, —(C(Ra)2)m—Rb, —O—(C(Ra)2)m—Rb, —S—(C(Ra)2)m—Rb, —O—(C(Rb)2)m—Ra, —N(Ra)—(C(Ra)2)m—Rb, —O—(CH2)m—CH((CH2)mRb)Rb, —C(O)N(Ra)—(C(Ra)2)m—Rb, —O—(C(Ra)2)m—C(O)N(Ra)—(C(Ra)2)m—Rb, —N((C(Ra)2)mRb)2, —S—(C(Ra)2)m—C(O)N(Ra)—(C(Ra)2)m—Rb, —N(Ra)—C(O)—N(Ra)—(C(Ra)2)m—Rb, —N(Ra)—C(O)—(C(Ra)2)m—C(Ra)(Rb)2 or —N(Ra)—(C(Ra)2)m—C(O)—N(Ra)—(C(Ra)2)m—Rb;
each Ra is independently for each occurrence H, deuterium, C1-6alkyl, C3-8cycloalkyl, C4-11cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 2-6 membered heteroalkyl, 3-10 membered heteroalicyclyl, 4-11 membered heteroalicyclylalkyl, 5-15 membered heteroaryl or 6-16 membered heteroarylalkyl;
each Rb is independently for each occurrence ?O, —ORa, —O—(C(Ra)2)m—ORa, haloC1-3alkyloxy, ?S, —SRa, ?NRa, ?NORa, —N(Rc)2, halo, —CF3, —CN, —NC, —OCN, —SCN, —NO, —NO2, ?N2, —N3, —S(O)Ra, —S(O)2Ra, —SO3Ra, —S(O)N(Rc)2, —S(O)2N(Rc)2, —OS(O)Ra, —OS(O)2Ra, —OSO3Ra, —OS(O)2N(Rc)2, —C(O)Ra, —CO2Ra, —C(O)N(Rc)2, —C(NRa)—N(Rc)2, —C(NOH)—Ra, —C(NOH)—N(Rc)2, —OC(O)Ra, —OC(O)ORa, —OC(O)N(Rc)2, —OC(NH)—N(Rc)2, —OC(NRa)—N(Rc)2, —N(Ra)—S(O)2H, —[N(Ra)C(O)]nRa, —[N(Ra)C(O)]nORa, —[N(Ra)C(O)]nN(Rc)2 or —[N(Ra)C(NRa)]n—N(Rc)2;
each Rc is independently for each occurrence Ra, or, alternatively, two Rc are taken together with the nitrogen atom to which they are bonded to form a 3 to 10-membered heteroalicyclyl or a 5-10 membered heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which is optionally substituted with one or more of the same or different Ra and/or Rd groups;
each Rd is ?O, —ORa, haloC1-3alkyloxy, C1-6alkyl, ?S, —SRa, ?NRa, ?NORa, —N(Ra)2, halo, —CF3, —CN, —NC, —OCN, —SCN, —NO, —NO2, ?N2, —N3, —S(O)Ra, —S(O2)Ra, —SO3Ra, —S(O)N(Ra)2, —S(O)2N(Ra)2, —OS(O)Ra, —OS(O)2Ra, —OSO3Ra, —OS(O)2N(Ra)2, —C(O)Ra, —CO2Ra, —C(O)N(Ra)2, —C(NRa)N(Ra)2, —C(NOH)Ra, —C(NOH)N(Ra)2, —OCO2Ra, —OC(O)N(Ra)2, —OC(NRa)N(Ra)2, —[N(Ra)C(O)]nRa, —(C(Ra)2)n-ORa, —N(Ra)—S(O)2Ra, —C(O)—C1-6haloalkyl, —S(O)2C1-6haloalkyl, —OC(O)Ra, —O(C(Ra)2)m—ORa, —S(C(Ra)2)m—ORa, —N(Ra)C1-6haloalkyl, —P(O)(ORa)2, —N(Ra)—(C(Ra)2)m—ORa, —[N(Ra)C(O)]nORa, —[N(Ra)C(O)]nN(Ra)2, —[N(Ra)C(NRa)]nN(Ra)2 or —N(Ra)C(O)C1-6haloalkyl; or two Rd, taken together with the atom or atoms to which they are attached, combine to form a 3-10 membered partially or fully saturated mono or bicyclic ring, optionally containing one or more heteroatoms and optionally substituted with one or more Ra;
each Re is independently for each occurrence C1-6alkyl, C3-8scycloalkyl, C4-11 cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 2-6 membered heteroalkyl, 3-10 membered heteroalicyclyl, 4-11 membered heteroalicyclylalkyl, 5-15 membered heteroaryl or 6-16 membered heteroarylalkyl;
p is 0, 1, 2, 3 or 4;
each m is 1, 2 or 3;
each n is 0, 1, 2 or 3;
two R2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered partially or fully saturated mono or bicyclic ring, optionally containing one or more heteroatoms and optionally substituted with one or more Ra and/or Rb;
Z1 and Z2 are each independently CH, CR2 or N;
R3 is H, optionally substituted C1-6alkyl or R50;
R4 is H, optionally substituted C1-6alkyl or R50; and
R5 is halo, —CN, optionally substituted C1-6alkyl, alkynyl, hydroxy, optionally substituted C1-6alkoxy, nitro, —N(Ra)2, —C(O)N(Ra)2, —CO2Ra or —C(O)Ra.

US Pat. No. 10,556,890

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Sunovion Pharmaceuticals ...

1. A compound selected from:
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,556,889

SALVINORIN DERIVATIVES

Blue Sky Pharmaceuticals,...

1. A compound of Formula Ib or a salt thereof,
wherein
R2, R3, and R4 are each independently selected from the group consisting of hydrogen, halogen, CH3, CN, O(CHF2), CF3, OCH3, and OCF3;
and Z is selected from the group consisting of O and NH.

US Pat. No. 10,556,888

PYRAZOLE COMPOUNDS OR SALTS THEREOF, PREPARATION METHODS THEREFOR, HERBICIDAL COMPOSITIONS AND USE THEREOF

QINGDAO KINGAGROOT CHEMIC...

11. A method for controlling a harmful plant comprising applying an herbicidally effective amount of at least one pyrazole compound or the salt thereof according to claim 1 or an herbicidal composition comprising the pyrazole compound or the salt thereof to the plant or an area with the plant.

US Pat. No. 10,556,887

PROCESSES FOR THE PREPARATION OF VELIPARIB AND INTERMEDIATES THEREOF

Apotex Inc., Toronto, On...

1. A process for preparing Veliparib (1):
or a salt thereof, comprising
(i) cyclizing, in the presence of an acid (A1), a compound of Formula (3):

wherein
G is CONH2 or R;
R is CO2R1 or CN; and
R1 is selected from the group consisting of H, an aliphatic group, a substituted aliphatic group, aryl, substituted aryl, arylalkyl and substituted arylalkyl;
to provide either Veliparib (1) when G is CONH2, or,
when G is R, a compound of Formula (2):

 and
wherein
R is CO2R1 or CN; and
R1 is selected from the group consisting of H, an aliphatic group, a substituted aliphatic group, aryl, substituted aryl, arylalkyl and substituted arylalkyl; and
(ii) when G is R, converting the compound of Formula (2) to Veliparib (1).

US Pat. No. 10,556,886

METAL-ORGANIC HYBRID STRUCTURES BUILT WITH MULTI-DIRECTIONAL POLYDENTATE LIGANDS

LG CHEM, LTD., Seoul (KR...

1. A metal-organic hybrid structure formed by the coordinate bonding of a compound represented by the following Chemical Formula 1 or a salt thereof with metal ions:
in the Chemical Formula 1,
R's are each independently —R1, —NH—CO—R2, or —NH—R3,
R1's are each independently —OH, a C6-60 aryl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, tert-pentyl, neopentyl, isopentyl, sec-pentyl, 3-pentyl, or an amino acid residue,
R2's are a C1-10 alkyl, a C6-60 aryl, or a C4-60 heteroaryl containing one of N, O, and S, and
R3's are a C1-10 alkyl, or a C4-60 heteroaryl containing one of O and S.

US Pat. No. 10,556,885

ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF

Samumed, LLC, San Diego,...

1. A compound, or a pharmaceutically acceptable salt thereof, of Formula I:
wherein:
R1, R2, R4, and R5 are H;
R3 is

R6 is selected from the group consisting of —(C1-2 alkylene)pheterocyclyl optionally substituted with 1-3 R36.; wherein —(C1-4 alkylene) is optionally substituted with one or more halides;
R32 is selected from the group consisting of H, halide, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 haloalkyl), and —N(R53)2;
each R36 is independently selected from the group consisting of halide, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 haloalkyl), —(C1-4 alkylene)OR42, —(C1-2 alkylene)pheterocyclyl optionally substituted with 1-2 R43, —(C1-2 alkylene)pcarbocyclyl optionally substituted with 1-2 R44, and —SO2(R52); wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more halides;
each R42 is independently selected from the group consisting of H and unsubstituted —(C1-3 alkyl);
each R43 is independently selected from the group consisting of halide and unsubstituted —(C1-3 alkyl);
each R44 is independently selected from the group consisting of halide, unsubstituted —(C1-5 alkyl), and unsubstituted —(C1-5 haloalkyl);
each R52 is selected from the group consisting of unsubstituted —(C1-3 alkyl) and -aryl optionally substituted with one or more halides;
each R53 is independently selected from the group consisting of H and unsubstituted —(C1-2 alkyl);
X is O or S; and
each p is independently 0 or 1;
wherein one or more H are optionally replaced by D;
wherein each heterocyclyl is independently a nonaromatic cyclic ring system comprising at least one hetereoatom in the ring system backbone.

US Pat. No. 10,556,884

PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULPHUR CONTAINING SUBSTITUENTS

Syngenta Participations A...

1. A compound of formula I,
wherein
G1 is nitrogen or CR2;
G2 is nitrogen or CR3;
G3 is nitrogen or CR4;
G4 is nitrogen or CR5;
G5 is nitrogen or CR6, with the proviso that not more than 2 nitrogen as G may follow consecutively;
R2, R3, R4, R5 and R6 are, independently from each other, hydrogen, halogen, C1-C6haloalkyl or C1-C6alkyl; or
R2, R3, R4, R5 and R6 are, independently from each other, C1-C6haloalkylsulfanyl, C1-C6haloalkylsulfinyl, C1-C6haloalkylsulfonyl, C1-C6alkylsulfanyl, C1-C6alkylsulfinyl, C1-C6alkylsulfonyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C4haloalkoxyC1-C4alkyl, C1-C4alkoxyC1-C4alkyl, SF5, cyano, C3-C6cycloalkylC1-C4alkyl or —C(O)C1-C6haloalkyl; or
R2, R3, R4, R5 and R6 are, independently from each other, C3-C6cycloalkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, cyano, C1-C4haloalkyl and C1-C4alkyl;
R8 is hydrogen, C1-C6alkyl, C1-C6haloalkyl or C1-C4alkyl substituted by C1-C4alkylsulfanyl;
R7 is a radical selected from the group consisting of formula Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13 and Q14

wherein the arrow denotes the point of attachment to the triazole ring;
A represents CH or N;
X is S, SO or SO2;
R1 is C1-C4alkyl or C1-C4haloalkyl; or
R1 is C3-C6cycloalkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl; or
R1 is C3-C6cycloalkyl-C1-C4alkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl;
R9 is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxyC1-C4alkyl, hydroxyl, C1-C6alkoxy or S(O)mR13; or
R9 is C3-C6cycloalkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl; or
R9 is C3-C6cycloalkyl-C1-C4alkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl;
R10 is hydrogen, C1-C6alkyl, cyano, C1-C6alkoxy, C1-C6haloalkoxy, C2-C6alkynyl, C2-C6alkenyl, amino, NH—CN, N—(C1-C4alkyl)amino, N—(C1-C4 alkyl)N—(C1-C4 alkyl)amino, N—(C3-C6cycloalkyl)amino, N—(C1-C4alkyl)N—(C3-C6cycloalkyl)amino, N—(C1-C4alkylcarbonyl)amino, N—(C1-C4alkyl)N—(C1-C4alkylcarbonyl)amino, N—(C1-C4 alkyl)N—(C3-C6cycloalkylcarbonyl)amino, N—(C3-C6cycloalkylcarbonyl)amino, N—(C1-C4alkylcarbonyl)N—(C3-C6cycloalkyl)amino or —S(O)mR13; or
R10 is C1-C4alkyl mono- or polysubstituted by substituents independently selected from the group Z; or
R10 is a five to six-membered ring aromatic or heteroaromatic system, said aromatic or heteroaromatic ring system can contain 1 to 4 hetero atoms selected from the group consisting of nitrogen, oxygen and sulfur, with the proviso that each ring system cannot contain more than 2 oxygen atoms and more than 2 sulfur atoms, said five to six-membered ring system can be mono- or polysubstituted by substituents independently selected from the group V;
R11 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C1-C6 haloalkoxy, amino, N—C1-C4alkylamino, N—(C1-C4 alkyl)N—(C3-C6 cycloalkyl)amino, N—(C3-C6 cycloalkyl)amino or N—(C1-C4 alkyl)N—(C1-C4 alkyl)amino; or
R11 is C1-C4alkyl mono- or polysubstituted by substituents independently selected from the group Z; or
R11 is C3-C6cycloalkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl; or
R11 is C3-C6cycloalkyl-C1-C4alkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl; or
R11 is a five- to six-membered aromatic or heteroaromatic ring system, said aromatic or heteroaromatic ring system can contain 1 to 4 hetero atoms selected from the group consisting of nitrogen, oxygen and sulfur, with the proviso that each ring system cannot contain more than 2 oxygen atoms and more than 2 sulfur atoms, said five- to six-membered aromatic or heteroaromatic ring system can be mono- or polysubstituted by substituents independently selected from the group V;
R12 is hydrogen, C1-C6 alkyl, C1-C6alkoxy, hydroxyl or C1-C6 haloalkoxy; or
R12 is C1-C4alkyl mono- or polysubstituted by substituents independently selected from the group Z; or
R12 is C3-C6cycloalkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl; or
R12 is C3-C6cycloalkyl-C1-C4alkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl;
R13 is C1-C4alkyl, C1-C4haloalkyl, N—C1-C4alkylamino, N,N—(C1-C4 alkyl)2amino or phenyl; said phenyl can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4alkyl, cyano, C1-C4haloalkyl and C1-C4alkoxy; or
R13 is C3-C6cycloalkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl; or
R13 is C3-C6cycloalkylC1-C4alkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl;
m is 0, 1 or 2;
R14 is hydrogen or C1-C6 alkyl;
R15 is hydrogen, C1-C6 alkyl, C1-C6alkoxy, C1-C6 haloalkoxy, amino, N—C1-C4alkylamino or N,N—(C1-C4 alkyl)2amino; or
R15 is C1-C4alkyl mono- or polysubstituted by substituents independently selected from the group Z; or
R15 is C3-C6cycloalkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl; or
R15 is C3-C6cycloalkyl-C1-C4alkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl;
p is 0 or 1;
R16 is hydrogen or C1-C6 alkyl;
R17 is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy or C1-C6 haloalkoxy; or
R17 is amino which can be mono- or disubstituted by substituents selected from the group consisting of cyano, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C3-C6cycloalkyl and C3-C6cycloalkyl-C1-C4alkyl, said C3-C6cycloalkyl and C3-C6cycloalkyl-C1-C4alkyl groups itself can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl; or
R17 is C1-C4alkyl mono- or polysubstituted by substituents independently selected from the group Z; or
R17 is C3-C6cycloalkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl; or
R17 is C3-C6cycloalkyl-C1-C4alkyl which can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl; or
R17 is a five- to six-membered ring aromatic or heteroaromatic ring system, said aromatic or heteroaromatic ring system can contain 1 to 4 hetero atoms selected from the group consisting of nitrogen, oxygen and sulfur, with the proviso that each ring system cannot contain more than 2 oxygen atoms and more than 2 sulfur atoms, said five- to six-membered aromatic or heteroaromatic ring system can be mono- to polysubstituted by substituents independently selected from the group V;
R18 is hydrogen, halogen, C1-C4haloalkyl, amino, cyano, C1-C4alkyl, C3-C6cycloalkyl, or is C3-C6cycloalkyl mono-, di- or tri-substituted by substituents selected from the group consisting of halogen, C1-C4haloalkyl, cyano and C1-C4alkyl;
R19 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C3-C6cycloalkylC1-C4alkyl, C3-C6cycloalkyl;
Z is cyano, halogen, hydroxy, —SH, amino, nitro, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylsulfanyl, C1-C4haloalkylsulfanyl, C1-C4alkylsulfinyl, C1-C4haloalkylsulfinyl, C1-C4alkylsulfonyl, C1-C4haloalkylsulfonyl or phenyl; said phenyl can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4alkylsulfanyl, C1-C4haloalkylsulfanyl, C1-C4 alkylsulfinyl, C1-C4haloalkylsulfinyl, C1-C4alkylsulfonyl, C1-C4haloalkylsulfonyl, cyano, C1-C4haloalkyl and C1-C4alkyl; or Z is pyridyl; said pyridyl can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4 alkylsulfanyl, C1-C4haloalkylsulfanyl, C1-C4alkylsulfinyl, C1-C4haloalkylsulfinyl, C1-C4alkylsulfonyl, C1-C4haloalkylsulfonyl, cyano, C1-C4haloalkyl and C1-C4alkyl; or Z is pyrimidyl; said pyrimidinyl can be mono- or polysubstituted by substituents selected from the group consisting of halogen, C1-C4alkylsulfanyl, C1-C4haloalkylsulfanyl, C1-C4alkylsulfinyl, C1-C4haloalkylsulfinyl, C1-C4alkylsulfonyl, C1-C4haloalkylsulfonyl, cyano, C1-C4haloalkyl and C1-C4alkyl; and
V is cyano, halogen, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4alkoxy, C1-C4alkoxyC1-C4 alkyl, C1-C4haloalkyl, C1-C4haloalkoxy, C1-C4alkylsulfanyl, C1-C4haloalkylsulfanyl, C1-C4alkylsulfinyl, C1-C4haloalkylsulfinyl, C1-C4alkylsulfonyl or C1-C4haloalkylsulfonyl; and agrochemically acceptable salts, stereoismers, enantiomers, tautomers and N-oxides of the compounds of formula I.

US Pat. No. 10,556,883

BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AND COSMETICS

1. A compound of formula (I), a salt thereof, or an enantiomer thereof,
wherein:
R1 is a hydrogen atom, an alkyl radical, a substituted alkyl radical, an alkenyl radical, a substituted alkenyl radical, an alkynyl radical, a substituted alkynyl radical, an aralkyl radical, a substituted aralkyl radical, a heteroaralkyl radical, a substituted heteroaralkyl radical, a cycloalkyl radical, a substituted cycloalkyl radical, a heterocyclic radical, a substituted heterocyclic radical, an amine radical, a substituted amine radical, a cyclic amine radical, or a heterocyclic amine radical;
R2 is a hydrogen atom, an alkyl radical or a substituted alkyl radical,
R3 is a hydrogen atom, an alkyl radical, a substituted alkyl radical, an alkynyl radical, a substituted alkynyl radical, an alkoxy radical, a halogen radical, or a nitrite radical; and
n is 0 or 1.

US Pat. No. 10,556,881

NRF2 ACTIVATING COMPOUNDS AND USES THEREOF

Rigel Pharmaceuticals, In...

1. A compound of formula (I):wherein:X1 and X2 are each independently selected from N and CH, wherein at least one of X1 and X2 is N;
either Y1 is sulfonyl and Y2 is hydrogen, or Y2 is sulfonyl and Y1 is hydrogen; and
R1 is R15, wherein R15 comprises a linking group and a compound of formula (I);
or a salt or stereoisomer thereof.

US Pat. No. 10,556,879

RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF

SHANGHAI INSTITUTE OF ORG...

1. A compound represented by formula I, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof,
wherein:
(i) U is N, V is CR9b, X is N, W is CR9d, and the compound is represented by:

(ii) U is CR9a, V is N, X is CR9c, W is N, and the compound is represented by:

(iii) U is N, V is CR9b, X is CR9c, W is N, and the compound is represented by:

(iv) U is CR9a, V is CR9b, X is CR9c, W is N, and the compound is represented by:

(v) U is CR9a, V is CR9b, X is CR9c, W is CR9d, and the compound is represented by:

in the definition of compound F, one, two, three, or four of R9a, R9b, R9c and R9d is not hydrogen;
in the definition of U, V, X and W, each of R9a, R9b, R9c and R9d is independently hydrogen, hydroxy, nitro, cyano, halogen, C1-C6 alkyl, C1-C6 alkyl substituted with halogen, C1-C6 alkoxy, —NR10R11,
or —COOR14;each of R10, R11, R12, R13 and R14 is independently hydrogen or C1-C6 alkyl;
the bond connecting AE, EG or GZ is independently a single bond;
Z is —O—, —S—, —S(?O)— or —SO2—;
E is —CH2—;
G is —CH2—;
A is —(CR2R3)—;
each of R2 and R3 is independently hydrogen, hydroxy, halogen, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkyl substituted with halogen, C1-C6 alkoxy, C1-C6 acyl, C6-C10 aryl or “C3-C6 heteroaryl having 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen”;
m is 0, 1, 2 or 3;
when there are more than one substituents of R1, the substituents are identical or different; R1 is hydrogen, hydroxy, nitro, cyano, halogen, C1-C6 alkyl, C1-C6 alkyl substituted with halogen, C1-C6 alkoxy, —NR6R7 or —COOR8;
each of R6, R7 and R8 is independently hydrogen or C1-C6 alkyl;
Y is —CN, —COOR15 or —CO2NHR16;
each of R15 and R16 is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl or C1-C6 alkylacyl;
with a proviso that the compound represented by formula I is not

US Pat. No. 10,556,878

THIOUREA COMPOUNDS AND THEIR USE AS INHIBITORS OF SIRT2 OR SIRT5

CORNELL UNIVERSITY, Itha...

1. A compound useful as a Sirt2 or Sirt5 inhibitor having the formula:
wherein:
R1 is a carboxylate salt, carboxylic acid, carboxylic acid ester, or thiocarboxylate group;
R2a, R2b, and R2c are independently selected from hydrogen atom and methyl groups;
X0, X1, X2, and X3 are independently selected from —(CH2)n— and a bond, wherein n represents 1, 2, or 3, provided that at least one of X0-X3 is —(CH2)n—; and
R3 is selected from hydrocarbon groups containing 1-20 carbon atoms and optionally containing one or more heteroatoms selected from oxygen, nitrogen, sulfur, and halogen atoms; and R4 comprises a cyclic hydrocarbon group optionally containing one or more heteroatoms selected from oxygen, nitrogen, sulfur, and halogen atoms.

US Pat. No. 10,556,877

PROCESS FOR PREPARATION OF DAPAGLIFLOZIN

Glenmark Life Sciences Li...

1. A process for the preparation of dapagliflozin in amorphous form, the process comprising:(a) reducing a compound of formula II to a compound of formula III in the presence of a Lewis acid;
wherein the compound of formula II is prepared by reacting 5-bromo-2-chlorobenzoyl chloride with ethoxybenzene;(b) silylating a compound of formula IV with hexamethyldisilazane to form a compound of formula V;

(c) reacting the compound of formula III with the compound of formula V in the presence of a strong base followed by treatment with an acid in the presence of an alcohol to prepare a compound of formula VII, wherein R is an alkyl group selected from C1-5 alkyl;

(d) converting the compound of formula VII to dapagliflozin;
(e) acetylating dapagliflozin to give D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, 2,3,4,6-tetraacetate, (1S)-, a compound of formula VIII;

(f) purifying the compound of formula VIII by a series of crystallizing steps to obtain the compound of formula VIII with a purity of ?99.6%, wherein the series of crystallizing steps comprises:
(1) crystallizing the compound of formula VIII with methanol,
(2) crystallizing the product of step (f)(1) with diisopropyl ether, and
(3) crystallizing the product of step (f)(2) with methanol;
(g) hydrolyzing the compound of formula VIII obtained in step (f) to give dapagliflozin;
(h) dissolving dapagliflozin of step (g) in isopropyl alcohol to form a solution; and
(i) recovering amorphous dapagliflozin from the solution of step (h), wherein the recovering comprises one of:
(1) removing the isopropyl alcohol from the solution obtained in step (h) comprising concentrating the solution of step (h) and degassing; or
(2) treating the solution of step (h) with cyclohexane,wherein the amorphous dapagliflozin is obtained in a purity of ?99.8% and wherein a level of impurity A and impurity B is less than 0.15%

US Pat. No. 10,556,875

BIS-DIAZENIUMDIOLATE COMPOUNDS AS ANTI-CANCER AGENTS

ARIZONA BOARD OF REGENTS ...

1. A compound selected from formula I:
wherein:
X is CH or N; and
L is selected from C1-C10 alkyldiyl, C1-C10 alkyldiyl-(C3-C6 cycloalkyldiyl), and C1-C10 alkyldiyl-(C3-C6 cycloalkyldiyl)-C1-C10 alkyldiyl, where alkyldiyl and cycloalkyldiyl are independently and optionally substituted with one or more groups selected from halo, hydroxy, nitro, cyano, (C1-C6) alkoxy, and oxo (?O);
or a pharmaceutically-acceptable salt thereof.

US Pat. No. 10,556,874

N-(1,3,4-OXADIAZOL-2-YL)ARYL CARBOXAMIDE DERIVATIVES WITH HERBICIDAL ACTION

BAYER CROPSCIENCE AKTIENG...

1. An N-(1,3,4-oxadiazol-2-yl)arylcarboxamide derivative of formula (I)wherein the symbols and indices are each defined as follows:W is N or CY,
X and Z are each independently hydrogen, nitro, halogen, cyano, formyl, thiocyanato, (C1-C6)-alkyl, (C1-C6)-haloalkyl, (C2-C6)-alkenyl, (C2-C6)-haloalkenyl, (C2-C6)-alkynyl, (C3-C6)-haloalkynyl, (C3-C6)-cycloalkyl, (C3-C6)-halocycloalkyl, (C3-C6)-cycloalkyl-(C1-C6)-alkyl, (C3-C6)-halocycloalkyl-(C1-C6)-alkyl, COR1, OR1, OCOR1, OSO2R2, S(O)nR2, SO2OR1, SO2N(R1)2, NR1SO2R2, NR1COR1, (C1-C6)-alkyl-S(O)nR2, (C1-C6)-alkyl-OR1, (C1-C6)-alkyl-OCOR1, (C1-C6)-alkyl-OSO2R2, (C1-C6)-alkyl-CO2R1, (C1-C6)-alkyl-SO2OR1, (C1-C6)-alkyl-CON(R1)2, (C1-C6)-alkyl-SO2N(R1)2, (C1-C6)-alkyl-NR1COR1, (C1-C6)-alkyl-NR1SO2R2, NR1R2, or P(O)(OR5)2, or
heteroaryl, heterocyclyl or phenyl, each substituted by s radicals selected from the group consisting of methyl, ethyl, methoxy, nitro, trifluoromethyl and halogen,
Y is hydrogen, nitro, halogen, cyano, thiocyanato, (C1-C6)-alkyl, halo-(C1-C6)-alkyl, (C2-C6)-alkenyl, halo-(C2-C6)-alkenyl, (C2-C6)-alkynyl, halo-(C2-C6)-alkynyl, (C3-C6)-cycloalkyl, (C3-C6)-cycloalkenyl, halo-(C3-C6)-cycloalkyl, (C3-C6)-cycloalkyl-(C1-C6)-alkyl, halo-(C3-C6)-cycloalkyl-(C1-C6)-alkyl, COR1, CO2R1, OCO2R1, NR1CO2R1, C(O)N(R1)2, NR1C(O)N(R1)2, OC(O)N(R1)2, C(O)N(R1)OR1, NR1SO2R2, NR1COR1, OR1, OSO2R2, S(O)nR2, SO2OR1, SO2N(R1)2, (C1-C6)-alkyl-S(O)nR2, (C1-C6)-alkyl-OR1, (C1-C6)-alkyl-OCOR1, (C1-C6)-alkyl-OSO2R2, (C1-C6)-alkyl-CO2R1, (C1-C6)-alkyl-CN, (C1-C6)-alkyl-SO2OR1, (C1-C6)-alkyl-CON(R1)2, (C1-C6)-alkyl-SO2N(R1)2, (C1-C6)-alkyl-NR1COR1, (C1-C6)-alkyl-NR1SO2R2, N(R1)2, P(O)(OR5)2, CH2P(O)(OR5)2, CH?NOR1, (C1-C6)-alkyl-CH?NOR1, or (C1-C6)-alkyl-O—N?C(R1)2, or
(C1-C6)-alkylphenyl, (C1-C6)-alkylheteroaryl, (C1-C6)-alkylheterocyclyl, phenyl, heteroaryl or heterocyclyl, each substituted by s radicals selected from the group consisting of halogen, nitro, cyano, (C1-C6)-alkyl, halo-(C1-C6)-alkyl, (C3-C6)-cycloalkyl, S(O)n—(C1-C6)-alkyl, (C1-C6)-alkoxy, halo-(C1-C6)-alkoxy, (C1-C6)-alkoxy-(C1-C4)-alkyl and cyanomethyl, and wherein heterocyclyl bears n oxo groups,
or
Y and Z together with the two atoms to which they are bonded form a 5-, 6- or 7-membered, unsaturated, partly saturated or saturated ring which, as well as carbon atoms, in each case has s nitrogen atoms, n oxygen atoms, n sulfur atoms and n S(O), S(O)2, C?N—R8, C(OR9)2, C[—O—(CH2)2—O—] or C(O) elements as ring members,
wherein the carbon atoms are substituted in each case by s radicals selected from the group consisting of halogen, cyano, (C1-C6)-alkyl, (C2-C10)-alkenyl, (C2-C10)-alkynyl, (C1-C6)-haloalkyl, (C1-C6)-alkoxy, phenoxy, halo-(C1-C6)-alkoxy, (C3-C8)-cycloalkyl, (C2-C8)-alkoxyalkyl and phenyl,
wherein the nitrogen atoms are substituted in each case by n radicals selected from the group consisting of (C1-C6)-alkyl and phenyl,
and in which the aforementioned phenyl radicals are substituted in each case by s radicals selected from the group consisting of cyano, nitro, halogen, (C1-C6)-alkyl, (C1-C6)-haloalkyl and (C1-C6)-alkoxy,
V is hydrogen, nitro, halogen, cyano, (C1-C4)-alkyl, (C1-C4)-haloalkyl, OR1 or S(O)nR2,
R1 is hydrogen, or
(C1-C6)-alkyl, (C1-C6)-haloalkyl, (C2-C6)-alkenyl, (C2-C6)-haloalkenyl, (C2-C6)-alkynyl, (C2-C6)-haloalkynyl, (C3-C6)-cycloalkyl, (C3-C6)-cycloalkenyl, (C3-C6)-halocycloalkyl, (C1-C6)-alkyl-O—(C1-C6)-alkyl, (C3-C6)-cycloalkyl-(C1-C6)-alkyl, phenyl, phenyl-(C1-C6)-alkyl, heteroaryl, (C1-C6)-alkylheteroaryl, heterocyclyl, (C1-C6)-alkylheterocyclyl, (C1-C6)-alkyl-O-heteroaryl, (C1-C6)-alkyl-O-heterocyclyl, (C1-C6)-alkyl-NR3-heteroaryl or (C1-C6)-alkyl-NR3-heterocyclyl, each substituted by s radicals selected from the group consisting of cyano, halogen, nitro, thiocyanato, OR3, S(O)nR4, N(R3)2, NR3OR3, COR3, OCOR3, SCOR4, NR3COR3, NR3SO2R4, CO2R3, COSR4, CON(R3)2 and (C1-C4)-alkoxy-(C2-C6)-alkoxycarbonyl, and wherein heterocyclyl bears n oxo groups,
R2 is (C1-C6)-alkyl, (C1-C6)-haloalkyl, (C2-C6)-alkenyl, (C2-C6)-haloalkenyl, (C2-C6)-alkynyl, (C2-C6)-haloalkynyl, (C3-C6)-cycloalkyl, (C3-C6)-cycloalkenyl, (C3-C6)-halocycloalkyl, (C1-C6)-alkyl-O—(C1-C6)-alkyl, (C3-C6)-cycloalkyl-(C1-C6)-alkyl, phenyl, phenyl-(C1-C6)-alkyl, heteroaryl, (C1-C6)-alkylheteroaryl, heterocyclyl, (C1-C6)-alkylheterocyclyl, (C1-C6)-alkyl-O-heteroaryl, (C1-C6)-alkyl-O-heterocyclyl, (C1-C6)-alkyl-NR3-heteroaryl, (C1-C6)-alkyl-NR3-heterocyclyl, each substituted by s radicals selected from the group consisting of cyano, halogen, nitro, thiocyanato, OR3, S(O)nR4, N(R3)2, NR3OR3, COR3, OCOR3, SCOR4, NR3COR3, NR3SO2R4, CO2R3, COSR4, CON(R3)2 and (C1-C4)-alkoxy-(C2-C6)-alkoxycarbonyl, and wherein heterocyclyl bears n oxo groups,
R3 is hydrogen, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C3-C6)-cycloalkyl or (C3-C6)-cycloalkyl-(C1-C6)-alkyl,
R4 is (C1-C6)-alkyl, (C2-C6)-alkenyl or (C2-C6)-alkynyl, (C3-C6)-cycloalkyl or (C3-C6)-cycloalkyl-(C1-C6)-alkyl,
R5 is (C1-C4)-alkyl,
n is 0, 1 or 2,
s is 0, 1, 2 or 3,
A is an A1, A2, or A3 radical

R is (C1-C6)-alkyl-OC(O)N(R3)2 or (C1-C6)-alkyl-OC(O)OR10,
R6 is hydrogen, or
(C1-C6)-alkyl, R1O—(C1-C6)-alkyl, CH2R7, (C3-C7)-cycloalkyl, halo-(C1-C6)-alkyl, (C2-C6)-alkenyl, halo-(C2-C6)-alkenyl, (C2-C6)-alkynyl, halo-(C2-C6)-alkynyl, OR1, NHR1, methoxycarbonyl, ethoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, methylcarbonyl, trifluoromethylcarbonyl, dimethylamino, acetylamino, methylsulfenyl, methylsulfinyl, or methylsulfonyl, or
heteroaryl, heterocyclyl, benzyl or phenyl, each substituted by s radicals selected from the group consisting of halogen, nitro, cyano, (C1-C6)-alkyl, halo-(C1-C6)-alkyl, (C3-C6)-cycloalkyl, S(O)n—(C1-C6)-alkyl, (C1-C6)-alkoxy, halo-(C1-C6)-alkoxy and (C1-C6)-alkoxy-(C1-C4)-alkyl,
R7 is acetoxy, acetamido, N-methylacetamido, benzoyloxy, benzamido, N-methylbenzamido, methoxycarbonyl, ethoxycarbonyl, benzoyl, methylcarbonyl, piperidinylcarbonyl, morpholinylcarbonyl, trifluoromethylcarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, (C1-C6)-alkoxy, or (C3-C6)-cycloalkyl, or
heteroaryl, heterocyclyl or phenyl, each substituted by s radicals from the group consisting of methyl, ethyl, methoxy, trifluoromethyl and halogen,
R8 is (C1-C6)-alkyl, halo-(C1-C6)-alkyl, (C1-C6)-alkoxy or halo-(C1-C6)-alkoxy,
R9 is (C1-C6)-alkyl or halo-(C1-C6)-alkyl, and
R10 is (C1-C6)-alkyl, halo-(C1-C6)-alkyl or (C1-C6)-cycloalkyl.

US Pat. No. 10,556,873

BIMODAL LIGANDS WITH MACROCYCLIC AND ACYCLIC BINDING MOIETIES, COMPLEXES AND COMPOSITIONS THEREOF, AND METHODS OF USING

ILLINOIS INSTITUTE OF TEC...

1. A compound of formula (II):
wherein: R? independently is OH, NH2, or OR?, wherein R? independently is alkyl, tert-butyl, or benzyl; m is 0 or 1; and Y is a structure of formula (a-1) or (a-2):
where: p is 0 or 1; Z is hydrogen, one of a group of formula (a-5), (a-6), or (a-7), orW is NH2; and each of R1-18 independently is or includes hydrogen, carboxyalkyl, alkylamido, alkyl, allyl, benzyl, benzyloxyalkyl, cycloalkyl, alkoxy, hydroxyalkyl, aryl, aryloxy, hydroxyaryl, heteroaryl, phenyl, vinyl, alkynyl, alkenyl, furannylalkyl, alkylthioalkyl, arylhydroxyalkyl, indanyl, inolylalkyl, naphthylalkyl, imidazolylalkyl, pyridiylalkyl, benzothiophenylalkyl, thiophenylalkyl, thioalkyl, thioaryl, thiobenzyl, hydroxy, carboxyl, carboxyalkyloxy, amino, carboxylic acid, haloalkylamido, aldehyde, ester, amido, tosyl, phthalimidyl, trityl, tert-butyloxycarbonyl, carbobenzyloxy, o-nosyl, acetyl, fluoroacetyl, dimethoxybenzyl, p-methoxybenzyl, an amide containing group, a thioamide containing group, an amino acid-containing group, an ester containing group, a protecting group, or one of the group of formula (a-5), (a-6), or (a-7):where n is 1 to 10, and each of X1-5 is or includes hydrogen, halo, cyano, alkyl, hydroxy, nitro, amino, alkylamino, thiocyano, isothiocyano, alkoxy, aryloxy, carboxyl, carboxyalkyl, carboxyalkyloxy, ester, amido, aldehydo, alkylamido, haloalkylamido, an ester containing group, an carbonyl containing group, an amide containing group, a thioamide containing group, or an amino acid-containing group, wherein when Y is the structure of formula (a-1) at least one R? of formula (a-1) is NH2.

US Pat. No. 10,556,872

FATTY ACID SYNTHASE INHIBITORS AND METHODS OF USE

Hampton University, Hamp...

1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein R1 is bromine; wherein each of R2 and R3 is hydrogen; wherein each of R4 and R5 is carbonyl; wherein X is ester; and wherein Y is between 4 and 20.

US Pat. No. 10,556,871

METHOD FOR PREPARING 5-(4-BROMOPHENYL)-4,6-DICHLOROPYRIMIDINE

ZHEJIANG XIANFENG TECHNOL...

1. A method for preparing 5-(4-bromophenyl)-4,6-dichloropyrimidine, comprising:Step 1: adding p-bromophenylacetic acid and a solid acid catalyst to a reactor, then adding methanol, heating with stirring, and refluxing to react for 5-6 hours under reflux; and cooling the reaction solution to 30° C. or below, filtering to recover the solid acid catalyst, distilling the resulting filtrate under reduced pressure to remove methanol, adding a hydrophobic solvent to dissolve the residue by stirring, washing the hydrophobic solvent with water, and concentrating under reduced pressure to obtain Intermediate 1 having a chemical structure (I) below;

Step 2: adding sodium methoxide and methanol to Intermediate 1 obtained in Step 1, mechanically stirring, then adding dimethyl carbonate, replacing the air in the reactor with nitrogen, heating to 70-80° C., and reacting for 4-8 hours, to obtain a mixture containing Intermediate 2 having a chemical structure (II) below;

Step 3: adding formamidine hydrochloride to the mixture containing Intermediate 2 obtained in Step 2, heating to 20-30° C. with stirring, and reacting for 15-17 hours, followed by post-treatment, to obtain Intermediate 3 having a chemical structure (III) below; and

Step 4: chlorinating Intermediate 3 obtained in Step 3 to obtain the product 5-(4-bromophenyl)-4,6-dichloropyrimidine.

US Pat. No. 10,556,869

PROCESS FOR THE PRODUCTION OF CONDENSED IMIDAZOLO DERIVATIVES

Novartis AG, Basel (CH)

1. A process for providing a compound of formula (I),
comprising the step of:
(i) reacting a compound of formula VII

with a base, which is lithium bis(trimethylsilyl)amide, in the presence of a lithium halide, wherein LG is a leaving group, and wherein the process is carried out at a temperature of ?100° C. to 0° C.

US Pat. No. 10,556,868

METHOD FOR SYNTHESIZING 3-(DIFLUOROMETHYL)-1-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID AND INTERMEDIATES THEREOF

ZHEJIANG YONGTAI TECHNOLO...

1. A method for synthesizing 3-(difluoromethyl)-1-methyl-1h-pyrazole-4-carboxylic acid represented by the following Formula III,
comprising the steps of:
(A) a diethyl ester compound represented by the following Formula IV is reacted under the action of an amine, a base and a carbonylating agent to form an acrylic diester compound represented by the following Formula I,

wherein,

wherein the definition of R1 is the same as above;
(B) the above compound represented by the Formula I is reacted with a fluoride reagent, a Lewis acid and a methyl hydrazine to form a pyrazole ring-containing diester compound represented by the following Formula II,

wherein the definition of R1 is the same as above:
(C) a heterocyclic-containing diester compound represented by the Formula II is reacted with a base to form the 3-(difluoromethyl)-1-methyl-1h-pyrazole-4-carboxylic acid represented by the Formula III.

US Pat. No. 10,556,867

PROCESS FOR PREPARING 3-FLUOROALKYL-5-PYRAZOLECARBOXYLATES AND 3-FLUOROALKYL-5-PYRAZOLECARBOXYLIC ACIDS

BAYER CROPSCIENCE AKTIENG...

10. A compound of formula (IV)
in which
R1 is difluoromethyl or trifluoromethyl;
R2 is methyl or ethyl; and
R4 is iso-propyl or benzyl.

US Pat. No. 10,556,866

ROR GAMMA (ROR?) MODULATORS

LEAD PHARMA HOLDING B.V.,...

1. A compound of Formula (I)
or a pharmaceutically acceptable salt thereof, wherein:
A11 is N or CR11;
A12 is N or CR12;
A13 is N or CR13;
A14 is N or CR14;
with the proviso that no more than two of the four positions A11, A12, A13, and A14 are simultaneously N;
R1 is C(2-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino, wherein each carbon atom of said alkyl groups is optionally substituted with one or more F, and each carbon atom of said cycloalkyl groups is optionally substituted with one or more F or methyl;
R2 and R3 are independently H, F, methyl, ethyl, hydroxy, or methoxy, or R2 and R3 are taken together with the carbon atom to which they are attached to form a carbonyl, wherein each alkyl group, if present, is optionally substituted with one or more F;
R4 is H or C(1-6)alkyl;
R5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl, each of which is optionally substituted with one or more F, Cl, C(1-2)alkyl, C(1-2)alkoxy or cyano;
the sulfonyl group containing R1 is in the meta or para position and is represented by one of R7, R8 or R9;
the remaining R6-R14 are independently H, halogen, amino, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl, wherein each alkyl group is optionally substituted with one or more F;
R15 is H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, each of which is optionally substituted with one or more F, Cl, C(1-2)alkyl, C(1-2)alkoxy or cyano; and
R16 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, each of which is optionally substituted with one or more F, Cl, C(1-2)alkyl, C(1-2)alkoxy or cyano, and
wherein:
(i) “C(1-9)heteroaryl” is a mono- or bicyclic aromatic group having 1-9 carbon atoms and 1-4 heteroatoms selected from the group consisting of nitrogen, sulfur and oxygen, and which can be attached via a nitrogen atom if feasible, or a carbon atom, and wherein each carbon atom is optionally substituted with one or more halogen or methyl; and
(ii) “C(2-5)heterocycloalkyl” is a saturated cyclic hydrocarbon group having 2-5 carbon atoms and 1-3 heteroatoms selected from the group consisting of nitrogen, sulfur and oxygen, and which can be attached via a nitrogen atom if feasible, or a carbon atom, and wherein each carbon atom is optionally substituted with one or more halogen or methyl.

US Pat. No. 10,556,865

SYNERGISTIC HERBICIDAL COMPOSITION CONTAINING CERTAIN PYRIDINE OR PYRIMIDINE CARBOXYLIC ACIDS AND CERTAIN CEREAL AND RICE HERBICIDES

Dow AgroSciences LLC, In...

1. A synergistic herbicidal mixture comprising an herbicidally effective amount of (a) a first herbicide selected from the group of a pyridine or a pyrimidine carboxylic acid of the formula (I)
wherein X represents CH, hal represents F, Cl or Br, and R represents methyl or ethyl,
or an agriculturally acceptable salt, ester or amide thereof, and (b) a second herbicide selected from the group consisting of aminopyralid, bispyribac, cyhalofop, triclopyr and mixtures thereof; wherein
the weight ratio of the first herbicide to aminopyralid ranges from 3.5:1 to 14:1;
the weight ratio of the first herbicide to bispyribac ranges from 1:6.39 to 2.5:1;
the weight ratio of the first herbicide to cyhalofop ranges from 70:90 to 4.38:200; or
the weight ratio of the first herbicide to triclopyr ranges from 1:16 to 1:32.

US Pat. No. 10,556,864

CARBAZOLE DERIVATIVE, AND LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE CARBAZOLE DERIVATIVE

Semiconductor Energy Labo...

1. A compound represented by a formula (193):



US Pat. No. 10,556,862

DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS

CAYMAN CHEMICAL COMPANY, ...

1. A compound of formula (10)
or salts thereof wherein:
L1 is
a) C3-C7alkylene, C3-C7alkenylene, or C3-C7alkynylene; or
b) —(CH2)n1-G2-(CH2)p—, —(CH2)n2—C?C-G2-, or —(CH2)n2—C(R12)?C(R12)-G2-, wherein n1 is 2, 3, 4, or 5, n2 is 1, 2, or 3, p is 0, 1, 2, or 3, and n1+p=2, 3, 4, 5, or 6;
G2 is

R1 is a carboxylic acid or a protected carboxylic acid;
R12, at each occurrence, is independently H or C1-C4alkyl;
R4 and R5 are each independently H or C1-C4 alkyl; or R4 and R5 together with the carbon to which they are attached form a C3-C5 cycloalkyl;
R6 is aryl, heteroaryl, C3-C10alkyl, C3-C10alkenyl, C3-C10alkynyl, C3-C10haloalkyl, C3-C10haloalkenyl, C3-C10haloalkynyl, or L3-R7; wherein the aryl and heteroaryl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C1-C4alkyl, C1-C3haloalkyl, cyano, halogen, C1-C3alkoxy, C1-C3haloalkoxy; and —C1-C3alkylene-C1-C3alkoxy;
L3 is C1-C6alkylene, C2-C6alkenylene, C2-C6alkynylene; and
R7 is C3-C8cycloalkyl, aryl, heteroaryl, or heterocyclyl; wherein R7 is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C1-C4alkyl, C1-C3haloalkyl, cyano, halogen, C1-C3alkoxy, C1-C3haloalkoxy, and —C1-C3alkylene-C1-C3alkoxy.

US Pat. No. 10,556,861

IONIZABLE CATIONIC LIPID FOR RNA DELIVERY

Arcturus Therapeutics, In...

1. A compound of formula I
wherein
R is a linear alkenyl of 2-18 carbons or an alkynal of 2-18 carbons;
L is a linear alkylene or alkenylene of 6 to 18 carbon atoms;
X is —CO—O— or —O—CO—;
Y is S or O;
R1 is a linear or branched alkylene of 1 to 6 carbons; and
R2 and R3 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; and
n is 1-6;
or a salt or solvate thereof.

US Pat. No. 10,556,860

HTERT MODULATORS AND METHODS OF USE

ARIZONA BOARD OF REGENTS,...

1. A compound selected from the group consisting of:
2-amino-N-((4-methoxy-3-methylphenyl)carbamoyl)benzamide,

2-amino-N-((4-((2-chloropyrimidin-5-yl)oxy)-3-methylphenyl)-carbamoyl)benzamide,

2-amino-N-((3-methyl-4-(pyrazine-2-yloxy)phenyl)carbamoyl)-benzamide,

2-amino-N-((3-methyl-4-((5-(trifluoromethyl)pyrimidin-2-yl)oxy)phenyl)carbamoyl)benzamide,

2-amino-N-((4-((5-methoxypyrimidin-2-yl)oxy)-3-methylphenyl)carbamoyl)benzamide,

N-((4-((5-bromopyrimidin-2-yl)oxy)-3-methylphenyl)carbamoyl)-4-(trifluoromethyl)benzamide,

N-((4-((5-bromopyrimidin-2-yl)oxy)-3-methylphenyl)carbamoyl)-4-fluorobenzamide,

N-((4-((5-bromopyrimidin-2-yl)oxy)-3-methylphenyl)carbamoyl)-4-methoxybenzamide,

2-amino-N-((4-(2-morpholinoethoxy)phenyl)carbamoyl)benzamide,

2-amino-N-((4-((5-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)oxy)phenyl)carbamoyl)benzamide,

N-((4-((5-bromopyrimidin-2-yl)oxy)phenyl)carbamoyl)-4-methoxybenzamide,

N-((3-chloro-4-((5-chloropyrimidin-2-yl)oxy)phenyl)carbamoyl)-4-methoxybenzamide,

4-methoxy-N-((3-methyl-4-((5-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)oxy)phenyl)carbamoyl)benzamide,

N-((4-((5-bromopyrimidin-2-yl)oxy)phenyl)(methyl)carbamoyl)-4-methoxybenzamide,

N-((4-((5-bromopyrimidin-2-yl)oxy)-3-methylphenyl)carbamoyl)picolinamide,

N-((4-guanidino-3-methylphenyl)carbamoyl)benzamide,

N-((4((5-chloropyrimidin-2-yl)oxy)-3-methylphenyl)carbamoyl)-4-(trifluoromethyl)benzamide,

N-((4((5-methoxypyrimidin-2-yl)oxy)-3-methylphenyl)carbamoyl)-4-(trifluoromethyl)benzamide,

N-((4-((5-chloropyrimidin-2-yl)oxy)-3-fluorophenyl)carbamoyl)-4-(trifluoromethyl)benzamide,

N-((3-methyl-4-(pyrazin-2-yloxy)phenyl)-carbamoyl)-4-(trifluoromethyl)benzamide, and

N-((4-((2-chloropyrimidin-5-yl)oxy)-3-methylphenyl)carbamoyl)-4-(trifluoromethyl)benzamide,
including a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a mixture thereof.

US Pat. No. 10,556,859

PHTHALONITRILE COMPOUND

LG CHEM, LTD., Seoul (KR...

1. A phthalonitrile resin comprising a polymerized unit derived from a compound of Formula 1 below:
wherein, A is an alkylene group or an alkylidene group, having 1 to 20 carbon atoms, Q1 and Q2 are an aromatic divalent radical substituted with at least one alkyl group, L1 and L2 are each independently an alkylene group, an alkylidene group, an oxygen atom or a sulfur atom, R1 to R10 are each independently hydrogen, an alkyl group, an alkoxy group, an aryl group or a cyano group, provided that at least two of R1 to R5 are a cyano group and at least two of R6 to R10 are a cyano group.

US Pat. No. 10,556,858

ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17

REATA PHARMACEUTICALS, IN...

1. A method of making a first compound defined as:
wherein:
R12 is ORd, or NRdRe, wherein:
Rd is hydrogen; or
alkyl(C?8), alkenyl(C?8), aryl(C?8), heteroaryl(C?8), aralkyl(C?8), heteroaralkyl(C?8), or a substituted version of any of these groups;
Re is alkyl(C?8), alkenyl(C?8), aryl(C?8), heteroaryl(C?8), aralkyl(C?8), heteroaralkyl(C?8), or a substituted version of any of these groups; or
Rd and Re are taken together and are -alkanediyl(C?8)-, substituted -alkanediyl(C?8)-, -alkenediyl(C?8)-, substituted -alkenediyl(C?8)-, or —N?CHCH?CH—;
wherein the first step of the synthesis comprises modification of the C-17 isocyanate group of the following compound:

US Pat. No. 10,556,857

HYDRAZIDE COMPOUNDS SUITABLE FOR NUCLEATING POLYLACTIC ACID POLYMER

3M Innovative Properties ...

1. A composition comprising:semicrystalline polylactic acid polymer; and
a nucleating agent having the formula:

wherein R1 is a C10-C20 alkylene group; and
R2 is an alkyl group.

US Pat. No. 10,556,856

ANTIBACTERIAL AGENTS

Rutgers, The State Univer...

1. A compound of formula I:wherein:R1 is a polyether or a (C1-C6)alkyl that is optionally substituted with one or more NRaRb;
R2 is a polyether or a (C1-C6)alkyl that is optionally substituted with one or more NRaRb;
each X is independently (C1-C20)alkyl;
Ra and Rb are each independently H or (C1-C6)alkyl;
each Y is independently —NH2, —N+(Rc)3W?, —NH—C(?NH)—NH2 or —NH—BOC;
each Rc is independently (C1-C6)alkyl;
W is a counter ion; and
n is 1, 2, 3, 4, 5, 6, 7, or 8;
or a salt thereof.

US Pat. No. 10,556,855

CATIONIC LIPIDS AND TRANSFECTION METHODS

Factor Bioscience Inc., ...

1. A compound of the formula:

US Pat. No. 10,556,854

BACTERIAL EFFLUX PUMP INHIBITORS

Rutgers, The State Univer...

1. A compound of formula I:
X is NR2 or O;
R1 is (C3-C12)alkyl substituted with two or more groups selectedfrom —NRb1Rc1, —NHNH2, —C(?NRa1)(NRb1Rc1), —NRa1C(?NRa1)(Rd1)and —NRa1C(?NRa1)(NRb1Rc1);R2 is hydrogen or (C1-C3)alkyl;
each R3 is independently hydrogen, halo or (C1-C4)alkyl;
R4 is aryl, heteroaryl, aryl(C1-C6)alkyl- or heteroaryl(C1-C6)alkyl- wherein any aryl, heteroaryl, aryl(C1-C6)alkyl- or heteroaryl(C1-C6)alkyl- of R4 is optionally substituted with one or more groups independently selected from halo, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy and (C1-C4)haloalkoxy;
R5 is hydrogen, (C1-C3)alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl- or heteroaryl(C1-C6)alkyl- wherein any aryl, heteroaryl, aryl(C1-C6)alkyl- or heteroaryl(C1-C6)alkyl- of R5 is optionally substituted with one or more groups independently selected from halo, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)alkoxy and (C1-C4)haloalkoxy, provided that when R5 is hydrogen or (C1-C3)alkyl, and R4 is optionally substituted phenyl, then n is not 0 or 1;
each Ra1 is independently hydrogen or (C1-C4)alkyl;
each Rb1 and Rc1 is independently hydrogen or (C1-C4)alkyl;
Rd1 is (C1-C3)alkyl and
n is 0, 1, 2 or 3;
or a salt thereof.

US Pat. No. 10,556,853

ANTICONVULSANT COMPOUNDS

OWEN-BARRY PHARMACEUTICAL...

1. A method for reducing the severity of convulsant activity, comprising administering to a subject a therapeutically effective amount of a compound of formula (I):
wherein,
R1=R2=CH3 or R1=H and R2=H;
R3=H;
F;
C(O)R5, wherein R5=H, CH3, C2H5, CH(CH3)2, CHCH3CN, or aryl, wherein aryl is a compound selected from the group consisting of:
phenyl, unsubstituted or substituted with one or two compounds selected from the group consisting of CH3, OH, OCH3, SO2CH3, SO2Ph, F, Cl, CF3, CN;
1- or 2-naphthyl;
2-, 3-, or 4-pyridyl, unsubstituted or substituted with one or two compounds selected from the group consisting of CH3, OCH3, SO2CH3, SO2Ph, F, Cl, CF3, CN;
2- or 3-furyl, unsubstituted or substituted with one or two compounds selected from the group consisting of CH3, OCH3, SO2CH3, SO2Ph, F, Cl, CF3, CN; and
2-or 3-thienyl, unsubstituted or substituted with one or two compounds selected from the group consisting of CH3, OCH3, SO2CH3, SO2Ph, F, Cl, CF3, CN;
C(O)—O?, or C(O)—O—R6, wherein R6=H, straight or branched C1 to C6 alkyl, phenyl,
CH2C6H5, or CH(CH2)n, and wherein n=2-5;
C(O)NH2, C(O)NHR6 or C(O)NR7R8 wherein R7 and R8 independently =straight or branched C1 to C6 alkyl, CH2C6H5, aryl, or R7 and R8 together =(CH2)n, and wherein n=3-5;
OH, OCH3, O—C(O)CH3 or OCH2C6H5;
S—CH3, S—C6H5, S(O)CH3, S(O)C6H5, SO2CH3, or SO2C6H5;
NO2, NH2, NHR6, NR7R8;
C?C—C(O)CH3, C?C—C(O)CH(CH3)2, C?C—C(O)C2H5, C?C—C(O)C6H5, C?C—C(O)—OH, or C?C—C(O)—O?; or
CN; and
R4=one or two compounds selected from the group consisting of H, CH3, OH, OCH3, SO2CH3, SO2Ph, F, Cl, CF3, or CN,
or a pharmaceutically acceptable salt thereof,
wherein when R1 and R2 are both H and R4 is OH, then R3 is not OH or OCH3.

US Pat. No. 10,556,852

PRODUCTION OF MALEIC ACID, FUMARIC ACID, OR MALEIC ANHYDRIDE FROM LEVULINIC ACID ANALOGS

SYRACUSE UNIVERSITY, Syr...

1. A method of producing maleic anhydride, comprising the step of oxidizing a quantity of methyl levulinate without forming levulinic acid to form maleic anhydride.

US Pat. No. 10,556,851

PROCESS FOR PREPARATION OF PROSTACYCLIN DERIVATIVES

Emcure Pharmaceutical Lim...

1. A process for the preparation of Treprostinil (1) and its pharmaceutically acceptable salts, comprising:(a) reacting compound (4) with compound (5) to provide compound (6)

wherein R is alkyl
(b) oxidizing compound (6) with MnO2 and asymmetrically reducing resulting compound (7) to provide compound (8),

(c) treating compound (8) with a hydroxyl protecting reagent to give compound (9), cyclizing compound (9) in presence of dicobalt octacarbonyl (Co2(CO)8) to give compound (10), and hydrogenating to provide compound (11),

(d) treating compound (11) with a reducing agent to give compound (12), deprotecting the side-chain hydroxyl group in compound (12) to give compound (13), and treating compound (13) with a deprotecting agent to provide compound (14)

(e) treating compound (14) with halogenated acetonitrile to provide compound (15), converting compound (15) with alkaline hydrolysis followed by acidification to give Treprostinil (1) and its pharmaceutically acceptable salts,

US Pat. No. 10,556,849

METHOD FOR PRODUCING METHANOL AND APPARATUS FOR PRODUCING METHANOL

MITSUBISHI GAS CHEMICAL C...

1. A method for producing methanol comprising:synthesis steps of synthesizing methanol from a synthesis gas comprising hydrogen, carbon monoxide and carbon dioxide; and
separation steps of separating an unreacted gas from a reaction mixture obtained by passing through one of the synthesis steps,
the method comprising a synthesis loop having at least two of the synthesis steps and at least two of the separation steps,
wherein the synthesis loop comprises:
a first mixing step of obtaining a first mixed gas by mixing a residual gas, obtained by removing a purge gas from a final unreacted gas separated from a final reaction mixture in a final separation step subsequent to a final synthesis step, with 10 to 90 mol % of a make-up gas comprising hydrogen, carbon monoxide and carbon dioxide;
a first synthesis step of synthesizing methanol from the first mixed gas;
a first separation step of separating a first unreacted gas from a first reaction mixture obtained in the first synthesis step;
a final mixing step of obtaining a final mixed gas by finally mixing the unreacted gas and at least a fraction of 10 to 90 mol % of the make-up gas;
the final synthesis step of synthesizing methanol from the final mixed gas; and
the final separation step of separating the final unreacted gas from the final reaction mixture obtained in the final synthesis step,
the synthesis loop also comprises:
a first preheating step of preheating the first mixed gas;
a final preheating step of preheating the final mixed gas; and
a pressure increase step of increasing the pressure of the final mixed gas having passed through the final preheating step before the final synthesis step by using a circulator, and
in the synthesis loop, a reaction temperature of a catalyst layer is controlled by indirect heat exchange with pressurized boiling water.